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ABSTRACT 
 
 The emergence and spread of multidrug resistance among human pathogenic bacteria 
is an increasing worldwide problem. A comprehensive understanding of the molecular basis 
of resistance mechanisms of bacteria will be vital for the future development of new and 
more effective antibiotics and for novel therapeutic treatment strategies. One of the common 
resistance mechanisms is the active efflux of toxic compounds from the cell by bacterial 
multidrug efflux systems, which are polyspecific and able to accommodate a variety of 
structurally and functionally unrelated compounds. Moreover, it is well recognized that the 
expression of these multidrug efflux transporters is tightly controlled by transcriptional 
regulators with the same multidrug recognition properties. Elucidation of structural and 
functional relationships of these multidrug efflux transporters and transcriptional regulators is 
the major concern of this dissertation. In order to understand the role of Rv3066 in regulating 
the expression level of the multidrug efflux pump Mmr in M. tuberculosis, we have 
determined the crystal structure of Rv3066, both in the absence and presence of ethidium 
bromide. With the aid of other experimental data, induction mechanism of Rv3066 is studied 
in detail. Currently available various methodologies to crystallize membrane proteins have 
also been outlined in this dissertation. Towards understanding the molecular mechanism of 
MtrCDE efflux pump of N. gonorrhoeae, which mediates the export of several structurally 
diverse toxic chemicals, we have determined the crystal structure of MtrD. In addition, the 
Mtr efflux system includes another inner membrane protein MtrF, which belongs to the 
AbgT family of transporters. To date, approximately 13,000 putative transporters of this 
family have been identified. However, no structural information has been made available and 
even functional data are fairly minimal. To understand how members of the AbgT family 
function, we have determined the crystal structure of MtrF and combination of functional 
studies suggests that MtrF acts as an antibiotic efflux pump. In addition, we have exploited 
our knowledge on AbgT transporter family, by determining the crystal structure of another 
member YdaH, of this family. Based on our observations, we believe that many members of 
the AbgT family transporters may serve as antimetabolite efflux pumps to protect cells 
against these noxious agents. 
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CHAPTER 1 
GENERAL INTRODUCTION 
 
The introduction of antibiotics for the treatment of infectious diseases in the 20th century 
is considered to be one of the major advances of modern medicine. Development of a wide range 
of antibiotics enabled successful treatment of the previously life-threatening diseases and 
radically improved global health and extended average life expectancy [1,2]. Not only did 
antibiotics save many millions of lives, but they also created wealth, and their discovery was a 
turning point in human history. Unfortunately, the use of these wonder drugs has been hampered 
by the rapid emergence of resistance strains. Today, drug resistance is common among all the 
major pathogens and all classes of antibiotics. Many of the bacterial pathogens associated with 
clinical infection have evolved in multidrug-resistant (MDR-resistant to one or more drugs) and 
extensive-drug resistant (XDR- only one or two classes of drugs left) forms. MDR/XDR has 
appeared in Acinetobacter baumannii, Campylobacter jejuni, Neisseria gonorrhoeae, Group B 
streptococcus, Klebsiella pneumoniae, MRSA, Escherichia coli, Neisseria meningitidis, 
Salmonella (non-typhoidal serotypes), Shigella, Streptococcus pneumoniae, Vancomycin-
resistant Enterococci (VRE), Vancomycin-Intermediate/Resistant Staphylococcus aureus 
(VISA/VRSA), Mycobacterium tuberculosis. Infections caused by these MDR/XDR bacteria are 
associated with substantial extra costs of treatments due to reduced options and the major risk to 
both the hospital and the community [3]. The World Health Organization (WHO) even warns of 
a post-antibiotic era, in which common infections and minor injuries can once again become 
deadly threats, if no efficient countermeasures are taken within the next few years [4]. Thus, 
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there is a pressing need for new antibiotics or for new therapeutic approaches to treat infectious 
diseases.  
A common and major antibiotic resistance mechanism is the active efflux of drugs from 
cells by membrane bound transporters. These transporter proteins are found in all organisms. In 
bacteria, genes encoding this class of proteins can be located on chromosomes or plasmids [5,6]. 
Although some of these efflux systems transport specific substrates, many are transporters of 
multiple substrates, designated multidrug resistance efflux pumps. These efflux pumps are 
prominent in terms of both their broad substrate specificities and high efficiency of drug 
extrusion. 
According to their sequence similarity, number of transmembrane spanning regions, 
energy sources and substrates, bacterial multidrug efflux transporters can be classified into five 
families: major facilitator superfamily (MFS)[7-9], resistance nodulation cell division (RND) 
[10] family, small multidrug resistance (SMR) family [11], ATP binding cassette (ABC) family 
[12], multidrug and toxic compound extrusion (MATE) family [13,14].  The transporters of 
MFS, RND, SMR and MATE families use proton motive force to drive the extrusion of their 
substrates by an antiport H+: drug mechanism, with the exception of the MATE family, which 
can also use sodium ion gradient as the energy source. On the other hand, transporters of ABC 
superfamily use ATP hydrolysis to drive the extrusion of their substrates [15].  
The RND family transporters are responsible for a large portion of intrinsic and acquired 
multidrug resistance to clinically significant antibiotics in Gram-negative bacteria [16]. The 
RND family can be further divided into two sub-families, the hydrophobic and amphiphilic 
efflux RND (HAE-RND) and heavy-metal efflux (HME-RND) subfamilies. The efflux systems 
of the RND family are organized as tripartite protein complex: composed of an inner membrane 
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component (RND protein), an adapter protein (membrane fusion protein) and an outer membrane 
protein. These three components form a continuous channel that traverse both the inner and outer 
membranes ensuring that the substrates, captured from the outer leaflet of the inner membrane 
bilayer, are effluxed directly across the periplasm and the outer membrane into the external 
medium using the proton-gradient as an energy source.  
At present, two crystal structures of HAE-RND type efflux pumps are available. These 
efflux pumps are the E. coli AcrB [17-25] and Pseudomonas aeruginosa MexB [26] multidrug 
transporters, both of which are involved in export of organic substances such as various 
antibiotics, bile salts, and other hydrophobic substances. Structural data suggested that both 
AcrB and MexB function as a trimer. Each monomer has a transmembrane domain composed of 
12 membrane-spanning helices and a large periplasmic domain. Their structures suggest that 
both AcrB and MexB span the entire width of the inner membrane and protrude approximately 
70 Å into the periplasm. Crystal structures of AcrB with its substrates reveal at least three 
alternative binding sites [19,22,23] and all are located in the periplasmic domain of AcrB. Drug 
export by RND transporters is proton-motive force dependent. Three amino acid residues, Asp 
407, Asp 408, and Lys 940, found on the fourth and tenth transmembrane domains, are crucial 
for proton translocation pathway [19,27]. The transmembrane domains of AcrB and MexB are 
particularly well conserved with almost all residues being identical, including the residues 
involved in proton translocation, suggesting that the mechanism may be common to all RND 
systems [26].  Along with the models of these two HAE-RND transporters, the crystal structures 
of other components of these tripartite complex systems have also been determined. These 
include the outer membrane channels E. coli TolC [28] and P. aeruginosa OprM [29], as well as 
the periplasmic membrane fusion proteins E. coli AcrA [30] and P. aeruginosa MexA [31,32].  
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In addition, crystal structures of two HME-RND transporters, CusA of E. coli and ZneA 
of Cupriavidus metallidurans CH34, have been solved recently [33,34]. Although HAE-RND 
proteins typically have broad substrate specificity, HME-RND proteins are highly substrate-
specific and are able to differentiate between monovalent and divalent ions. Crystal structures of 
their membrane fusion partner structures, CusB of E. coli and ZneB of C. metallidurans, have 
also been reported [35,36]. More recently, the crystal structure of CusC (outer membrane 
channel) of E. coli completed the structural analysis of components of the complex [37,38]. The 
first efflux complex of RND transporter with its adapter, CusBA of E. coli, has been reported 
recently [39]. This structure was critical in elucidating specific interactions between the pump 
and adaptor proteins and provided the backbone to develop models of tripartite efflux complexes 
[40]. Based on the cocrystal structure, functional studies on other RND efflux systems and cryo-
electron microscopy model of AcrAB-TolC, it is believed that a trimeric RND pump in the inner 
membrane is coupled by a hexameric periplasmic membrane fusion protein, to a pore formed by 
a trimeric outer membrane channel, forming a continuous channel that spans both inner and outer 
membranes [41-43].  
N. gonorrhoeae is a Gram-negative obligate human pathogen and is the causative agent 
of the sexually transmitted infection gonorrhea. The best characterized and most clinically 
important efflux system in N. gonorrhoeae is the MtrCDE tripartite multidrug efflux system (for 
multiple transferable resistance) [44-47].  The complex is formed by interactions between the 
inner membrane transporter MtrD (of the HAE-RND family), the periplasmic membrane fusion 
protein MtrC, and the outer membrane channel MtrE [48-52]. This powerful efflux complex 
provides resistance to a broad spectrum of antimicrobial agents, including bile salts, fatty acids, 
dyes, antibiotics, and spermicides [45,46,48]. The Mtr multidrug efflux system is also 
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responsible for resistance to host-derived cationic antimicrobial peptides, which are important 
mediators of the innate host defense [47]. Given that gonococci commonly infect mucosal sites 
bathed in fluids containing such peptides, the Mtr system indeed underscores the pathogenesis of 
gonococcal disease and its contribution to virulence. In addition, it has been shown that the 
MtrCDE tripartite efflux pump is capable of enhancing long-term colonization of the mouse 
vaginal mucosal layer and that gonococci lacking this efflux pump were highly attenuated [53]. 
In addition, the Mtr efflux system includes another inner membrane protein MtrF [54,55], 
which belongs to the AbgT family of transporters (for p-aminobenzoyl-glutamate transporter) 
[56].  It has been proposed that MtrF cooperates with the MtrCDE complex to export certain 
antimicrobials by a yet unknown mechanism [54]. To date, approximately 13,000 putative 
transporters of the AbgT family have been identified.  AbgT-type proteins are commonly found 
in Gram-negative bacteria such as S. enterica, Gram-positive bacteria such as S. aureus, as well 
as yeasts such as Saccharomyces arboricola.  Surprisingly, among proteins in this diverse AbgT 
family, only E. coli AbgT and N. gonorrhoeae MtrF [54-58] have been partially characterized.  
However, recent work demonstrated that E. coli AbgT is capable of catalyzing the uptake 
of the catabolite p-aminobenzoyl-glutamate for de novo folic acid synthesis [58].  Because of this 
finding, it is hypothesized that AbgT-family transporters contribute to the bacterial folate 
synthesis pathway by importing p-aminobenzoyl-glutamate for producing this essential vitamin.  
On the other hand, it has been observed that N. gonorrhoeae MtrF, also belonging to the AbgT 
family, functions as an antimicrobial resistant protein.  It is needed for the high-level resistance 
of gonococci to hydrophobic antimicrobials including erythromycin and TX-100 [54,55]. In 
addition, in some bacteria such as Alcanivorax borkumensis, AbgT family proteins exist, as a 
single transporter. In other words, the gene ydaH, which codes for YdaH transporter is preceded 
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neither by abgA, abgB genes nor by mtrC, mtrD, mtrE genes. Thus far, there is no structural 
information available for this family of membrane proteins, obscuring the details of their 
function and mechanism. 
Expression of the majority of efflux systems is subject to tight control by various 
transcriptional regulators, underlying their roles in facilitating the adaptation of bacteria to 
environmental changes. These regulatory proteins usually bind to many of the structurally 
unrelated toxic compounds that are effluxed by the transporters that they regulate. Although the 
function and composition of MDR efflux pumps are relatively conserved in different species but 
their regulatory mechanisms vary significantly. Among the >20 classes of regulatory families, 
members of the TetR family of regulators are best known for their roles as regulators of 
antibiotic efflux pumps and tolerance to toxic chemical compounds [59,60]. TetR family 
members consist of an N-terminal helix-turn-helix (HTH) DNA-binding domain, and a larger C-
terminal ligand-binding domain. While amino acid sequences of DNA-binding domain share 
high similarity among the family members, those of ligand-binding domain are diverse. TetR 
family proteins usually bind to their operators composed of ~10-30-bp palindromic sequences, to 
repress the target genes, and derepression occurs due to the conformational change within the 
dimer when cognate ligands bind to the regulators [61]. Understanding the structures and 
mechanisms of these efflux transporters and their transcriptional regulators will aid in the design 
and development of novel drugs to combat the multidrug resistant bacteria. 
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Thesis organization 
Chapter 1 is the general introduction that provides the background information of the 
RND efflux systems, AbgT transporter family and TetR family regulatory proteins. 
Chapter 2 is a manuscript published in Nucleic Acid Research, which describes the role 
of Rv3066 in regulating the expression level of the multidrug efflux pump Mmr in M. 
tuberculosis. The crystal structures of Rv3066 regulator both in the absence and presence of 
bound ethidium, together with the functional data provide new insight into the mechanisms of 
ligand binding and Rv3066 regulation.  
Chapter 3 is a review published in Philosophical Magazine, summarizing a variety of 
methodologies for use in crystallizing integral membrane proteins. Since 50% of currently 
administrative pharmaceutical agents are designed for targeting them, understanding the 
structure and function of these membrane proteins is hampered by difficulties in crystallizing 
these membrane proteins.  
Chapter 4 is a manuscript published in PLoS One, describing the crystal structure of the 
N. gonorrhoeae MtrD inner membrane multidrug efflux pump. The findings reveal a novel 
structural feature that is not found in other known RND efflux pumps. 
Chapter 5 is a manuscript submitted to Cell Reports, presenting the crystal structure of N. 
gonorrhoeae MtrF transporter, which belongs to AbgT family of transporters. The findings from 
the structure reveal a dimeric molecule with a fold very distinct from all other families of 
transporters. Functional analysis suggests that MtrF is an antibiotic efflux pump, mediating 
bacterial resistance to sulfonamide antimetabolite drugs.  
Chapter 6 is a manuscript submitted to Nature Communications, describing the crystal 
structure of the A. borkumensis YdaH transporter, which is also another member of AbgT family. 
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A combination of three-dimensional structure and functional analysis suggest a novel mechanism 
for sulfonamide antimetabolite resistance in bacteria.  
Chapter 7 outlines conclusions and future directions. In this chapter, all the findings are 
summarized and organized by theme of understanding bacterial multidrug efflux pumps.  
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Abstract 
 The Mmr multidrug efflux pump recognizes and actively extrudes a broad range of 
antimicrobial agents, and promotes the intrinsic resistance to these antimicrobials in 
Mycobacterium tuberculosis.  The expression of Mmr is controlled by the TetR-like 
transcriptional regulator Rv3066, whose open reading frame is located downstream of the mmr 
operon. To understand the structural basis of Rv3066 regulation, we have determined the crystal 
structures of Rv3066, both in the absence and presence of bound ethidium bromide, revealing an 
asymmetric homodimeric two-domain molecule with an entirely helical architecture.  The 
structures underscore the flexibility and plasticity of the regulator essential for multidrug 
recognition.  Comparison of the apo-Rv3066 and Rv3066-ethidium bromide crystal structures 
suggests that the conformational changes leading to drug mediated derepression is primarily due 
to a rigid body rotational motion within the dimer interface of the regulator.  The Rv3066 
regulator creates a multidrug-binding pocket, which contains five aromatic residues.  The bound 
ethidium is found buried within the multidrug-binding site, where extensive aromatic stacking 
interactions seemingly govern the binding.  In vitro studies reveal that the dimeric Rv3066 
regulator binds to a 14-bp palindromic inverted repeat sequence in the nanomolar range.  These 
findings provide new insight into the mechanisms of ligand binding and Rv3066 regulation. 
 
Introduction 
Tuberculosis (TB) is one of the most deadly diseases and was responsible for the death of 
1.7 million people in 2009 (1).  This disease is caused by the bacterium Mycobacterium 
tuberculosis, which infects an estimated nine million people each year.  TB is very difficult to 
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treat, requiring at least six months of a combination of medications.  The treatment must 
continue even long after the symptoms disappear.  However, M. tuberculosis has developed 
resistance to commonly used anti-TB agents, such as isoniazid and rifampicin.  The development 
of these drug resistant strains is mainly due to the mismatch between treatment and symptoms, 
such as the irregular intake of drugs throughout the course of treatment and inappropriate 
prescription of medications (2).  TB caused by multi-drug resistant (MDR) (3, 4), extensively 
drug-resistant (XDR) (2, 5), and most recently totally drug-resistant (TDR) (6) strains of M. 
tuberculosis have emerged and spread globally.  Based on our current knowledge, TDR-TB is 
untreatable.  The World Health Organization has predicted that there will be two million MDR or 
XDR cases worldwide by 2012.  It is obvious that the emergence of these drug-resistant TB 
strains has evolved into a major threat and challenges our global prospects for TB control.  Thus, 
knowledge of the molecular mechanisms underlying drug resistance in M. tuberculosis is 
essential for the development of new strategies to combat this disease. 
Recent evidence suggests that MDR strains of M. tuberculosis are associated with 
constitutive or inducible expression of multidrug efflux pumps (7).  These pumps have been 
classified into five different families: the ATP-binding cassette (ABC), resistance-nodulation-
division (RND), multidrug and toxic compound extrusion (MATE), major facilitator (MF), and 
small multidrug resistance (SMR) families (8).  It has been found that the genome of M. 
tuberculosis contains genes encoding efflux pumps from all these families (9, 10).  In addition, 
several of these MDR efflux pumps have been identified and characterized (9).   
One such pump is the Mmr (Rv3065) multidrug efflux pump, which belongs to the SMR 
family (11).  Mmr has been shown to mediate resistance to several toxic compounds, including 
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acriflavine, ethidium bromide, erythromycin, pyronin Y, safranin O, tetraphenylphosphonium, 
and thioridazine (11, 12). 
Elucidating the regulatory systems of multidrug efflux pumps in M. tuberculosis should 
allow us to understand how this bacterium contributes to multidrug resistance and how it adapts 
to environmental changes.  At present, little is known about the regulatory mechanisms 
modulating the expression of mmr in M. tuberculosis.  Here, we report the crystal structures of 
the Rv3066 efflux regulator both in the absence and presence of bound ethidium, suggesting that 
ethidium binding triggers a rotational motion of the regulator.  This motion results in inducing 
the expression of the Mmr efflux pump by releasing the Rv3066 regulator from its cognate DNA 
at the promoter region.  The rv3066 gene is located immediately downstream of mmr and 
encodes a 202 amino-acid protein that shares sequence homology to members of the TetR family 
of regulators (13, 14).  Our data indicate that Rv3066 is a TetR-family regulator, which represses 
the transcription of mmr by directly binding to the inverted repeat (IR) of the promoter. 
 
Material and methods 
Cloning of rv3066 
The rv3066 ORF from genomic DNA of M. tuberculosis strain H37Rv was amplified by 
PCR using the primers 5ʹ′-CCATGGCAACCGCAGGCTCCGACC-3ʹ′ and 5ʹ′-
GGATCCTCAATGGTGATGATGATGATGGTCGGGGGTTCGTCCCGCAT-3ʹ′ to generate a 
product that encodes a Rv3066 recombinant protein with a 6xHis tag at the C-terminus.  The 
corresponding PCR product was digested with NcoI and BamHI, extracted from the agarose gel, 
and inserted into pET15b as described by the manufacturer (Merck KGaA, Darmstadt, 
Germany).  The recombinant plasmid (pET15bΩrv3066) was transformed into DH5α cells and 
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the transformants were selected on LB agar plates containing 100 µg/ml ampicillin.  The 
presence of the correct rv3066 sequence in the plasmid construct was verified by DNA 
sequencing. 
  
Expression and purification of Rv3066 
Briefly, the full-length Rv3066 protein containing a 6xHis tag at the C-terminus was 
overproduced in E. coli BL21(DE3) cells possessing pET15bΩrv3066.  Cells were grown in 4 L 
of Luria Broth (LB) medium with 100 µg/ml ampicillin at 37oC.  When the OD600 reached 0.5, 
the culture was treated with 1 mM isopropyl-β-D-thiogalactopyranoside (IPTG) to induce 
Rv3066 expression, and cells were harvested within 3 h.  The collected bacterial cells were 
suspended in 100 ml ice-cold buffer containing 20 mM Na-HEPES (pH 7.2) and 200 mM NaCl, 
10 mM MgCl2 and 0.2 mg DNase I (Sigma-Aldrich).  The cells were then lysed with a French 
pressure cell.  Cell debris was removed by centrifugation for 45 min at 4oC and 20,000 rev/min.  
The crude lysate was filtered through a 0.2 µm membrane and was loaded onto a 5 ml Hi-Trap 
Ni2+-chelating column (GE Healthcare Biosciences, Pittsburgh, PA) pre-equilibrated with 20 
mM Na-HEPES (pH 7.2) and 200 mM NaCl.  To remove unbound proteins and impurities, the 
column was first washed with six column volumes of buffer containing 50 mM imidazole, 250 
mM NaCl, and 20 mM Na-HEPES (pH 7.2).  The Rv3066 protein was then eluted with four 
column volume of buffer containing 300 mM imidazole, 250 mM NaCl, and 20 mM Na-HEPES 
(pH 7.2).  The purity of the protein was judged using 12.5% SDS-PAGE stained with Coomassie 
Brilliant Blue.  The purified protein was extensively dialyzed against buffer containing 100 mM 
imidazole, 250 mM NaCl, and 20 mM Na-HEPES (pH 7.5), and concentrated to 20 mg/ml.    
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For 6xHis selenomethionyl-substituted (SeMet)-Rv3066 protein expression, a 2 ml LB 
broth overnight culture containing E. coli BL21(DE3)/pET15bΩrv3066 cells was transferred into 
40 ml of LB broth containing 100 µg/ml ampicillin and grown at 37oC.  When the OD600 value 
reached 1.2, cells were harvested by centrifugation at 6000 rev/min for 10 min, and then washed 
two times with 20 ml of M9 minimal salts solution.  The cells were re-suspended in 40 ml of M9 
media and then transferred into a 4 L pre-warmed M9 solution containing 100 µg/ml ampicillin.  
The cell culture was incubated at 37oC with shaking. When the OD600 reached 0.4, 100 mg/l of 
lysine, phenylalanine and threonine, 50 mg/l isoleucine, leucine and valine, and 60 mg/l of L-
selenomethionine were added. The protein expression was induced with 1 mM IPTG after 15 
min.  Cells were then harvested within 3 h after induction.  The procedures for purifying the 
6xHis SeMet-Rv3066 were identical to those of the native protein. 
 
Crystallization of Rv3066 
All crystals of the 6xHis Rv3066 regulator were obtained using hanging-drop vapor 
diffusion.  The form I SeMet-Rv3066 crystals were grown at room temperature in 24-well plates 
with the following procedures.  A 2 µl protein solution containing 20 mg/ml SeMet-Rv3066 
protein in 20 mM Na-HEPES (pH 7.5), 250 mM NaCl and 100 mM imidazole was mixed with a 
2 µl of reservoir solution containing 24% PEG 4000, 0.1 M Na-acetate (pH 5.0) and 0.2 M 
MgCl2.  The resultant mixture was equilibrated against 500 µl of the reservoir solution.  Crystals 
of form I grew to a full size in the drops within two weeks.  Typically, the dimensions of the 
crystals were 0.2 mm x 0.05 mm x 0.05 mm.  Cryoprotection was achieved by raising the PEG 
4000 concentration stepwise to 30% with a 3% increment in each step.   
20 
 
 
The form II crystals of Rv3066 were prepared using similar procedures.  The reservoir 
solution for the form II crystals consists of 24% PEG 4000, 0.1 M Na-HEPES (pH 8.0) and 0.2 
M MgCl2.  Crystals of this form grew to a full size in the drops within two weeks.  The 
dimensions of the mature crystals were 0.1 mm x 0.1 mm x 0.1 mm.  Cryoprotection was 
achieved by raising the PEG 4000 concentration stepwise to 30% with a 3% increment in each 
step.  
The Rv3066-ethidium complex crystals were prepared by incubating the form II crystals 
of apo-Rv3066 in solution containing 24% PEG 4000, 0.1 M Na-HEPES (pH 8.0), 0.2 M MgCl2 
and 0.5 mM ethidium bromide for 48 h at 25oC.  Cryoprotection was achieved by raising the 
PEG 4000 concentration stepwise to 30% with a 3% increment in each step. 
 
Data collection, structural determination and refinement  
All diffraction data were collected at 100K at beamline 24ID-E located at the Advanced 
Photon Source, using an ADSC Quantum 315 CCD-based detector.  Diffraction data were 
processed using DENZO and scaled using SCALEPACK (16).  The crystals of form I belong to 
space group P21212 (Table 1).  Based on the molecular weight of Rv3066 (22.78 kDa), a single 
dimer per asymmetric unit with a solvent content of 36.1% is expected.  Two selenium sites were 
identified using SHELXC and SHELXD (17) as implemented in the HKL2MAP package (18).  
Single-wavelength anomalous dispersion (SAD) phasing using the program PHASER (19) was 
employed to obtain experimental phases in addition to phases from the structural model of the 
EbrR regulator (residues 83-176) (PDB code: 3hta).  The resulting phases were then subjected to 
density modification and NCS averaging using the program PARROT (20).  The phases were of 
excellent quality and allowed for tracing of most of the molecule in PHENIX AutoBuild (22), 
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which led to an initial model containing 72% amino acid residues and 54% of which contained 
side-chains.  The remaining part of the model was manually constructed using the program Coot 
(21).  Then, the model was refined using TLS refinement techniques adopting a single TLS body 
as implemented in PHENIX (22) leaving 5% of reflections in Free-R set.  Iterations of 
refinement using PHENIX (22) and CNS (23) and model building in Coot (21) lead to the 
current model, which consists of 173 residues (residues 12-184) with excellent geometrical 
characteristics (Table 1). 
The form II and Rv3066-ethidium crystals took the space groups P21212 and P3121, 
respectively.  These two structures were phased using the molecular replacement (MR) program 
PHASER (19) by using the form I structure as the search model.  Structural refinements were 
then performed using PHENIX (22) and CNS (23) (Table 1). 
 
Electrophoretic mobility shift assay 
To determine the binding of Rv3066 to the operator region of mmr, electrophoretic 
mobility shift assay (EMSA) was performed according to the procedure described by Alekshun 
et al. (24).  The 30-bp oligonucleotide, 5ʹ′-CGAGCCTCCTTTGTGTACATTTGTACATGT-3ʹ′, 
containing the hypothetical operator site IR1 was labeled at the 3ʹ′ end with digoxigenin-11-
ddUTP (DIG-11-ddUTP) using the DIG Gel Shift Kit (Roche Applied Science, Indianapolis, IN).  
A random 30-bp internal rv3066 fragment was used as the control DNA for the gel shift assay.  
This control DNA fragment was also labeled with DIG-11-ddUTP.  The DIG-11-ddUTP-labeled 
DNA fragments (0.02 µM) were incubated with the purified Rv3066 protein at concentrations 
ranging from 0.04 µM to 0.64 µM in binding buffer composed of 20 mM HEPES, pH 7.6, 1 mM 
EDTA, 10 mM (NH4)2SO4, 5 mM dithiothreitol, 0.2% Tween 20 (w/v), 30 mM KCl, and 0.5 µg 
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of Poly [d(I-C)] as a nonspecific competitor.  The reaction mixtures were incubated at room 
temperature for 30 min and then subjected to electrophoresis on a 7.5% (w/v) nondenaturing 
polyacrylamide gel at 150 V for 30 min.  The DNA complexes in the gel were transferred to a 
nylon membrane with a vacuum blotter.  The DIG-labeled DNA was detected and visualized 
using antidigoxigenin-antibody and the chemiluminescent substrate CDP-star (Roche Applied 
Science).  For the competition experiments, different amounts (5 and 125-fold molar excesses) of 
either unlabeled 30-bp DNA or unlabeled internal random DNA were added as competitors 
during the binding step.  The ligand binding assays were done by incubating different 
concentrations of ethidium bromide (6.4, 64, 320, 640, 1,280 µM) with the purified Rv3066 
protein for 30 min before adding the labeled ds-DNA fragments for the experiments.    
 
Dye primer based DNase I footprint assay 
The DNase I footprint assay was performed as described by Zianni et al. (25).  A 226-bp 
fragment that encompasses bases –153 to +87, including IR1 (with the sequence of IR2 
removed), of the promoter region of mmr was generated by PCR and cloned into the pGEM-
Teasy vector.  The fluorescently labeled probe was amplified using the primers 6FAM-Mmr-F 
(5'-/6FAM/TCGAGATCTTTCACCATG-3') and HEX-Mmr-R (5'-
/HEX/CAACCGAGTGAACCCTTC-3').  0.6 pmol of the gel purified fluorescently labeled 
probe was incubated with various amounts of the dimeric Rv3066 protein (0, 1.5 and 3.0 pmol) 
for 30 minutes at room temperature in a binding buffer containing 20 mM HEPES, pH 7.6, 10 
mM (NH4)2SO4, 5 mM dithiothreitol, 0.2% Tween 20 (w/v), 30 mM KCl, and 0.5 µg of Poly 
[d(I-C)].  Bovine serum albumin (BSA) was used for the control experiment.  After incubation, 
10 mM MgCl2 and 5 mM CaCl2 was added to the reaction mixture to a final volume of 50 µl. 
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Then, 0.0025 U of DNase I (Worthington Biochemicals, Lakewood, NJ) was added and 
incubated for 5 min at room temperature.  The reaction was stopped by adding 0.25 M EDTA 
and extracted with phenol-chloroform-isoamylalcohol (25:24:1).  Control digestions with the 
probe were performed in the absence of Rv3066.  The digested DNA fragments were purified 
with the QIAqick PCR Purification kit (Qiagen, Valencia, CA) and eluted in 20 µl distilled 
water. After, 4 µl of the purified DNA was mixed with 5.98 µl HiDi formamide (Applied 
Biosystems, Foster City, CA) and 0.02 µl GeneScan-500 LIZ size standards (Applied 
Biosystems).  The samples were analyzed with the 3730 DNA analyzer coupled by G5 dye set, 
using an altered default genotyping module that increased the injection time to 30 sec and the 
injection voltage to 3 kV. 
The 226-bp fragment was sequenced with the primers 6FAM-Mmr-F and HEX-Mmr-R, 
respectively, using the Thermo Sequenase Dye Primer Manual Cycle Sequencing Kit (USB, Inc., 
Cleveland, OH) according to the manufacturer’s instructions. Each reaction was diluted fivefold 
in water, and 4 µl was added to 5.98 µl HiDi formamide and 0.02 µl GeneScan-500LIZ size 
standard. The samples were analyzed using the 3730 DNA analyzer as described above. 
Electropherograms were analyzed and aligned using the GENEMAPPER software (version 4.0, 
Applied Biosystems). 
 
Cloning of the Mycobacterium tuberculosis mmr-3066 operon into Mycobacterium smegmatis 
Primer pairs (FP: CGCGGATCCATCTTTCACCATGACACGAC, RP: 
CCCAAGCTTAGGACTGGTATTCGGCGGTT) with added BamHI and HindIII sites were 
used to amplify the complete mmr-rv3066 operon (including the promoter region) from M. 
tuberculosis H37Rv genomic DNA. The amplified fragment was digested and ligated into E. 
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coli-Mycobacterium shuttle vector pMV261 (kindly provided by Susan T. Howard, The 
University of Texas Health Science Center) to construct pMMR.  pMV261 is a shuttle plasmid 
commonly used for cloning and expression of genes in mycobacteria. The cloned mmr-rv3066 
operon carried its own promoter sequence. Although there should be constitutive base-level 
expression from the vector, mmr is inducible due to the binding of drug by the regulator. The 
constructed pMMR in E. coli DH5α was then purified and electroporated into M. smegmatis 
mc2155 (ATCC700084) (26). 
 
Real-time quantitative RT-PCR (qRT-PCR) analysis of mmr induction 
M. smegmatis mc2155 strain containing pMMR was inoculated into 30 ml of antibiotic-
free 7H9 broth.  The culture was incubated for overnight to the mid logarithmic phase (OD600 ≈ 
0.6) at 37 oC. The culture was divided into three aliquots.  One aliquot was used as the non-
treated control, while the other three were added with thioridazine (80 µg/ml), erythromycin (128 
µg/ml) and ethidium bromide (10 µg/ml), respectively.  The cultures were further incubated for 1 
h at 37oC. Total bacteria RNA was isolated from the three individual cultures by the Trizol 
method (27).  RNA was further purified by Qiagen RNeasy Column (Qiagen, Valencia, CA) and 
treated with the Turbo DNA-free Kit (Life Technologies, Grand Island, NY) to eliminate DNA 
contamination in each preparation.  Before being used for qRT-PCR, each RNA template and 
each primer set were tested with a conventional one-step RT-PCR kit and a regular PCR kit (Life 
Technologies) to ensure specific amplification from the target mRNA and no detectable DNA 
contamination in the RNA preparation.  Primer pairs 3065F (5’-
CCTATACCTCTTGTGCGCGAT-3’) and 3065R (5’-CGAAAGCGATGCCATAACCC-3’), 
specific for the mmr gene were designed for qRT-PCR analyses, which were conducted using the 
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iScript one-step RT-PCR kit with SYBR green (Bio-Rad, Hercules, CA) along with the MyiQ 
iCycler real-time PCR detection system (Bio-Rad).  Triplicate reactions in a volume of 15 µl 
were performed for each dilution of the RNA template.  Thermal cycling conditions were as 
follows: 10 min at 50oC, 5 min at 60oC followed by 5 min at 95oC, and then 40 cycles of 10 s at 
95oC and 30 s at 56oC.  Melt-curve analysis was performed immediately following each 
amplification.  Samples between treatments were normalized using the aph gene which was 
located on the pMV261 vector as an internal standard.  Cycle threshold values were determined 
with the MyiQ software (Bio-Rad).  The relative changes (n-fold) in mmr transcription between 
the antibiotic treated and nontreated samples were calculated using 2-ΔΔCT method as described 
by Livak and Schmitten (28). 
 
Site-directed mutagenesis 
Site-directed point mutations on residues that are expected to be critical for the binding of 
drugs were performed to generate single point mutants, W80A, Y101A, N112A, Y115A, 
W131A and D156A, and a double-point mutant W80A-W131A.  The primers used for these 
mutations are listed in Table 2.  All oligonucleotides were purchased from (Integrated DNA 
Technologies, Inc., Coralville, IA) in a salt-free grade.  
 
Fluorescence polarization assay for the DNA binding affinity  
Fluorescence polarization assays were used to determine the DNA binding affinity of the 
Rv3066 regulator. Both the 30-bp oligodeoxynucleotide and fluorescein labeled 
oligodeoxynucleotide were purchased from Integrated DNA Technologies, Inc. (Coralville, IA). 
These oligodeoxynucleotides contain the predicted 14-bp IR1 site for Rv3066 binding. Their 
26 
 
 
sequences were 5ʹ′-CGAGCCTCCTTTGTGTACATTTGTACATGT-3ʹ′ and 5ʹ′-F-
ACATGTACAAATGTACACAAAGGAGGCTCG-3ʹ′, where F denotes the fluorescein which 
was covalently attached to the 5ʹ′ end of the oligodeoxynucleotide by a hexamethylene linker. 
The 30-bp fluoresceinated ds-DNA was prepared by annealing these two oligodeoxynucleotides 
together.  Fluorescence polarization experiment was done using a DNA binding solution 
containing 10 mM Na-phosphate (pH 7.2), 100 mM NaCl, 1 nM fluoresceinated DNA, and 1 µg 
of poly(dI-dC) as non-specific DNA. The protein solution containing 500 nM dimeric Rv3066 
and 1 nM fluoresceinated DNA was titrated into the DNA binding solution until the 
millipolarization (mP) become unchanged.  All measurements were performed at 25oC using a 
PerkinElmer LS55 spectrofluorometer equipped with a Hamamatsu R928 photomultiplier. The 
excitation wavelength was 490 nm, and the fluorescence polarization signal (in ΔP) was 
measured at 520 nm.  Each titration point recorded was an average of 15 measurements.  Data 
were analyzed using the equation, P = {(Pbound – Pfree)[protein]/(KD + [protein])} + Pfree, where P 
is the polarization measured at a given total protein concentration, Pfree is the initial polarization 
of free fluorescein-labeled DNA, Pbound is the maximum polarization of specifically bound DNA, 
and [protein] is the protein concentration. The titration experiments were repeated for three times 
to obtained the average KD value. Curve fitting was accomplished using the program ORIGIN 
(OriginLab Corporation, Northampton, MA). 
To study if the binding affinity between Rv3066 and DNA affects by ethidium, 
fluorescence polarization experiment was carried out in the presence of 1 µM ethidium.  All 
experimental procedures are the same as above, except that the protein and DNA binding 
solutions also contain 1 µM ethidium.   
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Fluorescence polarization assay for ligand binding affinity  
Fluorescence polarization was used to determine ethidium binding affinities of Rv3066 
and its mutants.  This approach was also employed to study the interaction between the Rv3066 
regulator and the anti-TB drug thioridazine.  The experiment was done using a ligand binding 
solution containing 10 mM Na-phosphate (pH 7.2), 100 mM NaCl and 1 µM ethidium bromide.  
The protein solution consisting of Rv3066 or Rv3066 mutant in 10 mM Na-phosphate (pH 7.2), 
100 mM NaCl and 1 µM ethidium bromide was titrated into the ligand binding solution until the 
polarization (P) was unchanged.  As this is a steady-state approach, fluorescence polarization 
measurement was taken after a 5 min incubation for each corresponding concentration of the 
protein and bile acid to ensure that the binding has reached equilibrium.  All measurements were 
performed at 25oC using a PerkinElmer LS55 spectrofluorometer equipped with a Hamamatsu 
R928 photomultiplier. The excitation and emission wavelengths were 483 and 620 nm for 
ethidium binding, whereas these wavelengths were 320 and 430 nm for thioridazine 
measurement.  Fluorescence polarization signal (in ΔP) was measured at the emission 
wavelength.  Each titration point recorded was an average of 15 measurements.  Data were 
analyzed using the equation, P = {(Pbound – Pfree)[protein]/(KD + [protein])} + Pfree, where P is the 
polarization measured at a given total protein concentration, Pfree is the initial polarization of free 
ligand, Pbound is the maximum polarization of specifically bound ligand, and [protein] is the 
protein concentration.  The titration experiments were repeated for three times to obtain the 
average KD value.  Curve fitting was accomplished using the program ORIGIN (OriginLab 
Corporation, Northampton, MA). 
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Gel filtration 
A protein liquid chromatography Superdex 200 16/60 column (GE Healthcare 
Biosciences, Pittsburgh, PA) with a mobile phase containing 20 mM Tris-HCl (pH 8.5) and 300 
mM NaCl was used in the gel filtration experiments. Blue dextran (Sigma-Aldrich, St. Louis, 
MO) was used to determine the column void volume, and proteins for use as gel filtration 
molecular weight standards were cytochrome C (Mr 12,400), carbonic anhydrase (Mr 29,000), 
albumin bovine serum (Mr 66,000), alcohol dehydrogenase (Mr 150,000), and β-Amylase (Mr 
200,000). All these standards were purchased from Sigma-Aldrich. The molecular weights of the 
experimental samples were determined following the protocols supplied by the manufacturers.  
 
Results 
Overall structure of Rv3066  
In the absence of inducer molecule, the Rv3066 regulator was crystallized in two 
different forms, I and II (Fig. S1).  The form I (SeMet) crystal structure was determined to a 
resolution of 2.3 Å (Table 1 and Fig. 1a).  The asymmetric unit contains a single homodimer, 
suggesting that this regulator is dimeric in nature.  Similar to LfrR (30), the left and right 
subunits of Rv3066 are asymmetrical.  The dimeric form I structure of Rv3066, indicating an all-
helical protein, is shown in Fig. 1b.  Superimposition of both subunits of Rv3066 gives rise to an 
overall rms deviation of 1.3 Å calculated over the Cα atoms.   
The crystal structure of form II was refined to a resolution of 1.8 Å (Table 1).  Like form 
I, the structure of form II indicates that this protein is an asymmetric homodimer.  
Superimposition of the Cα atoms of the two subunits of form II results in an rms deviation of 1.8 
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Å.  Surprisingly, the conformations of the structures of forms I and II are quite distinct from each 
other, suggesting that these two structures probably represent two different transient states of the 
regulators.  Superimposition of the entire dimer of these two apo-Rv3066 structures (forms I and 
II) provides an rms deviation of 3.0 Å (Fig. 2).  Overall, the architecture of these two Rv3066 
structures are in good agreement with those of the homolog proteins TetR (31, 32), QacR (33, 
34), CprB (35), EthR (36, 37), CmeR (38), AcrR (39), SmeT (40) and LfrR (30).  Each subunit 
of Rv3066 is composed of nine α helices (α1-α9 and α1ʹ′-α9ʹ′, respectively) (Figs. 1b and 2) and 
can be divided into two motifs: an N-terminal DNA-binding domain and a C-terminal ligand-
binding domain.  The helices of Rv3066 are designated numerically from the N-terminus as α1 
(15-30), α2 (37-44), α3 (48-54), α4 (58-86), α5 (90-103), α6 (105-120), α7 (122-143), α8 (145-
165), and α9 (171-182).  In this arrangement, the smaller N-terminal domain includes helices α1 
through α3 and the N-terminal end of α4 (residues 58-68), with α2 and α3 forming a typical 
helix-turn-helix motif.  However, the larger C-terminal domain comprises the C-terminal end of 
helices α4 (residues 69-86) through α9, and helices α6, α8 and α9 are involved in the 
dimerization of the regulator.  The smaller N-terminal domain shares considerably high sequence 
and structural similarities with the TetR-family regulators, suggesting that Rv3066 belongs to the 
TetR family.  For example, residues 13-68 possess 20% amino acid identity and 68% homology 
to that of TetR (31). This N-terminal region also shows identities of 29% and 25%, and 
similarities of 62% and 63% to those of the M. smegmatis LfrR (30) and M. tuberculosis EthR 
repressors (37), respectively.  Protein sequence alignment of Rv3066 with the TetR-family 
members of other Mycobacterium species is shown in Fig. S2.  The alignment suggests that 
Rv3066 is a typical TetR-family regulator. 
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Conformational flexibility of the Rv3066 regulator 
Two distinct conformations of apo-Rv3066 were captured using crystallography, 
suggesting that this regulatory protein is quite flexible in nature.  A comparison of the N-terminal 
DNA-binding domains of the dimeric structures of forms I and II indicates that these two 
structures may depict two different transient states of the regulator.  Apparently, these two 
conformations are related in which an 8o rotational motion of the right subunit (helices α1ʹ′-α9ʹ′) 
with respect to the left protomer (helices α1-α9) is attributed to the difference (Fig. S3).  Indeed, 
we can easily generate the form II conformation using the form I structure as a starting point and 
then following the rigid-body rotational trajectory based on the TLS 
(translation/Libration/Screw) parameters.  The resulting final B-factors and overall R-factor/R-
free of this form II dimeric Rv3066 structure are 24.0 Å2/22.9 Å2 (left/right subunits) and 
21.4%/25.5%, respectively.  Thus, there is a chance that ligand binding triggers a rotational 
motion within the dimer of the regulator.  Presumably, this movement prohibits the binding of 
the dimeric regulator at its cognate DNA, which in turn releases the regulator from the promoter 
region and allows for the expression of the Mmr efflux pump. 
The C-terminal domain of the form II structure forms a large cavity, presumably creating 
a ligand-binding pocket of the regulator (Fig. S4). This cavity cannot be found in the form I 
structure.  Thus, it is likely that the form II crystal structure mimics the ligand-bound form of 
Rv3066.  The pocket, predominately formed by helices 5-8, opens horizontally from the side of 
each protomer. The total volume of these two binding pocket is about 540 Å3 (230 Å3 for the left 
subunit and 310 Å3 for the right subunit).  
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Helices α4-α6 of each subunit of form II make the entrance of the binding pocket, with 
residues V100, D104 and Y108 participating to form this entrance.   
 
Structure of the Rv3066-ethidium complex 
 The crystal structure of the Rv3066-ethidium complex (Figs. 3 and S5) was refined to a 
resolution of 2.3 Å (Table 1), revealing that ethidium indeed binds within the ligand-binding 
pocket formed by the C-terminal domain.  Helices 5-8 contribute to form this pocket, and each 
subunit of Rv3066 is found to bind an ethidium molecule within the binding pocket.  
Superimposition of the dimeric Rv3066-ethidium structure to those of forms I and II apo-Rv3066 
result in overall rms deviations of 3.4 and 1.9 Å, respectively.  
Although the conformations of the two subunits within the dimer are not identical, their 
ethidium binding modes are quite similar.  Both ethidium sites utilize the same set of amino 
acids to accommodate the binding, with a slight difference in the interaction distances.  The Fo - 
Fc electron density maps of the two bound ethidiums within the dimer are illustrated in Fig. 4a.  
Interestingly, the total volume of the two ligand-binding pocket has expanded to 929 Å3 (443 Å3 
for the left subunit and 486 Å3 for the right subunit) in the ethidium bound structure.   
 Each bound ethidium molecule is completely buried in the Rv3066 binding pocket.  The 
ligand binding pocket is found to be hydrophobic in nature.  Five aromatic residues, W80, Y101, 
Y115, W131 and F155, participate to make aromatic stacking interactions and hydrophobic 
contacts with the bound ethidium (Figs. 4b, 4c and S6).  In addition, L76, T98, L111 and T159 
are involved to secure the binding through hydrophobic interaction.  Further, the N1 and N2 
amino group nitrogen of the phenanthridinium system of ethidium is hydrogen bonded to the side 
chain oxygen of T159 and S73 respectively (Table 3).  Additional hydrogen bonds have also 
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been found between the N1 and N2 amino group nitrogens of the bound ethidium and the 
backbone oxygens of F155 and S73 to secure the binding (Table 3).  In addition, a negatively 
charged residue D156 participates to form the ligand binding site, and this residue is ~3.3 Å 
away from the phenyl groups of the bound ethidium in each subunit of the dimer (Figs. 4b and 
S6).  
 
Electrophoretic mobility shift assay 
Bacterial multidrug efflux regulators usually bind to the palindromic IR sequences at the 
promoter regions to control the expression of the multidrug efflux pumps.  In the mmr-rv3066 
operon, it appears that there are two 14-bp palindromic IR sequences located upstream of mmr.  
These two IRs (IR1 and IR2) are located right next to one another, where their sequences are 
complementary to each other (Fig. S7).  The sequences of IR1 and IR2 are 5ʹ′-
TGTACATTTGTACA-3ʹ′ and 5ʹ′-TGTACAAATGTACA-3ʹ′, respectively.  The presence of 
these IRs suggests potential binding sites for the Rv3066 regulator.  Thus, EMSA was performed 
using a 30-bp double-stranded DNA containing the IR1 sequence and purified Rv3066 protein to 
detect if the regulator specifically binds IR1.  As shown in Fig. 5a and b, the shift of the labeled 
DNA band was dependent upon the protein concentration as well as the addition of the unlabeled 
specific 30-bp double-stranded DNA.  The data indicate that the IR1 sequence potentially forms 
the specific binding site for Rv3066.  
EMSA was further performed with the purified Rv3066 protein and 30-bp DNA fragment 
containing the IR1 site in the presence of ethidium, which is a substrate of the Mmr efflux pump 
and is found to be bound in the ligand binding site of the Rv3066 regulator.  As shown in Fig. 5c, 
the addition of ethidium to the Rv3066-DNA complex resulted in the loss of the retarded band, 
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indicating the separation of the protein and DNA components.  The result suggests that ethidium 
is a substrate of Rv3066 and that the binding of ethidium triggers significant conformational 
change to the regulator, which in turn renders it unable to bind its cognate operator DNA.  
 
Dye primer based DNase I footprint assay 
To further confirm the binding site of Rv3066 in the mmr-rv3066 promoter region, 
DNase I footprint assay was performed using the method of dye primer sequencing (25).  In 
comparison with different electropherograms at various concentrations of the dimeric Rv3066 
protein, we were able to uncover the specific DNA sequence, 
TTGTGTACATTTGTACACAAAGG, which was protected by the regulator (Figs. 6 and S8).  
Interestingly, the IR1 sequence (TGTACATTTGTACA) was found within this protected 
region, suggesting that Rv3066 is likely to specifically bind IR1. 
 
Impact of drugs on mmr transcription in Mycobacterium smegmatis 
We cloned the mmr-rv3066 operon into M. smegmatis to assess its function and induction 
by antimicrobials.  It has been reported that the anti-TB drug thioridazine was used to cure 10 
XDR-TB patients (41).  Thus, this drug was chosen to investigate its effect on the expression of 
the Mmr multi-drug efflux pump using qRT-PCR.  We also studied the effect of ethidium and 
erythromycin on mmr transcription using the same approach.  After 1 h induction with 
thioridazine, the mmr gene was up-regulated by 2.70 ± 0.09 fold (p value = 0.0001).  No obvious 
induction of the mmr gene was observed in the presence of ethidium or erythromycin at the same 
time-point.  
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Fluorescence polarization assay 
Presumably, Rv3066 suppresses the expression of the Mmr multidrug efflux pump by 
directly binding to its target DNA.  Fluorescence polarization-based assay was carried out to 
study the interaction between Rv3066 and the 30-bp DNA containing the IR1 sequence.  Fig. 7a 
illustrates the binding isotherm of Rv3066 in the presence of 1 nM fluoresceinated DNA.  The 
titration experiment indicated that this regulator binds the 30-bp IR1 operator with a dissociation 
constant, KD, of 4.4 ± 0.3 nM. This value is similar to that of the QacR regulator where it binds 
DNA with the KD of 5.7 nM  (42).  The binding data also indicate that Rv3066 binds its cognate 
DNA with a stoichiometry of one Rv3066 dimer per IR1. 
  To investigate whether the presence of ethidium affects the binding of Rv3066 with IR1, 
fluorescence polarization was also carried out to study the interaction between Rv3066 and IR1 
in the presence of this drug.  The experimental results suggest that the KD of Rv3066-IR1 
becomes 10.7 ± 0.9 nM in the presence of 1 µM ethidium (Fig. S9), indicating that ethidium 
significantly weakens the binding affinity between Rv3066 and IR1 by 2.4 times.   
In addition, fluorescence polarization was used to determine the binding affinity of 
ethidium and the anti-TB drug thioridazine by Rv3066.  The measurements indicate that the KD 
values of the Rv3066-ethidium and Rv3066-thioridazine complexes are 2.9 ± 0.2 and 211.8 ± 
34.2 µM, respectively (Fig. 7b and c). These binding data suggest that the protein employs a 
simple binding stiochiometry with a 1:1 monomeric Rv3066-to-drug molar ratio.  This molar 
ratio is indeed in good agreement with the crystal structure where each monomer of Rv3066 
binds one ethidium molecule.  
The structure of Rv3066-ethidium indicates that residues W80, Y101, N112, Y115, 
W131 and D156 are involved in ligand binding.  These residues were mutated into alanines 
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(W80A, Y101A, N112A, Y115A, W131A and D156A).  The corresponding mutant regulators 
were then expressed and purified.  The ability of these mutant regulators to bind ethidium was 
tested using fluorescence polarization assay (Table 4).  The results demonstrate that several of 
these point mutants show a significant decrease in the binding affinity for ethidium when 
compared with the wild-type Rv3066 regulator.  Particularly, mutant D156A increases the 
dissociation constant, KD, of ethidium binding by 20-fold, suggesting that D156 is a critical 
residue in the multidrug binding site of Rv3066.  Moreover, mutants W80A, N112A and W131A 
decrease the affinity for ethidium binding by 3-4 times.  A double-point mutant W80A-W131A 
was then produced to investigate how these tryptophans affect the binding of ethidium.  Similar 
to the D156A mutant, the W80A-W131A double mutant indicates a significantly weaker binding 
affinity (20-fold decrease) when compared with that of the wild-type Rv3066, suggesting these 
two tryptophans, W80 and W131, are important residues for drug recognition.        
 
Gel filtration 
To confirm the stiochiometry of one Rv3066 dimer bound to one IR1 operator site, gel 
filtration experiment was performed using the purified Rv3066 protein pre-incubated with the 
purified, complementary, annealed 30-bp oligonucleotides containing the IR1 sequence.  The 
result suggests an average molecular weight of 67.3 ± 3.8 kDa for the Rv3066-DNA complex 
(Fig. 8). This value is in good agreement with the theoretical value of 66.0 kDa for two Rv3066 
molecules bound to the 30-bp DNA. Thus, the stoichiometry of the Rv3066-IR1 complex is 1:1 
dimeric Rv3066-to-DNA molar ratio.   
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Discussion 
With the rising incidences of multidrug resistant strains of TB, it has become increasingly 
important to understand how individual proteins function to recognize and confer resistance to 
multiple antibiotics in this pathogen.  The crystal structures of Rv3066 both in the absence and 
presence of the bound ethidium provide direct information about how this regulator controls the 
expression of the Mmr multidrug efflux pump, which mediates the resistance of several 
antimicrobial agents.  It appears that ethidium binding triggers a series of cooperativity motions 
of the C-terminal helices, including the horizontal shifts of helices α5, α6 and α7 toward the 
dimer interface, and an upward movement of helix α8 within one subunit of the regulator.  These 
conformational changes initiate a rotational motion of the second subunit of Rv3066 with respect 
to the horizontal axis passing through the two ligand-binding pockets of the dimer (Figs. 3b, 5a 
and 5b), presumably making the relative orientation of the two N-terminal DNA-binding 
domains no longer compatible with the two consecutive major grooves of the operator B-DNA.  
The net result is that this dimeric regulator is released from the promoter, initiating the 
expression of the Mmr multidrug efflux pump. 
By comparing with the apo-Rv3066, Rv3066-ethidium structures, it appears that the 
induction mechanism of Rv3066 seems to be attributed to the rigid body rotational motion of the 
two subunits triggered by ethidium binding (Fig. 5c).  As mentioned above, this motion changes 
the relative orientation of the two DNA-binding domains of Rv3066, which makes the dimer 
incompatible with the two successive major grooves of the IR and results in disallowing the 
regulator to bind the DNA duplex.  This induction mechanism is quite distinct from those of 
QacR (33, 34) and TetR (31, 32).  However, a similar induction mechanism, which is triggered 
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by the movement as rigid bodies, can be found in the SimR regulator (43), where rigid body 
rotation within subunits of the dimer in relation to one another contributes to the induction. 
In comparison with the form I and ethidium bound structures, the shift in position of 
helices α5, α6 and α7 toward the dimer interface results in the formation of four new hydrogen 
bonds.  These hydrogen bonds are found within the dimer interface between H120 and R109ʹ′, 
and between R121 and Q113ʹ′.  In addition, the backbone oxygens of R129 and T165 also 
contribute to the dimer interface.  These backbone oxygens interact with I164ʹ′ and R129ʹ′ to form 
two hydrogen bonds.  The formation of these new hydrogen bonds is presumed to stabilize the 
tertiary structure of the ligand bound form of the Rv3066 dimer.     
Coupled with the movements of these C-terminal helices, residues located at the binding 
site are also found to readjust their positions to accommodate for the binding of ethidium.  
Noticeably, Y115 shifts upward by 2.4 Å presumed to make an interaction with the phenyl group 
of the bound ethidium, whereas F155 is found to swing upward by 90o to enlarge the volume of 
the binding site.  In addition, W131 adjusts its position to shift upward by 2.3 Å and makes an 
aromatic stacking interaction with the three-ring system of the phenanthridinium group of 
ethidium.  W80 and Y101 also slightly switch in location by 1.1 and 2.0 Å to contribute aromatic 
π-π and stacking interactions with the bound ligand (Fig. 4c).  One common characteristic of 
multi-drug binding proteins is their flexibility to accommodate for different ligands in a single 
ligand-binding pocket.  This plasticity and flexibility can easily be seen in the Rv3066 regulator 
in which many of these residues lining the binding site are found to participate and relocate their 
side chain positions upon ethidium binding.  
A distinguishing feature of multidrug binding proteins that bind cationic drugs is the 
presence of buried acidic glutamates or aspartates in the ligand binding pockets.  This was 
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clearly demonstrated by the structures of the QacR-ligand complexes (33).  Indeed, a completely 
buried negatively charged aspartate, which is essential for cationic ligand recognition, has also 
been found in the ligand-binding pocket of the AcrR multidrug efflux regulator (39).  A similar 
characteristic for the TetR-family regulators that recognize negatively charged antimicrobials has 
also been observed through x-ray crystallography (38, 44).  In this case, positively charged 
histidines or lysines within the ligand-binding pockets are critical for interacting with the 
negatively charged drugs.  For Rv3066, it is found that there is one negatively charged residue 
(D156) inside the multidrug binding pocket.  D156 is critical for ethidium binding as shown 
using fluorescence polarization and mutagenesis studies, although this residue does not seem to 
contribute a significant electrostatic interaction to the cationic ligand.  A mutation of D156 with 
an alanine drastically decreases the Rv3066-ethidium binding affinity by 20-fold.  Instead of 
contributing hydrogen-bonded interaction to neutralize the formal positive charge of the bound 
ethidium, the D156 residue, together with N112, is responsible for forming hydrogen bonds with 
the aromatic residues, Y101, Y115 and W131 (Fig. 4b).  These three residues, in addition to 
W80, form an aromatic cage-like binding pocket to position the bound ethidium (Fig. S6), 
suggesting that D156 is important for the organization of the ligand binding site.  The importance 
of the cage-like arrangement of these aromatic residues to bind ethidium is further demonstrated 
using mutagenesis and fluorescence polarization studies, in which the W80-W131 double mutant 
has been found to bind ethidium 20 times weaker than the wild-type Rv3066.  
It is found that the Rv3066 dimer binds two drug molecules, with each subunit of the 
regulator contributing to bind one drug.  Gel filtration experiment confirmed that the Rv3066-
IR1 complex should be in the form of 1:1 dimeric Rv3066-to-DNA molar ratio.  Real-time 
quantitative RT-PCR analysis suggested that the mmr gene was significantly up-regulated by 
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thioridazine induction.  This result is indeed in good agreement with a recent finding that the 
treatment of thioridazine on M. tuberculosis causes a profound increase in the expression of the 
Mmr multidrug efflux pump (12).  The structures of the Rv3066 regulator both in the absence 
and presence of bound ethidium, together with the experimental data from electrophoretic 
mobility shift, footprinting analysis, qRT-PCR, mutagenesis, gel filtration and fluorescence 
polarization, support the role of Rv3066 in regulating the expression level of the multidrug efflux 
pump Mmr in M. tuberculosis.  
  
Protein data bank accession codes 
Coordinates and structural factors for the structures of Rv3066 have been deposited at the 
RCSB Protein Data Bank with accession codes 3T6N (form I, apo-Rv3066), 3V6G (form II, apo-
Rv3066), and 3V78 (Rv3066-ethidium). 
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Table and figure legends 
Table 1.  Data collection, phasing and structural refinement statistics. 
!
 Form I Form II Rv3066-ethidium 
Data Collection    
   Wavelength (Å) 0.978 0.978 0.978 
   Space group P21212 P21212 P3121 
   Cell constants(Å) a=78.7, b=118.9, 
c=42.1 
a=91.4, b=119.9, 
c=30.9 
a=99.1, b=99.1, 
c=66.5 
   Resolution(Å) 2.32 (40.00-2.32) 1.83 (40.00-1.83) 2.30 (40.0-2.30) 
   Completeness (%) 99.9 (99.9) 96.0 (98.4) 100.0 (99.6) 
   Total no. of        
     reflections 
556,100 524,555 670,642 
   No. of unique  
     reflections 
17,973 31,246 17,079 
   Redundancy 2.4 (2.5) 2.7 (2.9) 3.1 (3.2) 
   Rmerge (%) 36.4 (7.7) 39.8 (4.9) 36.4 (5.7)    (I/σ(I)) 2.17 (11.65) 2.08 (23.47) 2.94 (26.33) 
Phasing    
   Selenium atom sites 2   
   Resolution range of  
     data used (Å) 
40.00-2.32   
   Figure of merit      
     (acentric/centric) 
56.1/42.4   
Refinement    
   Rwork (%) 20.28 20.40 20.59 
   Rfree (%) 27.06 24.71 26.16    B-factors    
      Overall (Å2) 38.5 24.6 48.0 
      Protein chain A/B   
        (Å2) 
39.0/36.9 25.8/23.3 45.8/50.3 
      Ligand chain A/B   
        (Å2) 
- - 37.0/36.6 
      Water   (Å) 39.2 29.3 41.1 
   No. of atoms in    
      protein chain A/B 
 
1,329/1,329 
 
1,321/1,321 
 
1,322/1,329 
   No. of ligands 0 0 2 
   No. of waters 77 67 64 
Rms deviations    
   Bond angles (°) 1.1 0.9 1.0 
   Bond length (Å) 0.008 0.007 0.008 
Ramachandran analysis    
   Most favored regions  
     (%) 
94.9 94.3 94.2 
   Allowed regions (%) 5.1 5.7 5.8 
   Generously allowed  
     regions (%) 
0.0 0.0 0.0 
   Disallowed regions  
     (%) 
0.0 0.0 0.0 
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Table 2.  Primers for site-directed mutagenesis. 
W131A-forward 5'-GTCTGGCTCGTCTGGCGCCGGATGGTCTGC-3' 
W131A-reverse 5'-GCAGACCATCCGGCGCCAGACGAGCCAGAC-3' 
S73A-forward 5'-CATGCCGCAAATGCAGCCGCAGAT-3' 
S73A-reverse 5'-ATCTGCGGCTGCATTTGCGGCATG-3' 
T159A-forward 5'-GTTTTTCGACGGCGCCGCGCTGCACGCACTG-3' 
T159A-reverse 5'-CAGTGCGTGCAGCGCGGCGCCGTCGAAAAAC-3' 
Y101A-forward 5'-CGTCTGACCACGGTCGCACTGGCAGATCAGGAC-3' 
Y101A-reverse 5'-GTCCTGATCTGCCAGTGCGACCGTGGTCAGACG-3' 
Y115A-forward 5'-CACCCTGAACGAACTGGCAATGGCGGCCGCACATC-3' 
Y115A-reverse 5'-GATGTGCGGCCGCCATTGCCAGTTCGTTCAGGGTG-3' 
W80A-forward 5'-CTGCTGGCCCAGGCGCGTTCTGATCTG-3' 
W80A-reverse 5'-CAGATCAGAACGCGCCTGGGCCAGCAG-3' 
D156A-forward 5'-GTCACCGTGTTTTTCGCAGGCGCCACGCTGCAC-3' 
D156A-reverse 5'-GTGCAGCGTGGCGCCTGCGAAAAACACGGTGAC-3' 
N112A-forward 5'-CGTTACCGCACCCTGGCAGAACTGTATATGGC-3' 
N112A-reverse 5'-GCCATATACAGTTCTGCCAGGGTGCGGTAACG-3' 
!
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Table 3.  Rv3066-ethidium contacts.  Contacts within 4.8 Å of the bound ethidiums are listed. 
! Distance)(Å)!
Residue0ligand)contacts! A!chain! B!chain!
S73! 2.7a! 2.7a!
S73)(backbone)oxygen)! 2.9a! 2.9a!
L76! 3.1! 3.6!
W80! 3.6! 3.7!
T98! 3.5! 3.5!
Y101! 3.4! 3.5!
L111! 4.6! 4.3!
N112! 3.5! 3.2!
Y115! 3.3! 3.4!
W131! 3.0! 3.0!
F155) 3.9! 3.8!
F155)(backbone)oxygen)! 2.9a! 2.7a!
D156! 3.3! 3.3!
T159! 2.9a! 2.7a!
!  
Table 4.  Dissociation constants for ethidium binding. 
 KD (µM) 
Wild-type Rv3066 2.9 ± 0.2 
W80A 8.5 ± 0.6 
Y101A 2.1 ± 0.2 
N112A 10.3 ± 0.7 
Y115A 6.1 ± 0.6 
W131A 12.9 ± 1.0 
D156A 41.0 ± 5.9 
W80A-W131A 43.2 ± 5.2 
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Figure 1.  Stereo view of the experimental density map and ribbon diagram of the crystal 
structure of Rv3066. (a) Representative section of electron density in the vicinity of helices α5 
and α8. The solvent-flattened electron density (40-2.3 Å) is contoured at 1σ and superimposed 
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with the final refined model (magenta, carbon; red, oxygen; blue nitrogen). (b) Ribbon diagram 
of the Rv3066 dimer. Helices α1-α9 (left subunit) and α1ʹ′-α9ʹ′ (right subunit) are labeled.  The 
Figure was prepared using PyMOL (http://www.pymol.sourceforge.net). 
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Figure 2.  Structural comparison of forms I and II of the Rv3066 regulator.  This is a 
superimposition of the dimeric structures of forms I and II (orange, form I; blue, form II).  
Helices α1-α9 (left subunit) and α1ʹ′-α9ʹ′ (right subunit) are labeled.  The arrow indicates a 
change in orientation of the right subunit of form II when compared with the structure of form I. 
49 
 
 
 
50 
 
 
Figure 3.  Crystal structure of the Rv3066-ethidium complex.  (a) Ribbon diagram of the 
Rv3066-ethidium complex.  The bound ethidiums are shown as sticks (magenta, carbon; blue, 
nitrogen).  (b) Structural comparison of form I and Rv3066-ethidium.  This is a superimposition 
of the dimeric structures of form I (orange) and Rv3066-ethidium (green).  The bound ethidiums 
are in yellow sticks.  Helices α1-α9 (left subunit) and α1ʹ′-α9ʹ′ (right subunit) are labeled.  The 
arrow indicates a change in orientation of the right subunit of dimeric Rv3066-ethidium when 
compared with the form I structure.  This conformational change can be interpreted as a 
rotational motion of the right subunit of Rv3066 with respect to the horizontal axis passing 
through the two ligand-binding pockets of the dimer upon ethidium binding.  
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Figure 4.  Electron density maps and the ethidium binding site.  (a) Stereo view of the Fo – Fc 
electron density map of the bound ethidium in the left subunit of dimeric Rv3066 (the orientation 
corresponds to Fig. 3a).  The bound ethidium is shown as a stick model (magenta, carbon; blue, 
nitrogen).  The Fo – Fc map is contoured at 3.0 σ (blue mesh).  The surrounding secondary 
structural elements are shown as yellow ribbons.  (b) The ethidium-binding site of the left 
subunit of the dimeric Rv3066-ethidium complex.  Residues involved in ethidium binding are in 
green sticks.  The bound ethidium is shown as yellow sticks.  Dotted lines depict the hydrogen 
bonds.  (c) Superimposition of the ligand-binding pocket before and after ethidium binding.  
Residues involved in ethidium binding are shown as sticks (orange, form I; green, Rv3066-
ethidium). 
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Figure 5.  Electrophoretic mobility shift assay for Rv3066 and IR1 binding.  (a) The DIG-11-
dUTP-labeled DNA (0.02 µM) was incubated with increasing concentrations (0, 0.04, 0.16 and 
0.64 µM) of the purified Rv3066 protein (lanes 1-4, respectively).  With Rv3066 at 0.64 µM, the 
binding was competed by the unlabeled 30-bp DNA (0.10 and 2.50 µM, lanes 5 and 6, 
respectively), and unlabeled internal random DNA fragment (0.10 and 2.50 µM, lanes 7 and 8, 
respectively).  (b) Control experiment of EMSA.  The control experiments were performed using 
0.02 µM labeled internal random DNA with different concentrations of the Rv3066 regulator (0, 
0.64 and 1.28 µM, lanes 1, 2 and 3, respectively).  (c) Ethidium bromide dissociates the Rv3066-
IR1 complex.  Different concentrations (0, 6.4, 64, 320 and 1,280 µM) of ethidium bromide were 
incubated with 0.64 µM of purified Rv3066 (lanes 2-7, respectively) for 30 min before adding 
the DIG-11-dUTP-labeled 30-bp DNA (0.02 µM) for the assays.  Lane 1 indicates the signal of 
the free DIG-11-dUTP-labeled DNA. 
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Figure 6.  Direct binding of Rv3066 to the mmr-rv3066 promoter by dye primer based DNase I 
footprint assay.  Electropherograms indicating the protection pattern of the mmr-rv3066 
promoter after digestion with DNase I following incubation with (a) 0, (b) 1.5 pmol, and (c) 3.0 
pmol of dimeric Rv3066 are shown.  The protected DNA sequence 
TTGTGTACATTTGTACACAAAGG containing IR1 is also shown. 
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Figure 7.  Representative fluorescence polarization of Rv3066.  (a) The binding isotherm of 
Rv3066 with the 30-bp DNA containing the IR1 sequence, showing a KD of 4.4 ± 0.3 nM.  (b) 
The binding isotherm of Rv3066 with ethidium, showing a KD of 2.9 ± 0.2 µM.  (c) The binding 
isotherm of Rv3066 with thioridazine, showing a KD of 211.8 ± 34.2 µM.  Fluorescence 
polarization is defined by the equation, FP = (V – H) / (V + H), where FP equals polarization, V 
equals the vertical component of the emitted light, and H equals the horizontal component of the 
emitted light of a fluorophore when excited by vertical plane polarized light.  FP is a 
dimensionless entity and is not dependent on the intensity of the emitted light or on the 
concentration of the fluorophore.  mP is related to FP, where 1 mP equals one thousandth of a 
FP. 
Rv3066&IR1)complex)
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Figure 8.  Representative gel filtration experiment. The experiment demonstrated that two 
Rv3066 molecules are bound to one 30-bp DNA containing the IR1 operator. The y-axis values 
were defined as: Kav = (Ve – V0)/(VT – V0), where VT, Ve, and V0 are the total column volume, 
elution volume, and void volume of the column, respectively. Standards used were: A, 
cytochrome C (Mr 12,400); B, carbonic anhydrase (Mr 29,000); C, albumin bovine serum (Mr 
66,000); D, alcohol dehydrogenase (Mr 150,000); and E, β-Amylase (Mr 200,000). The void 
volume was measured using blue dextran (Mr 2,000,000). 
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Supplementary data 
Supplementary Figures 
(a) (b) 
(c) 
 
Fig. S1.  Packing diagrams of the Rv3066 crystals.  (a) Packing diagram of the form I crystal 
viewed along the c axis.  The two subunits of one of the dimeric Rv3066 are colored green and 
magenta.  The rest of the other dimers are colored gray.  (b) Packing diagram of the form I 
crystal viewed along the c axis.  The two subunits of one of the dimeric Rv3066 are colored 
green and magenta.  The rest of the other dimers are colored gray.  (c) Packing diagram of the 
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form I crystal viewed along the c axis.  The two subunits of one of the dimeric Rv3066 are 
colored blue and magenta.  The rest of the other dimers are colored gray. 
M. tuberculosis H37Rv Rv3066 (NP_217582.1)    1 MTAGSDRRPRDPAGRRQAIVEAAERVIARQGLGGLSHRRVAAEANVPVGSTTYYFNDLDALREAALAHAANASAD 75 
M. kansasii ATCC12478 ZP_04749354.1           1 MTAEPHRRPRDPVGRRQAIIEAAGRVIARHGLGELTHRRVAAEADVPVGSTTYYFSDLGTLREAALAHAATSAAD 75 
M. ulcerans Agy99 YP_907070.1                 1 MTREVERRPRDPAGRRQTIIEAAGRLIARHGLGDLTHRRVAAEADVPVGSTTYYFSDLGELREAALAHVATSATD 75 
M. sp MCS YP_641729.1                         1 MLIVTAAVTPKGERRRYALVSAAADLLCEGGFDAVRHRAVARRAGLPLASTTYYFSSLDDLIVKAVEYEGSREAE 75 
M. sp JLS YP_001073208.1                      1 MLIVTAAVTPKGERRRYALVSAAADLLCEGGFDAVRHRAVARRAGLPLASTTYYFSSLDDLIVKAVEYEGSREAE 75 
M. vanbaalenii PYR-1 YP_955925.1              1 ---MTAAVTPKGERRRYALVSAAADLLCEGGFDAVRHRAVARRAGLPLASTTYYFSSLDDLIAKAVEHVGTRESE 72 
M. gilvuM PYR GCK YP_001132880.1              1 MLKVTAAVTPKGERRRYALVSAAADLLCEGGFDAVRHRAVARRAGLPLASTTYYFSSLDDLIANAVEHVGSRETE 75 
M. phlei RIVM601174 ZP_09976328.1             1 MLVVTAAVTPKGERRRYALVSAAADLLCEGGFDAVRHRAVARRAGLPLASTTYYFSSLDDLIARAVEHVGEREAE 75 
                                                        . .   ** :::.**  ::.. *:. : ** ** .*.:*:.******..*. *   *: : .   :: 
 
M. tuberculosis H37Rv Rv3066 (NP_217582.1)   76 LLAQWRSDLDKDRDLAATLARLTTVYLADQDR-------YRTLNELYMAAAHRPELQRLAR----LWPDGLLALL 139 
M. kansasii ATCC12478 ZP_04749354.1          76 WLEQWRRDLDRAADLPVTLARLTAEYLTDPDR-------HRTLSELYVAASHRPELQSLAR----LWPEGLVALL 139 
M. ulcerans Agy99 YP_907070.1                76 WLEHWERDLDESTDIPATLARLTADYLTDPDR-------HRTLNELYVAASHQPELQSLAQ----LWSDGLVALL 139 
M. sp MCS YP_641729.1                        76 RLQQRVAALSRRRRGAEATADVLVDLLLGDAPGTRGGEELISRYERYIACARQPALRDAQRRILRQRTDAVVAVM 150 
M. sp JLS YP_001073208.1                     76 RLQQRVAALSRRRRGAEATADVLVDLLLGDAPGTRGGEELISRYERYIACARQPALRDVQRRILRQRTDAVVAVM 150 
M. vanbaalenii PYR-1 YP_955925.1             73 QLRTRVETLSRRRRGAESTADIIVDLLVGDNP-ERVTEQIISRYERYIACARQPGLRDIQRRILRQRSDAVVEVV 146 
M. gilvuM PYR GCK YP_001132880.1             76 QLRHRVAALSRRRRGAESTADILVDLLVGDNP-ERVTEQMISRYERYIACARQPGLRDIQRRILRQRSDAVVEVV 149 
M. phlei RIVM601174 ZP_09976328.1            76 QLRARVAMLSRRRRGAESTADILVDLLVEEAAGQRASEQLISRYERYIACARHPMLRDIQRRILRQRTEAVIEVV 150 
                                                 *      *..    . : * : .  *              :  * *:*.:::* *:   :      .:.:: :: 
 
M. tuberculosis H37Rv Rv3066 (NP_217582.1)  140 EPR---IGRRAANAVTVFFDGATLHALIT-G---TPLSTDELTDAIARLVADGPEQREVGQSAHAGRTPD 202 
M. kansasii ATCC12478 ZP_04749354.1         140 EPR---IGRRAAEAVTVFLDGATVHSLIT-G---TPLSVEALTDAVARLAADP----------------- 185 
M. ulcerans Agy99 YP_907070.1               140 EPR---IGPRAARVVSIFLDGATLHAMIS-D---TPLDAPALTDAIARLVGNDTGTPGSR---------- 192 
M. sp MCS YP_641729.1                       151 ERSGRTVRADFLTALVCAVDGAVVAALVGDGDGPRATARATLIDVIDVLAPVG----------------- 203 
M. sp JLS YP_001073208.1                    151 ERSGRTVRADFLTALVCAVDGAVVAALVGDGDGPRATARATLIDVIDVLAPVG----------------- 203 
M. vanbaalenii PYR-1 YP_955925.1            147 ERSGRSVRTELVTALVCAVDGAVVAALVGDGEGPRATARATLIDVIDVLAPFN----------------- 199 
M. gilvuM PYR GCK YP_001132880.1            150 ERSGRSVRAELVTALVCAVDGAVVAALVGDGDGPRATARATLIDVIDVLAPFN----------------- 202 
M. phlei RIVM601174 ZP_09976328.1           151 ERSGRAVRPEYVNALVNAVDGAVVAALVSDGAGPRASARATLIEVIDVLAPIDERVAQV----------- 209 
                                                *     :      .:   .***.: :::  .    .     * :.:  *.                          
!  
Fig. S2.  Alignment of amino acid sequences of the TetR-type regulators of different 
Mycobacterium species using CLUSTAL W.  *, identical residues; :, >60% homologous 
residues.  The alignment suggests that these full-length regulators only share 16% identity and 
44% similarity.  However, the N-terminal DNA-binding domains of these regulators possess 
40% identity and 79% homology.  
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Fig. S3.  Side view of the superimposition of the dimeric structures of forms I and II (orange, 
form I; blue, form II).  This view depicts an 8o rigid body rotation of the right subunit (α1ʹ′-α9ʹ′) 
of form II with respect to that of form I.  
 
Fig. S4.  The hydrophobic binding pocket of form II of apo-Rv3066.  This pocket was calculated 
using the program CAVER (http://loschmidt.chemi.muni.cz/caver).  The binding tunnel on each 
subunit of Rv3066 is colored gray. 
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Fig. S5.  Structural comparison of form I and Rv3066-ethidium.  (a) Side view of the 
superimposition of the dimeric structures of form I and Rv3066-ethidium (orange, form I; green, 
ethidium bound).  This view depicts a 10o rigid body rotation of the right subunit (α1ʹ′-α9ʹ′) of 
Rv3066-ethidium with respect to that of form I.  (b) Superimposition of the N-terminal domains 
of form I and Rv3066-ethidium.  The secondary structural elements are shown as ribbons 
(orange, form I; green, Rv3066-ethidium).  (c) A schematic representation illustrating the rigid-
body rotation of the subunits relative to one another.  This side view demonstrates a 10o rotation 
of the right subunit of Rv3066 with respect to the left one after ethidium binding.  
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Fig. S6.  The ethidium binding pocket and electron density map of the right subunit of dimeric 
Rv3066.  This 2Fo - Fc electron density map is contoured at 1.5 σ (gray mesh).  The figure 
indicates that the aromatic residues W80, Y101, Y115 and W131 (green) form a cage-like 
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binding site to house the bound ethidium (orange), suggesting aromatic stacking interactions 
govern drug recognition of the regulator.  The hydrogen bond distances between D156 and 
Y115, D156 and W131, and N112 and Y101 are 2.7, 2.7, and 2.7 Å, respectively.   
!
!mmr# rv3066#
 5’-ACGAGCCTCCTTTGTGTACATTTGTACATGTACAAATGTACACAAAGGAGGG-3’ 
 
 3’-TGCTCGGAGGAAACACATGTAAACATGTACATGTTTACATGTGTTTCCTCCC-5’  
IR1! IR2!
 
Fig. S7.  The palindromic inverted repeat at the promoter region of the mmr-rv3066 operon.  
Operons of mmr and rv3066 (red, mmr; blue, rv3066).  The IR1 and IR2 sequences are in green 
and purple, respectively.   
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Fig. S8.  Binding of BSA to the mmr-rv3066 promoter by dye primer based DNase I footprint 
assay.  Electropherograms indicating that no protection pattern of the mmr-rv3066 promoter has 
been found after digestion with DNase I following incubation with (a) 0, (b) 3.0 pmol, and (c) 
6.0 pmol of BSA.  The protected DNA sequence TTGTGTACATTTGTACACAAAGG 
containing IR1 by Rv3066 is also shown. 
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Fig. S9. The binding isotherm of Rv3066 with the 30-bp IR1 in the presence of 1 µM of 
ethidium.  The binding isotherm indicates a KD of 10.7 ± 0.9 nM.   
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Abstract 
Integral membrane proteins comprise approximately 30% of the sequenced genomes, and 
there is an immediate need for their high-resolution structural information.  Currently, the most 
reliable approach to obtain these structures is x-ray crystallography.  However, obtaining crystals 
of membrane proteins that diffract to high resolution appears to be quite challenging, and 
remains a major obstacle in structural determination.  This brief review summarizes a variety of 
methodologies for use in crystallizing these membrane proteins.  Hopefully, by introducing the 
available methods, techniques, and providing a general understanding of membrane proteins, a 
rational decision can be made about now to crystallize these complex materials.     
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1.  Introduction 
High-resolution crystal structures of membrane proteins are in great demand, as these 
structures often provide an immediate insight into the mechanisms on how these protein 
machines work.  Membrane proteins play a vital role in numerous cellular functions.  They act as 
receptors, transporters, channels, and are involved in cell adhesion, signaling, as well as a variety 
of metabolic pathways.  About 30% of the mammalian genome encodes these integral membrane 
proteins [1], and more than 50% of currently administrative pharmaceutical agents are designed 
for targeting them [2].  Unfortunately, the understanding of the structure and function of these 
membrane proteins is hampered by the difficulties associated with expressing and handling them.  
Membrane proteins are not soluble in aqueous buffer because of their intrinsic characteristics.  
These proteins possess large hydrophobic surfaces, thus detergents are required to extract them 
from cell membranes and to maintain them in a soluble form in aqueous solution (Fig. 1).  Mild 
detergents are widely used in handling membrane proteins, however, many of these proteins tend 
to aggregate or denature when solubilized by these amphiphilic chemicals.  Because of the 
complications related to the stability and solubility of membrane proteins, it is often difficult to 
study these proteins using common biophysical techniques such as x-ray scattering, magnetic 
and optical spectroscopies.   
Like many chemical compounds, proteins can be crystallized as they become 
supersaturated in aqueous solution.  The crystallization process is often initiated by the addition 
of various precipitating agents, including salts like NaCl, (NH4)2SO4 etc., polymers like 
polyethylene glycols (PEGs), and/or a variety of organic molecules like ethanol, isopropanol, 2-
methyl-2,4-pentanediol (MPD), etc.  These precipitating agents reduce the solubility of protein 
molecules and eventually supersaturate them in solution.   
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As the pH and temperature also affect the solubility of protein samples, the process of 
protein crystallization is often found to be pH and temperature dependent. 
Different from other chemical crystals, protein crystals possess high solvent content.  The 
solvent content of protein crystals was first studied by Matthews [3] in 1968.  The study was 
based on the known soluble protein crystal structures at that time.  It was found that the crystal 
volume occupied by solvent ranged from 27 to 65%, with the most common solvent content at 
43%.  Although the high solvent content often results in a poorer crystal quality, it provides an 
environment that is close to the native cellular environment for these protein molecules.  Thus 
this high crystal solvent content indeed offers an opportunity for the protein molecule to better 
mimic its native structure in the cellular environment.  In the case of membrane proteins, this 
solvent content is even higher (between 65 and 80%) because of the presence of detergent and/or 
amphiphilic molecules.  As a result, membrane protein crystals are often found to diffract x-ray 
poorly, and many of these crystals can only provide low to medium resolution structural 
information. 
Vapor diffusion is the most popular method that allows the protein samples to reach 
supersaturation [4].  This method is achieved by increasing the protein concentration gradually 
through a relatively slow dehydration process.  Typically, a drop composed of a mixture of 
protein sample and precipitating agents is placed in vapor equilibrium with a hydroscopic 
reservoir solution containing two times higher in concentration of these precipitating agents (Fig. 
2).  As water leaves the drop, the protein concentration undergoes an increase in relative 
supersaturation, which eventually initiates nucleation of protein bearing crystals.  Although the 
idea is simple, many proteins simply refuse to form crystals.  Thus, protein crystallization is 
often found to be labor intensive and time consuming. 
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The principle of membrane protein crystallization is very similar to that of water-soluble 
proteins except that the presence of detergent, which adds another layer of difficulty, is required 
to solubilize the membrane protein molecules in aqueous solution.  This review provides a brief 
overview of different approaches in the crystallization of these membrane proteins.  To date, a 
great deal of useful information in the field can be found in internet-based resources.  For 
example, the web sites of “membrane proteins of known structure” 
(http://blanco.biomol.uci.edu/mpstruc/) and “membrane protein data bank” 
(http://www.mpdb.ul.ie/) [5] frequently update the lists of all known membrane protein 
structures, as well as their crystal growth methods and conditions. 
 
2.  Detergent-based methods 
Membrane proteins can be crystallized for use in macromolecular structural 
determination by a variety of methodologies.  The detergent-based methods (Fig. 3) employ 
detergent-solubilized, purified membrane protein samples directly in crystallization trials [6].  To 
obtain a stable protein sample suitable for crystallization, one needs to get through many 
obstacles, including finding an effective system for protein expression and choosing the right 
detergent for protein solubilization and purification.  In many successful cases, the membrane 
proteins were produced in Escherichia coli cells.  However, Pichia pastoris yeasts [7, 8], 
Saccharomyces cerevisiae yeasts [9] as well as Sf9 insect cells [10] have also been commonly 
used to express the proteins of interest for crystallization.  After obtaining the expressed 
membrane proteins, the proteins have to be extracted from lipid membranes with mild detergents 
and then purified to stable, homogeneous samples that are essential for crystallization.  Table 1 
and Figure 4 summarize some of the most frequently used detergents for membrane protein 
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purification and crystallization.  The detergent-based crystallization methods include vapor 
diffusion [11], micro-batch [12, 13], dialysis [11, 14] and counter-diffusion [15, 16] and micro-
fluidics [17].  A schematic for the detergent-based crystallization approach is shown in Figure 3.  
At present, the step of crystallizing purified, detergent-solubilized membrane proteins remains 
the major bottleneck.  Nevertheless, the rate of progress is accelerating, especially in the past 
decade. 
Among the detergent-based methods, it appears that vapor diffusion (both of the hanging-
drop and sitting-drop types [11]) is the most common approach (Fig. 2).  The primary advantage 
of this approach is that the crystallization setup is rather straightforward and relatively easy to 
handle.  Membrane protein molecules surrounded by belt-like detergent micelles can be treated 
as ordinary soluble protein molecules (Fig. 1b), and thus standard vapor diffusion crystallization 
procedures can be used to obtain the crystals.  The major drawback, however, is that the protein 
molecules have to withstand the harsh environment in detergent micelles.  Nonetheless, vapor 
diffusion, which is the first to have been applied to membrane proteins, has been proven to be the 
most successful approach in crystallizing membrane proteins.  The first crystal structure of 
membrane protein obtained in 1985 is photosynthetic reaction center [18].  This structure was 
determined using the method of vapor diffusion.  To date, over 80% of membrane protein 
structures in the Protein Data Bank (http://www.rcsb.org/) were solved based on crystals grown 
with this method.  A general protocol for the crystallization of membrane proteins using this 
approach can be found in an article published by Newby et al. [19]. 
If crystallization of particular membrane proteins does not work, one may want to try to 
co-crystallize the proteins with antibodies.  This approach is especially useful when the 
membrane protein molecules contain relatively small hydrophilic domains [20].  Antibody 
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fragments, including Fab and Fv, that recognize native protein conformations have been shown 
to facilitate crystallization of membrane proteins by increasing the polar surface area for protein-
protein contacts.  In addition, these antibody fragments can be used to stabilize specific 
conformations of the proteins by restricting the flexibility of mobile domains, in turn aiding the 
success of crystallization attempts [20].  The approach of co-crystallizing monoclonal antibody 
fragments with integral membrane proteins using vapor diffusion has been successfully led to 
several important crystal structures, including cytochrome c oxidate [21], KcsA potassium 
channel [22], ClC chloride channel [23], and most recently the human β2 adrenergic receptor 
[24].  To date, more that 50 membrane protein structures have been reported in the Protein Data 
Bank using this approach. 
Membrane protein molecules tend to be more stable in the presence of lipid.  Indeed, it 
has been revealed that there is a direct link between the presence of lipid environment and the 
structure and function of integral membrane proteins [25].  Thus, one should be aware of the 
importance of bound lipid molecules in membrane protein crystallization.  It has been shown that 
the addition of lipid molecules can significantly improve the quality of the membrane protein 
crystals and allow them to diffract x-rays at high-resolution [26, 27].  If the crystallization trials 
do not result in high quality membrane protein crystals, one may want to conduct crystallization 
by adding lipid and changing the protein:lipid molar ratio in the vapor diffusion trials.  This 
approach has been proven to be successful in obtaining high quality crystals of the cytochrome 
b6f complex [26, 27]. 
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3.  Crystallization of the CusBA adaptor-transporter efflux system 
The approach of vapor diffusion has allowed researchers in our laboratory to determine 
the crystal structures of different components, either alone or in a complex form, of the CusBA 
heavy-metal efflux complex (Figs. 5 and 6) [28-30].  The raw proteins of the CusA transporter 
and CusB adaptor were individually produced in E. coli cells.  Then, the CusA protein was 
extracted and purified with a detergent 6-cyclohexyl-1-hexyl-β-D-maltoside (CYMAL-6) [28].  
As CusB is a soluble protein, the presence of detergent was not required for protein extraction 
and purification.  However, it was found that the addition of a detergent n-dodecyl-β-D-
maltoside (DDM) was helpful to produce a more homogeneous sample and avoid protein 
aggregation during purification procedures [29]. 
Crystals of the CusA transporter were grown at 298K using vapor diffusion in the 
presence of CYMAL-6 with PEG 3350 as precipitant and ammonium sulfate as salt [28].  
Crystals of the CusB adaptor were grown using the same approach in the presence of the 
detergent DDM with PEG 1000 and sodium citrate as precipitant and salt [29].  For the 
crystallization of the CusBA adaptor-transporter complex, the crystals were produced using 
vapor diffusion at room temperature in the presence of CYMAL-6.  The precipitant and salt for 
crystallizing the CusBA complex were PEG 6000 and ammonium acetate [30].  Crystals of 
CusA, CusB and CusBA grew to a full size in the drops within a month (Fig. 5).  
For x-ray data collections, a single crystal of CusA or CusBA was flash-cooled in 
cryoprotectant solutions containing 30% glycerol at 100K.  As for CusB, a single crystal was 
cryoprotected in solution containing 30% PEG 1000 before freezing at 100K.  All diffraction 
data were collected at 100K at beamline 24ID-C located at the Advanced Photon Source, using 
an ADSC Quantum 315 CCD-based detector.  
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Crystals of the CusA transporter were found to be trigonal with space group R32 (a = b = 
178.4 Å, c = 285.8 Å).  In the asymmetric unit, only one CusA protomer was found.  The crystal 
structure of the CusA transporter was then determined at a resolution of 3.5 Å [28].  For the 
CusB adaptor, the crystals belonged to orthorhombic space group I222, with a = 85.2 Å, b = 
113.3 Å, c = 258.5 Å.  The asymmetric unit consists of two CusB protomers.  The structure of 
CusB was then resolved to a resolution of 3.4 Å [29].  
The co-crystals of the CusBA adaptor-transporter complex took a trigonal space group 
R32 with unit cell parameters a = b = 160.2 Å, c = 682.7 Å.  The asymmetric unit contains one 
CusA and two CusB molecules.  The final structure of the CusBA adaptor-transporter complex 
was determined to 2.9 Å resolution [30] (Fig. 6). 
       
4.  Lipid-based methods 
As the presence of phospholipids tends to stabilize membrane protein molecules, and in 
some cases the presence of these lipid molecules is a prerequisite for the protein activity, there is 
a strong rationale to crystallize membrane proteins in the presence of phospholipids.  The lipid-
based methods utilize biomolecular lipid bilayers to facilitate membrane protein crystallization 
[31].  These include the bicelle [32, 33], vesicle [34, 35], and lipidic cubic phase [36, 37] 
methods.  In contrast to the detergent-based methods, these approaches promote the use of lipid 
bilayers, which mimic the native environment of membrane proteins, as an embedded system to 
stabilize the protein molecules.  A schematic of the lipid-based crystallization is illustrated in 
Figure 7.  The bicelle and vesicle methods are still new and have not been extensively evaluated.  
However, the lipidic cubic phase approach has been found to be very successful.  All these 
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methods offer an advantage that the protein molecules are removed from the harsh detergent 
environment and placed into a more hospitable surrounding during the process of crystallization.  
Crystallization of membrane proteins in lipidic cubic phases has only been developed in 
the past 15 years.  Nonetheless, this method has already been proven to be effective and essential 
for crystallizing a certain membrane proteins.  The first crystal structure determined using this 
crystallization method is bacteriorhodopsin [38, 39].  To date, about one in ten integral 
membrane protein structures in the Protein Data Bank have been solved using crystals grown by 
this technique.  Recent successes with this technique include the crystal structures of β2-
adrenergic [40] and adenosine A2A [41] G protein-coupled receptors. 
In the cubic phase method, the crystallization process takes place in and from a semi-
solid bicontinuous lipid matrix (Fig. 8).  Thus, this technique involves making a highly ordered 
artificial lipid bilayer, namely cubic phase, before crystallization trials.  The protein of interest is 
then incorporated into the highly ordered cubic phase.  This bicontinuous lipidic cubic phase 
contains extended water channels, which promote the detergent-solubilized membrane protein 
molecules to return to the lipid bilayer environment.  After, precipitating agents are added to 
initiate protein crystallization. 
1-mono-olein-rac-glycerol (MO) is the most commonly used lipid for forming these 
highly ordered cubic phases.  The difficulty of this method is that it is a time consuming process 
in obtaining the initial cubic phase.  As mentioned earlier, cubic phase is a semi-solid lipid 
matrix.  It is also hard to work with because it is extremely viscous and sticky, making it difficult 
to handle and to dispense accurately in small volumes for setting up protein crystallization trials.  
A detailed protocol for crystallizing membrane proteins using the technique of lipidic 
mesophases is described in a review article by Caffrey and Cherezov [37].  
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Another closely related lipid-based approach is the lipidic spongy phase method [42].  A 
liquid lipid bilayer in the form of spongy phase can be obtained by adding an additional solvent 
such as PEGs, MPD, or jeffamine M600 to the MO:water system.  The aqueous pores in the 
spongy phase can be up to three times as large as those in the cubic phase.  Thus, the spongy 
phase method may be more useful in crystallizing membrane proteins with large extracellular 
domains.  
One major advantage of employing lipidic spongy phase for membrane protein 
crystallization is that it is liquid in form at room temperature, thus it is easy to handle during the 
course of setting up crystallization trials.  This liquid property also makes it suitable for 
conventional hanging-drop and sitting-drop vapor diffusion experiments.  A nice summary of the 
lipidic spongy phase approach can be found in a literature by Wöhri et al. [42]. 
Both cubic and spongy phases form three-dimensional continuous lipid bilayers and 
interconnected water channels.  This architecture promotes the lateral diffusion of protein 
molecules in the matrices.  Presumably, the membrane protein molecules are first reconstituted 
in the lipid phase and then diffuse laterally to concentrate and assemble at the nucleation point to 
form small protein crystals at some point. 
Recently, the bicelle method [32, 33] has been gaining popularity in the field after a few 
successes in crystallizing membrane proteins, including the mouse VADC1 channel [43] and 
human β2 adrenergic receptor [44], by using this approach.  Bicelles, formed in a lipid-detergent 
mixture, have small disc-like features constituting of a planar lipid-bilayer (Fig. 9).  The 
procedures for the bicelle approach are rather simple.  First, the protein is mixed with bicelle 
components containing a mixture of lipid and detergent.  Crystallization is then achieved using 
the method of vapor diffusion.  Thus, the bicelle method can be considered as a compromise 
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between the user-friendly vapor diffusion approach and the more protein-friendly lipidic 
mesophase technique.     
The vesicle method, which makes use of successive fusion of vesicular assemblies, is a 
lipid bilayer approach initially developed by Takeda et al. [34] to crystallize bacteriorhodopsin.  
First, the vesicles are formed from the purple membrane fragments in the presence of detergent 
and precipitating agents.  These spherical vesicles can be fused successively to form stacks of 
planar membranes by altering temperature as well as increasing the concentration of precipitating 
agents.  Similar method has been used to crystallize the light-harvesting complex of photosystem 
II by reconstituting the purified membrane protein into liposomes [35].  In this case, the purified 
membrane protein molecules were first reconstituted in liposomes to form two-dimensional 
arrays.  These proteoliposomes containing the two-dimensional arrays of protein molecules were 
then crystallized to form lattice.  This approach may be useful for crystallizing membrane 
proteins that are unstable in a detergent environment.  Yet, it remains to be seen if this 
remarkable approach can be applied generally in crystallizing other membrane proteins. 
 
5.  Detergents 
Choosing the right detergent has been the key success for membrane protein 
crystallization.  It is one of the most important factors for obtaining high quality membrane 
protein crystals suitable for x-ray diffraction.  Thus, the rule of thumb is that more efforts should 
be made in screening a variety of mild detergents than in optimizing other parameters when 
crystallizing a new membrane protein.  Nonionic and zwitterionic detergents are usually used for 
crystallization of membrane proteins (Table 1 and Fig. 2).  The most successfully used detergents 
are nonionic alkyl sugars with C8-C12 alkyl chains.  Thus far, the most common detergent for 
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use in crystallizing α-helical type membrane proteins is n-dodecyl-β-D-maltopyranoside, which 
contains 12 carbons in the main alkyl chain.  The second most popular detergent in membrane 
protein crystallization is n-octyl-β-D-glucopyranoside, which is a C8-alkyl chained detergent.     
During the past several years, the development of new detergents has been emerged as a 
new tool for handling these membrane proteins.  Low molecular weight agents, such as 
hemifluorinated surfactants [45, 46] and cholate acid-based amphiphiles [47], have been proven 
to be promising in aiding the study of membrane proteins in aqueous solution.  In addition, a new 
family of detergents, designated as maltose-neopentyl glycol amphiphiles [48], is of particular 
attractive in the field.  The new generation of amphiphiles may have a wide application in 
solubilization, stabilization and crystallization of membrane proteins, and eventually yielding 
high-quality crystals for diffraction analysis.  
 
6.  Concluding remarks 
This review is an attempt to outline different methods for use in three-dimensional 
membrane-protein crystallization.  Crystallization of membrane proteins can be a rather difficult 
and discouraging process.  It is hope that this brief summary will provide with a useful guide for 
researchers to tackle this problem.  Particularly, the authors hope that this  review will encourage 
more physicists to undertake research projects in this exciting field.  
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Legends of figures 
a"
b"
c"
 
Figure 1.  Cartoon of an α-helical membrane protein molecule.  (a) The molecule is embedded in 
cell membrane.  (b) The molecule is surrounded by detergent micelle.  (c) The molecule is 
surrounded by detergent-lipid mixture. 
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a" b"  
Figure 2.  Vapor diffusion methods.  (a) Hanging-drop vapor diffusion.  (b) Sitting-drop vapor 
diffusion.  In both (a) and (b), the drop composed of a mixture of protein sample and 
precipitating agents is in red.  The hydroscopic reservoir solution containing two times higher in 
concentration of these precipitating agents is colored green.  A cover slip is placed on the top of 
the vessel, which is sealed with a small amount of vaseline (yellow). 
Detergent'
micelle'
Cell'membrane'
Detergent'micelle'
 
Figure 3.  Schematic of detergent-based crystallization of membrane proteins.  The membrane 
85 
 
 
protein is removed from native cell membrane using detergent micelle.  The purified protein is 
then crystallized in detergent micelles.  The hydrophobic and hydrophilic domains of the 
membrane protein molecule are in green and pink colors.  The cell membrane is colored red. 
OG#
DDM#
CYMAL*6#
MEGA*10#
Nonionic&Detergents&
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Figure 4.  Chemical structures of represented detergent molecules.  (a) Nonionic detergents (OG, 
n-octyl-β-D-glucopyranoside; DDM, n-dodecyl-β-D-maltopyranoside; CYMAL-6, 6-cyclohexyl-
1-pentyl-β-D-maltoside; MEGA-10, Decanoyl-N-methylglucamide).  (b) Zwitterionic detergents 
(CHAPS, 3-[(3-cholamidopropyl)dimethylammonio]-1-propanesulfonate; CHAPSO, 3-[(3 
Cholamidopropyl)dimethylammonio]-2-hydroxy-1-propanesulfonate; LDAO, n-dodecyl-N,N-
dimethylamine-N-oxide). 
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Figure 5.  Crystals of the E. coli Cus efflux proteins.  (a) A crystal of the CusA heavy-metal 
transporter.  (b) A crystal of the CusB adaptor protein.  (c) A crystal of the CusBA adaptor-
transporter efflux complex. 
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Figure 6. Crystal structure of the CusBA adaptor-transporter complex.  (a) X-ray diffraction 
pattern of the CusBA crystal.  The crystal took a trigonal space group R32 with unit cell 
parameters a = b = 160.2 Å, c = 682.7 Å.  (b) Electron density map at a resolution of 2.9 Å.  The 
CusA and two CusB molecules are colored yellow, green and blue, respectively.  (c) Packing 
diagram of the CusBA crystal complex viewed along the c axis (green, CusA; blue, CusB; 
orange, CusB).  (d) Packing diagram of the CusBA crystal complex viewed orthogonal to (c).  
(e) Structure of the CusBA efflux complex viewed in the membrane plane (green, CusA; blue, 
CusB; orange, CusB). 
Lipid/&
cubic&phase/&
spongy&phase&
Cell&membrane&
Lipid&molecules&
 
Figure 7.  Schematic of lipid-based crystallization of membrane proteins.  The purified protein is 
crystallized in the presence of lipid.  The hydrophobic and hydrophilic domains of the membrane 
protein molecule are in green and pink colors.  The cell membrane and lipid molecules are 
colored red. 
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Figure 8.  A cartoon representation of lipidic cubic phase.  The membrane protein molecules 
embedded in the cubic phase are colored green. 
Lipid%
Detergent%molecules%
 
Figure 9.  A cartoon representation of a disc-like bicelle.  The membrane protein molecule 
embedded in the bicelle is colored blue.   
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Table 1. A list of commonly used detergents in membrane protein crystallization. 
 
Detergent  Common Name  CMC1 (mM) 
   
NONIONIC   
n-octyl-β-D-glucopyranoside OG 18.00 
n-nonyl-β-D-glucopyranoside NG 6.50 
n-dodecyl-β-D-glucopyranoside DDG 0.19 
n-octyl-β-D-maltopyranoside OM 19.50 
n-nonyl-β-D-maltopyranoside NM 6.00 
n-decyl-β-D-maltopyranoside DM 1.80 
n-undecyl-β-D-maltopyranoside UDM 0.59 
n-dodecyl-β-D-maltopyranoside DDM 0.17 
5-cyclohexyl-1-pentyl-β-D-maltoside CYMAL-5 2.40 
6-cyclohexyl-1-pentyl-β-D-maltoside CYMAL-6 0.56 
Tetraethylene glycol monoctyl ether  C8E4 8.50 
Pentaethylene glycol monoctyl ether C8E5 7.10 
Polyoxyethylene(5)dodecyl ether C10E5 0.81 
Polyoxyethylene(8)dodecyl ether C12E8 0.09 
Polyoxyethylene(9)dodecyl ether C12E9 0.05 
Decanoyl-N-methylglucamide MEGA-10 6.00 
   
ZWITTERIONIC    
n-decyl-N,N-dimethylamine-N-oxide DDAO 10.48 
n-undecyl-N,N-dimethylamine-N-oxide UDAO 3.21 
n-dodecyl-N,N-dimethylamine-N-oxide LDAO 1.00 
3-[(3-cholamidopropyl)dimethylammonio]- 
1-propanesulfonate 
CHAPS 8.00 
3-[(3-Cholamidopropyl)dimethylammonio]- 
2-hydroxy-1-propanesulfonate 
CHAPSO 8.00 
   
 
1Critical Micelle Concentration (CMC) 
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Abstract 
Neisseria gonorrhoeae is an obligate human pathogen and the causative agent of the 
sexually-transmitted disease gonorrhea.  The control of this disease has been compromised by 
the increasing proportion of infections due to antibiotic-resistant strains, which are growing at an 
alarming rate.  The MtrCDE tripartite multidrug efflux pump, belonging to the hydrophobic and 
amphiphilic efflux resistance-nodulation-cell division (HAE-RND) family, spans both the inner 
and outer membranes of N. gonorrhoeae and confers resistance to a variety of antibiotics and 
toxic compounds.  We here report the crystal structure of the inner membrane MtrD multidrug 
efflux pump, which reveals a novel structural feature that is not found in other RND efflux 
pumps.   
 
Introduction 
Neisseria gonorrhoeae is a Gram-negative obligate human pathogen.  It is the causative 
agent of the sexually-transmitted disease gonorrhea and rare cases of disseminated disease.  
Although gonorrhea is one of the oldest described diseases, it remains a significant global 
problem with more than 100 million cases reported annually worldwide and antibiotic resistance 
is a major concern [1].  The gonococcus employs a number of strategies to evade host attack.  It 
possesses an intricate mechanism of antigenic variability through differential expression of the 
genome and can easily acquire new genetic material to develop resistance to antimicrobial agents 
[1,2].  Gonococci utilize a number of resistance mechanisms, including antimicrobial 
inactivation, target modification and strategies that reduce antimicrobial concentration, such as 
reduced permeability of the cell envelope mediated through alteration of porin proteins and 
active export of multiple antimicrobial compounds from the cell by efflux pumps.  Among these 
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different mechanisms, multidrug efflux is considered to be one of the major causes of failure of 
drug-based treatments of infectious diseases, which appears to be increasing in prevalence [3].  
These bacterial multidrug efflux pumps have enormous clinical consequences.  Simultaneously 
rendering the cell resistant to multiple structurally-unrelated compounds, their expression results 
in bacterial strains resistant to most clinically-relevant antibiotics [3].  
The best characterized and most clinically important of these multidrug efflux systems in 
N. gonorrhoeae is the MtrCDE tripartite efflux pump [4-7].  It is composed of the MtrD inner 
membrane transporter, belonging to the HAE-RND protein family [8]; the MtrC periplasmic 
protein, a member of the membrane fusion protein family; and the MtrE integral outer membrane 
channel protein.  This system provides resistance to a broad spectrum of antimicrobial agents, 
including bile salts, fatty acids, dyes, antibiotics and spermicides.  The Mtr multidrug efflux 
system is also responsible for resistance to host-derived cationic antimicrobial peptides [7], 
which are important mediators of the innate host defense.  Given that gonococci commonly 
infect mucosal sites bathed in fluids containing such peptides, the Mtr system indeed underscores 
the pathogenesis of gonococcal disease and its contribution to virulence.  In addition, it has been 
shown that the MtrCDE tripartite efflux pump is capable of enhancing long-term colonization of 
the mouse vaginal mucosal layer and that gonococci lacking this efflux pump were highly 
attenuated [9]. 
At present, only two crystal structures of HAE-RND-type efflux pumps are available.  
These efflux pumps are the Escherichia coli AcrB [10-18] and Pseudomonas aeruginosa MexB 
[19] multidrug transporters.  Their structures suggest that both AcrB and MexB span the entire 
width of the inner membrane and protrude approximately 70Å into the periplasm.  Along with 
the models of these two HAE-RND transporters, the crystal structures of the other components 
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of these tripartite complex systems have also been determined.  These include the outer 
membrane channels E. coli TolC [20] and P. aeruginosa OprM [21], as well as the periplasmic 
membrane fusion proteins E. coli AcrA [22] and P. aeruginosa MexA [23-25].  
Currently, no structural information is available for any protein component of the 
MtrCDE tripartite complex system.  To elucidate the mechanism used by this efflux system for 
multidrug recognition and extrusion, we here describe the crystal structure of the inner 
membrane MtrD multidrug efflux pump.  The findings reveal a novel structural feature that is not 
found in other known RND efflux pumps.   
 
Results and discussion 
Overall structure of the N. gonorrhoeae MtrD multidrug efflux pump 
We cloned, expressed and purified the full-length MtrD efflux pump containing a 6xHis 
tag at the C-terminus.  We obtained crystals of this membrane protein following an extensive 
screening for crystallization conditions with different detergents.  We then used molecular 
replacement, utilizing the structure of the “access” protomer of AcrB (pdb code: 2DHH) [12] to 
determine the three-dimensional structure.  The diffraction data can be indexed to the space 
group R32.  Data collection and refinement statistics are summarized in Table 1.  The resulting 
electron density maps (Fig. 1) reveal that the asymmetric unit consists of one protomer.  The 
crystal structure of the MtrD multidrug efflux pump has been determined to a resolution of 3.53 
Å (Table 1).  Currently, 97% of the amino acids (residues 2-493 and 508-1040) are included in 
the final model (Fig. 2a).  The final structure is refined to Rwork and Rfree of 27.9% and 33.3%, 
respectively.   
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The structure of MtrD is closer to the conformation of the “access” protomer of AcrB.  
However, superimposition of these two structures results in a high RMSD of 7.6 Å over 1,000 Cα 
atoms, suggesting that there are significant differences between these two transporters (Fig. S1).   
MtrD assembles as a 125-Å long and 95-Å wide homotrimer (Fig. 2b).  Each protomer 
comprises 12 transmembrane helices (TM1-TM12).  Like other RND transporters, the N-
terminal (TM1-TM6) and C-terminal (TM7-TM12) halves of MtrD are related by a pseudo-
twofold symmetry.  A large periplasmic domain is created by two extensive periplasmic loops 
connecting TM1 with TM2 and TM7 with TM8, respectively.  As in AcrB [10-18] and MexB 
[19], this periplasmic domain can be divided into six sub-domains: PN1, PN2, PC1, PC2, DN 
and DC (Figs. 2 and 3).  Sub-domains PN1, PN2, PC1 and PC2 form the pore domain, with PN1 
making up the central pore and stabilizing the trimeric organization.  However, sub-domains DN 
and DC contribute to form the docking domain, presumably interacting with the outer membrane 
channel MtrE.  The trimeric MtrD structure suggests that sub-domains PN2, PC1 and PC2 are 
located at the outermost core of the periplasmic domain, facing the periplasm.  Sub-domains PC1 
and PC2 also form an external cleft, and this cleft is open in the MtrD structure (Fig. 2).  Based 
on the co-crystal structure of CusBA [26,27] of the CusCBA tripartite efflux system [28-33], the 
upper regions of PN2, PC1, PC2 and sub-domains DN and DC should directly interact with the 
MtrC membrane fusion protein to form a functional adaptor-transporter complex. 
The N. gonorrhoeae MtrCDE tripartite efflux system has the advantage that all these 
protein components are encoded by the same operon.  Thus, the interactions between different 
proteins are likely to be specific, facilitating analyses of how different components function 
cooperatively. 
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Periplasmic multidrug binding site 
Crystallization of AcrB with a variety of substrates [12,16-18] has identified that the 
periplasmic cleft of the pump forms several mini-binding pockets within the extensive, large 
periplasmic multidrug binding site.  This site is supposed to play a predominant role in the 
selection of drugs for export.  Protein sequence alignment reveals that many of the amino acids 
forming the large periplasmic binding site of AcrB are conserved among MexB and MtrD, 
indicating that these three multidrug efflux pumps may have a similar substrate binding profile 
for drug recognition.  These conserved amino acids in MtrD include several charged and polar 
residues, such as S79, S134, R174, D272, E669 and R714, and aromatic residues, such as F136, 
F176, F610, F612 and F623 (Fig. 3). 
A flexible loop is found inside the large periplasmic cleft (Fig. S1), which form the 
multidrug binding site of the pump.  This flexible loop is located deep inside the cleft between 
subdomains PC1 and PC2, composed of residues 608-619, and should correspond to the Phe-617 
loop [16] in AcrB.  The loop is highly conserved among MtrD, AcrB and MexB.  It is expected 
that this flexible loop is important for drug recognition and extrusion.  There is a chance that this 
loop may shift positions during the course of the extrusion process to facilitate drug export.    
 
Transmembrane helix TM9 
Perhaps the most interesting secondary structural feature appears in TM9 of the MtrD 
pump.  In contrast to other known structures of the RND transporters, MtrD contains an extended 
region that protrudes into the periplasm and contributes part of the periplasmic domain (Figs. 2 
and 3).  This region (residues 917-927) comprises an α-helix extending from the upper portion of 
TM9 and also to the loop connecting TM9 and TM10.  Protein sequence alignment suggests that 
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these extra residues are only found in MtrD and not other homologous RND proteins.  Therefore, 
this fragment should represent a unique feature of this pump that cannot be found in other RND 
pumps.  TM9 is distinct in that it is not vertically oriented.  Instead, it is inclined from the 
horizontal membrane plane by 54o.  The spatial arrangement between the extra elongated helix 
and loop (upper portion of TM9) and the periplasmic cleft formed between PC1 and PC2 
suggests that these extra structural features may help the pump to transport its substrates more 
effectively from the outer leaflet of the inner membrane to the multidrug binding site at the 
periplasmic domain (Fig. 4). 
 
Proton-relay network 
Drug export by RND transporters is proton motive force (PMF)-dependent.  Based on the 
crystal structure of MtrD, it is expected that the charged residues D405 and D406 of TM4 and 
K948 of TM10 are important for forming the proton-relay network of the pump (Fig. 5).  These 
residues are supposed to undergo protonation and deprotonation within the transport cycle.  The 
involvement of these charged amino acids in proton translocation was supported by a previous 
study that showed mutations of these residues inhibits proton translocation [34].  In turn, the 
MtrE outer membrane channel protein is blocked and unable to dissociate from the MtrCDE 
tripartite efflux complex [34]. 
The MtrD multidrug efflux pump should operate through an alternating-access 
mechanism, similar to the AcrB transporter.  Thus, the pump has to go through the transport 
cycle, which should involve different transient conformations, including the “access”, “binding” 
and “extrusion” states of this protein.  In the MtrD trimer, the conformations of the three 
protomers are identical to each other, suggesting that these protomers represent the same 
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transient state.  In comparison with the structures of AcrB, the conformation of MtrD is closer to 
that of the “access” protomer of AcrB (Fig. S1).  Therefore, our MtrD structure should represent 
the “access” transient state of the pump.  It is expected that this pump will change in 
conformation to go through the cycle.  This conformational change should be coupled to the 
PMF initiated by the proton-relay network.    
 
Methods 
Cloning, expression and purification of the inner membrane MtrD efflux pump 
Briefly, the full-length MtrD membrane protein containing a 6xHis tag at the C-terminus 
was overproduced in E. coli C43(DE3)ΔacrB cells, which harbor a deletion in the chromosomal 
acrB gene,  possessing pET15bΩmtrD.  Cells were grown in 12 L of 2xYT medium with 100 
µg/ml ampicillin at 25oC.  When the OD600 reached 0.6, the culture was treated with 1 mM IPTG 
to induce mtrD expression, and cells were harvested within 15 h.  The collected bacteria were 
resuspended in low salt buffer containing 100 mM sodium phosphate (pH 7.2), 10 % glycerol, 1 
mM ethylenediaminetetraacetic acid (EDTA) and 1 mM phenylmethanesulfonyl fluoride 
(PMSF), and then disrupted with a French pressure cell.  The membrane fraction was collected 
and washed twice with high salt buffer containing 20 mM sodium phosphate (pH 7.2), 2 M KCl, 
10 % glycerol, 1 mM EDTA and 1 mM PMSF, and once with 20 mM HEPES-NaOH buffer (pH 
7.5) containing 1 mM PMSF.  The membrane protein was then solubilized in 2% (w/v) 6-
cyclohexyl-1-hexyl-β-D-maltoside (Cymal-6).  Insoluble material was removed by 
ultracentrifugation at 100,000 x g.  The extracted protein was purified with a Ni2+-affinity 
column.  The purity of the MtrD protein (>95%) was judged using 10% SDS-PAGE stained with 
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Coomassie Brilliant Blue.  The purified protein was then dialyzed and concentrated to 20 mg/ml 
in a buffer containing 20 mM Na-HEPES (pH 7.5) and 0.05% Cymal-6. 
 
Crystallization of MtrD 
Crystals of the 6xHis MtrD were obtained using sitting-drop vapor diffusion.  The MtrD 
crystals were grown at room temperature in 24-well plates with the following procedures.  A 2 µl 
protein solution containing 20 mg/ml MtrD protein in 20 mM Na-HEPES (pH 7.5) and 0.05% 
(w/v) Cymal-6 was mixed with a 2 µl of reservoir solution containing 30% PEG 400, 0.1 M Na-
Bicine (pH 8.5), 0.1 M NH4Cl, 0.05 M BaCl2 and 9% glycerol.  The resultant mixture was 
equilibrated against 500 µl of the reservoir solution.  Crystals of MtrD grew to a full size in the 
drops within a week.  Typically, the dimensions of the crystals were 0.2 mm x 0.2 mm x 0.2 mm.  
The crystals were flash-cooled, using solution containing 40% PEG 400, 0.1 M Na-Bicine (pH 
8.5), 0.1 M NH4Cl, 0.05 M BaCl2, 9% glycerol and 0.05% Cymal-6 as a cryoprotectant before 
data collection.   
 
Data collection, structural determination and refinement  
All diffraction data were collected at 100K at beamline 24ID-C located at the Advanced 
Photon Source, using an ADSC Quantum 315 CCD-based detector.  Diffraction data were 
processed using DENZO and scaled using SCALEPACK [35]. 
Crystals of the MtrD efflux pump belong to the space group R32 (Table 1) and the best 
crystal diffracted x-ray to a resolution of 3.53 Å.  Analysis of Matthew’s coefficient indicated the 
presence of one MtrD protomer (113.69 kDa) per asymmetric unit, with a solvent content of 
66.7%.   
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The structure of MtrD was phased using molecular replacement, utilizing the structure of 
the “access” protomer of AcrB (pdb id: 2DHH) [12] as a search model.  After tracing the initial 
model manually using the program Coot [36], the model was refined against the native data at 
3.53 Å-resolution using TLS refinement techniques adopting a single TLS body as implemented 
in PHENIX [37] leaving 5% of reflections in Free-R set.  Iterations of refinement using PHENIX 
[37] and CNS [38] and model building in Coot [36] lead to the current model, which consists of 
1,025 residues with excellent geometrical characteristics (Table 1). 
 
Accession code 
Atomic coordinates and structure factors have been deposited in the Protein Data Bank 
with accession code 4MT1.  
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Legends of figures 
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Fig. 1.  Stereo view of the electron density map of the MtrD efflux pump at a resolution of 3.53 
Å.  (a) The electron density map contoured at 1.2 σ is in blue.  The Cα traces of MtrD are in red.  
(b) Representative section of the electron density at the interface between TM11 and TM12 of 
MtrD.  The electron density (colored white) is contoured at the 1.2 σ level and superimposed 
with the final refined model (green, carbon; red, oxygen; blue, nitrogen). 
 
Fig. 2.  Structure of the N. gonorrhoeae MtrD efflux pump.  (a) Ribbon diagram of a protomer of 
MtrD viewed in the membrane plane.  The molecule is colored using a rainbow gradient from the 
N-terminus (blue) to the C-terminus (red).  Sub-domains DN, DC, PN2, PC1 and PC2 are 
labeled.  The location of PN1 is behind PN2, PC1 and PC2.  (b) Ribbon diagram of the MtrD 
trimer viewed in the membrane plane.  Each subunit of MtrD is labeled with a different color.  
Residues 917-927 (only found in MtrD) forming the upper portion of TM9 and the loop 
connecting TM9 and TM10 are in blue color. 
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Fig. 3.  Sequence and topology of MtrD, AcrB and MexB.  Alignment of the amino acid 
sequences of MtrD, AcrB and MexB were done using CLUSTAL W (*, identical residues; :, 
>60% homologous residues).  Secondary structural elements are indicated: TM, transmembrane 
helix; Nα and Nβ, helix and strand, respectively, in the N-terminal half; Cα and Cβ, helix and 
strand, respectively, in the C-terminal half.  The MtrE docking domain is divided into two sub-
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domains, DN and DC; whereas the pore domain is divided into four sub-domains, PN1, PN2, 
PC1 and PC2.  The sequence and topology of MtrD are shown at the top. 
 
Fig. 4.  Spatial arrangement between TM9 and the periplasmic cleft.  TM9 is inclined from the 
horizontal membrane plane by 54o.  The extra feature (yellow), which is only found in the MtrD 
pump within the family, is located right next the cleft formed by subdomains PC1 and PC2.   
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Fig. 5.  Ion pairs in the transmembrane domain viewed from the cytoplasmic side.  Residues 
D405 and D406 of TM4 and K948 of TM10 that form ion pairs, which may play an important 
role in proton translocation, are in green sticks. 
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Figure S1: Comparison of the structures of the MtrD and AcrB efflux pumps. (a) Ribbon 
diagram of protomers of MtrD and AcrB viewed in the membrane plane. This is a 
superimposition of a subunit of MtrD (red) onto an “access” protomer of AcrB (pdb: 2DHH) 
(green), indicating that the structures of these two efflux pumps are quite distinct. 
Superimposition of these two structures result in a high RMSDs of 7.6 Å over 1,000 Cα atoms. 
(b) Front view of the periplasmic clefts, formed by subdomains PC1 and PC2, of MtrD and 
AcrB. The secondary structural elements of these two transporters are colored red (MtrD) and 
green (AcrB). (c) Potential multidrug binding within the periplasmic cleft of MtrD. The flexible 
loop created by residues 608–619 is colored blue. This loop should correspond to the Phe-617 
loop in AcrB. It is suspected that this flexible loop may swing into this drug binding site to 
facilitate export during drug extrusion. The rest of the secondary structural elements of MtrD are 
colored red. 
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Table 1.  Data collection and refinement statistics.  
Data set MtrD 
   Data Collection         
Wavelength (Å) 0.98 
   Space group R32 
   Resolution (Å) 50 – 3.53 
   
 
(3.68-3.53) 
   Cell constants (Å) 
         a 152.99 
        b 152.95 
        c 360.74 
        α, β, γ (°) 90, 90, 120 
   Molecules in ASU 1 
   Redundancy 2.9 (2.9) 
   Total reflections 377,955 
   Unique reflections 20,296 
   Completeness (%) 97.7 (98.0) 
   Rsym (%) 7.7 (42.9) 
   I / σ(I) 17.16 (1.9) 
   Refinement 
 
            
Resolution (Å) 50 – 3.53 
   Rwork 27.9 
   Rfree  33.3 
   rms deviation from ideal 
            bond lengths (Å) 0.003 
           bond angles (°) 0.794 
   Ramachandran         
most favoured (%) 89.6 
   additional allowed (%) 10.1 
   generously allowed (%) 0.3 
   disallowed (%) 0 
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Summary 
Neisseria gonorrhoeae is an obligate human pathogen and the causative agent of the 
sexually-transmitted disease gonorrhea.  Although gonorrhea is one of the oldest described 
diseases, it remains a significant global problem with more than 100 million cases reported 
annually worldwide.  The control of this disease has been compromised by the increasing 
proportion of infections due to antibiotic-resistant strains, which are growing at an alarming rate.  
N. gonorrhoeae MtrF is an integral membrane protein, which belongs to the AbgT family of 
transporters.  Approximately 13,000 putative transporters of this family have been identified.  
However, no structural information is available and even existing functional data are fairly 
minimal for these membrane proteins.  Here in we describe the crystal structure of N. 
gonorrhoeae MtrF, revealing a dimeric molecule with an architecture distinct from all other 
families of transporters.  MtrF is a bowl-shaped dimer with a solvent-filled basin extending from 
the cytoplasm to halfway across the membrane bilayer.  Each subunit of the transporter contains 
nine transmembrane helices and two hairpins.  The structure directly suggests a plausible 
pathway for substrate transport.  A combination of the crystal structure, genetic analysis and 
substrate accumulation assays indicates that MtrF is an exporter, capable of removing the 
metabolite p-aminobenzoic acid from bacterial cells.  Further experimental data based on drug 
susceptibility and radioactive transport assays suggest that N. gonorrhoeae MtrF is an antibiotic 
efflux pump, which mediates bacterial resistance to sulfonamide antimetabolite drugs.   
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Introduction 
Neisseria gonorrhoeae is a gram-negative diplococcus, which is found only in humans 
and causes the sexually transmitted disease gonorrhea.  Since it is a strictly human pathogen and 
can colonize both male and female genital mucosal surfaces and other sites, it has developed 
mechanisms to overcome antimicrobial systems of the host’s innate defense.  One major 
mechanism that N. gonorrhoeae uses to resist antimicrobial agents is the expression of multidrug 
efflux pumps that recognize and actively export a variety of structurally unrelated toxic 
compounds from the bacterial cell, including antibacterial peptides, long-chain fatty acids, and 
several clinically important antibiotics (Lee and Shafer, 1999; Rouquette-Loughlin et al., 2003; 
Shafer et al., 1998; Shafer et al., 2001; Unemo and Shafer, 2014).  
The best characterized efflux system in N. gonorrhoeae is the MtrC-MtrD-MtrE 
multidrug efflux system (Delahay et al., 1997; Lucas et al., 1995; Hagman et al., 1995; Hagman 
et al., 1997; Veal and Shafer, 2003; Warner et al., 2008).  This system is similar to other efflux 
pumps of the resistance-nodulation-cell division (RND) superfamily (Tseng et al., 1999) 
possessed by many Gram-negative bacteria.  MtrD (Bolla et al., 2014; Hagman et al., 1995; 
Hagman and Shafer, 1995; Hagman et al., 1997) is the inner membrane transporter component of 
the tripartite RND pump.  The complex is formed by interactions between MtrD, the periplasmic 
membrane fusion protein MtrC (Hagman et al., 1995; Hagman et al., 1997; Veal et al., 2002; 
Janganan et al., 2013), and the outer membrane channel MtrE (Delahay et al., 1997; Lei et al., 
2014; Janganan et al., 2011; Janganan et al., 2013).  This powerful efflux complex mediates the 
export of several structurally diverse hydrophobic antimicrobial agents, such as antibiotics, 
nonionic detergents, antibacterial peptides, bile salts, and gonadal steroidal hormones (Delahay 
et al., 1997; Hagman et al., 1995; Hagman et al., 1997; Shafer et al., 1998).  In addition, the Mtr 
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efflux system includes another inner membrane protein MtrF (Veal and Shafer, 2003; Folster and 
Shafer, 2005), which belongs to the AbgT family of transporters (Prakash et al., 2003).  It has 
been proposed that MtrF cooperates with the MtrC-MtrD-MtrE complex to export certain 
antimicrobials by a yet unknown mechanism (Veal and Shafer, 2003).  
To date, approximately 13,000 putative transporters of the AbgT family have been 
identified.  AbgT-type proteins are commonly found in Gram-negative bacteria such as 
Salmonella enterica, Gram-positive bacteria such as Staphylococcus aureus, as well as yeasts 
such as Saccharomyces arboricola.  Surprisingly, among proteins in this diverse AbgT family, 
only Escherichia coli AbgT (Hussein et al., 1998; Carter et al., 2007) and N. gonorrhoeae MtrF 
(Folster and Shafer, 2005; Veal and Shafer, 2003) have been partially characterized.  Thus far, 
there is no structural information available for this family of membrane proteins, obscuring the 
details of their function and mechanism. 
The products of the E. coli abg genes have been shown to catalyze the uptake and 
cleavage of the folate catabolite p-aminobenzoyl-glutamate (Carter et al., 2007).  Particularly, E. 
coli AbgT has been demonstrated to import the catabolite p-aminobenzoyl-glutamate for de novo 
folic acid synthesis (Carter et al., 2007).  As E. coli AbgT and N. gonorrhoeae MtrF belong to 
the same family of membrane transporters, it is expected that the MtrF protein may act as an 
importer to uptake p-aminobenzoyl-glutamate and related small molecules for the synthesis of 
the essential folate vitamin.  However, since MtrF is needed for the high-level resistance of 
gonococci to hydrophobic antimicrobials, including erythromycin and TX-100 (Folster and 
Shafer, 2005), it seems more likely to participate in drug efflux.  To understand the transport 
functions of members of the AbgT family, we present herein the crystal structure of the N. 
gonorrhoeae MtrF transporter.  Importantly, we show that N. gonorrhoeae MtrF is capable of 
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exporting the folate metabolite p-aminobenzoic acid (PABA) from cells.  A combination of the 
three-dimensional structure and genetic analysis allows us to identify key MtrF residues that are 
important for the function of this membrane protein.  Finally, we demonstrate that MtrF does 
behave as an antibiotic efflux pump, which is responsible for removing sulfonamides from the 
cell and mediating bacterial resistance to this class of antimetabolites.   
 
Results and discussion 
Overall structure of N. gonorrhoeae MtrF 
The N. gonorrhoeae MtrF transporter is composed of 522 amino acids, sharing 38% 
identity with E. coli AbgT (Fig. S1).  The crystal structure of this membrane protein was 
determined to a resolution of 3.95 Å using single isomorphous replacement with anomalous 
scattering (SIRAS) (Table 1).  Two molecules of MtrF, which assemble as a dimer, are found in 
the asymmetric unit (Fig. S2 and Fig. 1).  Superimposition of these two MtrF molecules gives an 
RMSD of 0.5 Å over 506 Cα atoms, indicating that their conformations are nearly identical to 
each other. 
The fold of MtrF is unique and composed of a number of unusual structural elements.  
Each subunit of MtrF comprises nine α-helical transmembrane segments and two helical 
hairpins: TM1 (a (12-22) and b (26-47)), TM2 (a (78-92), b (94-112) and c (114-125)), HP1 (a 
(128-145) and b (147-164)), TM3 (a (168-182) and b (191-205)), TM4 (218-240), TM5 (269-
292), TM6 (310-334), TM7 (a (341-353), b (356-374) and c (376-391)), HP2 (a (396-413) and b 
(417-434)), TM8 (a (438-451) and b (462-471)) and TM9 (480-506).  It should be noted that five 
of these TMs (TM1, TM2, TM3, TM7 and TM8) are broken into segments within the membrane.  
In addition, HP1 and HP2 are formed by relatively short helices, which are only long enough to 
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span half of the membrane (Fig. 1a and b).  Interestingly, the intramembrane loops of several of 
these TMs and HPs are right next to each other, allowing the transporter to form an internal 
cavity within the membrane (Fig. 1c and d). 
Each protomer of MtrF contains a relatively small periplasmic domain.  This domain is 
made up of two long loops formed between TMs 1 and 2, and TMs 5 and 6, respectively.  Below 
the inner leaflet of the membrane, a small cytoplasmic domain links TMs 4 and 5 together.  This 
domain is comprised by a relatively long random loop and helix (α1) (Fig. 1a). 
Viewed in parallel to the membrane, the MtrF dimer is bowl-shaped with a concave 
aqueous basin facing the intracellular solution (Fig. 1b).  The dimer is about 75 Å tall, 80 Å wide 
and 50 Å thick, with the transmembrane portion of the transporter lying approximately in the 
middle.  The rim of the basin is as large as 45 Å.  The bowl-shaped structure is 25 Å in depth and 
deeply penetrates into the inner leaflet of the cytoplasmic membrane (Fig. 1c).  This basin 
probably allows aqueous solution to reach the midpoint of the membrane bilayer.  
The structure of each MtrF protomer can be roughly divided into the inner and outer 
cores (Fig. 2).  The outer core contains TMs 1, 2, 5, 6, and 7, creating a frame-like structure to 
house the inner core of the protein (Fig. 2a).  A portion of this outer core is responsible for 
forming a dimerization domain of the transporter.  Viewed along the membrane normal, TMs 1b, 
2a, 2b, 6, 7a, and 7b, as well as their counter parts from the next subunit, contribute to this 
distinct dimerization domain. 
Noticeably, the inner core of the MtrF protomer, comprising TMs 3, 4, 8, and 9, as well 
as HPs 1 and 2, folds into a cylindrical structural feature (Fig. 2a).  It is most likely that this inner 
core cylinder forms a substrate-binding site and transport pathway.  Based on the crystal 
structure, it was found that the inner core cylinder contributes to form a tunnel spanning 
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approximately from the middle of the inner membrane up to the periplasmic space (Fig. 2b).  
This tunnel is surrounded with HPs 1 and 2, as well as TMs 3 and 8.  Interestingly, this tunnel is 
connected to the cytoplasmic space through an opening located at the basin of the bowl-shaped 
structure.  The loop regions of HP1, HP2, TM3, and TM8 form this opening.  Several conserved 
residues, including D193, S417, W420, P438, R446, D449, and P457, are found to line the wall 
of the channel (Fig. 2b).  These residues may play an important role for the function of this 
transporter. 
 
MtrF is capable of exporting p-aminobenzoic acid from the cell   
As E. coli AbgT has been shown to enable uptake of the folate catabolite p-
aminobenzoyl-glutamate (Carter et al., 2007), we investigated if E. coli cells expressing N. 
gonorrhoeae MtrF can grow in liquid minimal medium (containing 90.4 mM Na2HPO4, 22.0 
mM KH2PO4, 8.5 mM NaCl, 0.1 mM CaCl2, 1.0 mM MgSO4, 20.0 mM NH4Cl, and 22.2 mM 
glucose) supplemented with p-aminobenzoyl-glutamate.  To facilitate this work, we made an E. 
coli knockout strain BL21(DE3)∆abgT∆pabA that lacks both the abgT (Hussein et al., 1998; 
Carter et al., 2007) and pabA (Kaplan and Nichols, 1986) genes.  We then transformed these 
double knockout cells with pET15bΩmtrF, expressing N. gonorrhoeae mtrF, or the empty vector 
pET15b.  Surprisingly, the double knockout E. coli BL21(DE3)∆abgT∆pabA cells, transformed 
with either pET15bΩmtrF or pET15b, could not grow in this liquid medium supplemented with 
p-aminobenzoyl-glutamate up to 1 mM.  However, these cells were capable of growing in liquid 
minimal medium when supplemented with 30 nM p-aminobenzoic acid (PABA).  Within the E. 
coli abg operon, there are two additional genes, abgA and abgB, located upstream of abgT.  The 
products of these two genes are the AbgA and AbgB aminoacyl aminohydrolases, which cleave 
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the catabolite p-aminobenzoyl-glutamate imported by the AbgT transporter to form PABA for 
folic acid synthesis (Carter et al., 2007).  In contrast, the mtr operon of N. gonorrhoeae does not 
possess abgA or abgB related genes (www.genome.ou.edu).  Thus, our data suggest that MtrF 
and AbgT may function differently even though these two membrane proteins belong to the same 
family.     
As PABA is an important precursor for folic acid synthesis, we thought that N. 
gonorrhoeae MtrF might enable uptake of PABA.  It should be noted that PABA is capable of 
diffusing into bacterial cells through the membrane, participating as an intermediate in de novo 
synthesis of the essential vitamin folic acid.  Nonetheless, we decided to compare the radioactive 
PABA content over time in cells transformed with either pET15bΩmtrF or the empty vector 
pET15b.  Surprisingly, as demonstrated in Fig. 3a, E. coli cells producing N. gonorrhoeae MtrF 
showed a significant decrease in the level of [3H]-PABA, in contrast to cells transformed with 
the empty pET15b vector.  Instead of an importer, the data strongly suggested to us that MtrF 
may act as an exporter, capable of expelling the intracellular PABA metabolite from the cell.  
In order to determine whether the conserved MtrF residues, D193, S417, W420, P438, 
R446, D449, and P457, lining the inner wall of the tunnel formed by each protomer are 
important for the function of the transporter, we mutated each residue to alanine, individually 
(Table S2).  We expressed these mutant transporters in BL21(DE3)∆abgT∆pabA.  Western 
analysis suggested that the expression levels of these mutant transporters are comparable with 
that of the wild-type MtrF protein (Fig. S3).  We then measured the accumulation of [3H]-PABA 
in cells harboring the mutant transporters, D193A, S417A, W420A, P438A, R446A, D449A, and 
P457A.  The results showed a significant increase in the levels of [3H]-PABA accumulation in 
cells possessing the mutant transporter D193A, W420A, P438A, D449A, or P457A, when 
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compared with cells expressing wild-type N. gonorrhoeae MtrF (Fig. 3b).  However, cells 
expressing S417A and R426A only indicated a modest change in the [3H]-PABA concentration 
when compared with cells carrying wild-type MtrF (Fig. 3b).  On the contrary, the levels of [3H]-
PABA accumulation in cells expressing the mutants W420A and D449A were nearly the same as 
those transformed with the empty vector, indicating that these mutant transporters are not 
functional and cannot export PABA from cells.  The data suggest that MtrF acts as an efflux 
pump, and these amino acids are important for its function. 
  
Expression of the MtrF transporter decreases intracellular folic acid concentration 
We hypothesized that N. gonorrhoeae MtrF is capable of catalyzing the efflux of the 
folate metabolite PABA.  If this is the case, then cells expressing MtrF should show a lower level 
of intracellular folic acid concentration.  Therefore, we decided to measure the intracellular folic 
acid content of these cells microbiologically using Lactobacillus casei (Wilson and Horne, 
1982).  Cells were grown in liquid minimal medium supplemented with 30 nM PABA.  These 
cells were harvested when the optical density (OD600 nm) reached 0.5 and then assayed to obtain 
their folic acid concentrations.  Consistent with the results from PABA accumulation, the folic 
acid concentration in cells producing MtrF were markedly reduced in comparison with cells 
transformed with the empty vector (Fig. 4).  These data further support our hypothesis that MtrF 
acts as an efflux pump and participates in exporting PABA from the cell.   
We next investigated how residues D193, S417, W420, P438, R446, D449, and P457 
affect the intracellular folic acid concentration. When transformed with plasmids expressing the 
mutant transporter W420A, folic acid production was nearly restored in these cells and the level 
of intracellular folic acid concentration was similar to that of the double knockout strain 
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transformed with the empty vector (Fig. 4).  In addition, cells carrying the mutants, D193A, 
S417A, P438A, D449A, and P457A, indicated a significant increase in the level of folic acid 
concentration when compared with cells expressing wild-type MtrF (Fig. 4).  Again, the data 
indicate that these residues are important for the function of the MtrF efflux pump.  However, for 
cells expressing R446A, the intracellular folic acid content was similar to that of cells carrying 
the wild-type MtrF transporter.     
 
MtrF is an antibiotic efflux pump 
As PABA is an important metabolite for producing the essential folic acid in bacteria, we 
questioned why the function of MtrF appears to be decreasing the intracellular PABA 
concentration.  We postulated that the answer may lie in the ability of MtrF to protect bacterial 
cells by extruding antimetabolites that are structurally similar to PABA, specifically 
sulfonamides.  Sulfonamides are antimicrobial agents, sometimes referred to as antimetabolites 
or growth factor analogs, which are designed to specifically inhibit the essential metabolic 
pathway for folic acid synthesis in bacterial pathogens.  At the chemical level, sulfonamides are 
structurally similar to the metabolite PABA, making them ideal competitive inhibitors.  
Sulfonamides were used in the late 1930s and early 1940s to treat gonorrhea, but the rapid 
emergence of strains resistant to this class of drug resulted in its removal once penicillin became 
available (Unemo & Shafer, 2014); resistant strains were later found to contain mutations in folP 
that encodes the target for sulfonamides.  We therefore suspect that MtrF may be a drug efflux 
pump, which is capable of recognizing and extruding sulfonamide antimetabolites.  In fact, we 
found that the minimum inhibitory concentration (MIC) of sulfanilamide for the N. gonorrhoeae 
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strain WV16 (an mtrF knockout strain) differed from that of the N. gonorrhoeae parental strain 
FA140 by twofold (Table S3). 
To determine if MtrF behaves like a sulfonamide efflux pump, we used E. coli as a 
surrogate host.  We transformed BL21(DE3)∆abgT∆pabA with pET15bΩmtrF or pET15b and 
tested for the susceptibility of these transformants to two different sulfonamide antimetabolites, 
sulfamethazine and sulfanilamide (Table S3).  We found that the BL21(DE3)∆abgT∆pabA cells 
producing MtrF were 32-fold less sensitive to sulfamethazine when compared with 
BL21(DE3)∆abgT∆pabA cells containing the empty pET15b vector.  In addition, this 
BL21(DE3)∆abgT∆pabA/pET15bΩmtrF transformant was found to be eight times more resistant 
to sulfanilamide in comparison to the double knockout cells transformed with pET15b.  These 
data indeed indicate that MtrF functions as a drug efflux pump and reduced bacterial 
susceptibility to sulfonamides. 
In order to further test the drug efflux capability of MtrF, we expressed the mutant 
transporters D193A, S417A, W420A, P438A, R446A, D449A, and P457A in 
BL21(DE3)∆abgT∆pabA and evaluated for their ability to confer sulfamethazine and 
sulfanilamide resistance in vivo.  In most cases, we found that strain BL21(DE3)∆abgT∆pabA 
carrying these MtrF mutants are more sensitive to these two sulfonamides in comparison with 
cells expressing wild-type MtrF (Table S3), thus agreeing with the idea that these residues are 
essential for the function of MtrF. 
To confirm these drug susceptibility testing results, we measured the accumulation of 
radioactive sulfonamide in BL21(DE3)∆abgT∆pabA cells carrying pET15bΩmtrF or pET15b.  
For these experiments, we compared the accumulation of [3H]-sulfamethazine over time in these 
cells.  As shown in Fig. 5, the results indicate a much lower level of [3H]-sulfamethazine 
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accumulation in BL21(DE3)∆abgT∆pabA cells producing MtrF, compared to controlled cells 
harboring the empty pET15b vector, suggesting that MtrF is capable of exporting sulfamethazine 
from the cell. 
When transformed with plasmids expressing the mutant transporters, D193A, S417A, 
W420A, P438A, R446A, D449A, and P457A, the level of intracellular sulfamethazine 
accumulation were much higher than that of cells expressing wild-type MtrF (Fig. 5).  Again, 
these data indicate that residues D193, S417, W420, P438, R446, D449, and P457 are critical for 
the function of the MtrF efflux pump.   
 
MtrF behaves as a PMF-dependent drug efflux pump 
It has been suggested that members of the AbgT family use the proton-motive-force 
(PMF) to transport substrates across the membrane (Prakash et al., 2003).  To elucidate if N. 
gonorrhoeae MtrF is a PMF-dependent transporter, we measured the level of intracellular 
sulfamethazine accumulation in the presence of carbonyl cyanide m-chlorophenylhydrazone 
(CCCP), a de-coupler of the membrane proton gradient.  After the addition of CCCP into the 
assay solution, the accumulation of [3H]-sulfamethazine increased drastically in the MtrF-
expressing cells (Fig. 6a), suggesting the possibility that MtrF is PMF-dependent.   
We then investigated the accumulation level of radioactive sulfamethazine in strain 
BL21(DE3)∆abgT∆pabA/pET15bΩmtrF in the presence of NaCl or KCl.  The concentrations of 
these metal ions were either 5 or 100 mM.  In all cases, the levels of accumulation of [3H]-
sulfamethazine were similar to that in the MtrF-producing strain without the addition of any 
metal ions (Figs. 5 and 6a), indicating that the function of MtrF is metal ion independent. 
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The drug accumulation data strongly suggest that MtrF is a PMF-dependent efflux pump.  
To test this possibility, we next measured the efflux of [3H]-sulfamethazine that had accumulated 
in strain BL21(DE3)∆abgT∆pabA/pET15bΩmtrF over time, both in the absence and presence of 
Na+.  Cells were first loaded with [3H]-sulfamethazine and CCCP was added to inhibit the pump.  
Cells were then re-energized by removing CCCP and adding glucose; thereafter, radioactive 
measurements were performed both in the absence and presence of 5 mM NaCl.  As shown in 
Fig. 6b, the addition of Na+ has essentially no effect on sulfamethazine efflux in 
BL21(DE3)∆abgT∆pabA/pET15bΩmtrF.  These data suggest that MtrF is a PMF-dependent 
efflux pump.                     
 
Conclusions 
In this paper, we report the crystal structure of the N. gonorrhoeae MtrF transporter, 
which reveals a dimeric molecule with a fold very distinct from all other families of transporters.  
Our experimental data strongly suggest that N. gonorrhoeae MtrF is a drug efflux pump, capable 
of removing sulfonamide antimetabolites and mediating resistance to this class of drugs in 
bacterial cells.  It is likely that many members of the AbgT family of transporters may serve as 
antimetabolite efflux pumps to protect cells against these noxious agents. 
 
Experimental procedures 
Cloning, expression and purification of N. gonorrhoeae MtrF 
Briefly, the full-length MtrF membrane protein containing a 6xHis tag at the N-terminus 
was overproduced in E. coli BL21(DE3)ΔacrB cells, which harbor a deletion in the 
chromosomal acrB gene,  possessing pET15bΩmtrF.  Cells were grown in 12 L of Luria-Bertani 
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(LB) medium with 100 µg/mL ampicillin at 25oC.  When the OD600 nm reached 0.5, the culture 
was treated with 0.2 mM isopropyl-β-D-thiogalactopyranoside (IPTG) to induce mtrF 
expression, and cells were harvested within 15 h.  The collected bacteria were resuspended in 
low salt buffer containing 100 mM sodium phosphate (pH 7.2), 10% glycerol, 1 mM 
ethylenediaminetetraacetic acid (EDTA) and 1 mM phenylmethanesulfonyl fluoride (PMSF), 
and then disrupted with a French pressure cell.  The membrane fraction was collected and 
washed twice with high salt buffer containing 20 mM sodium phosphate (pH 7.2), 2 M KCl, 10% 
glycerol, 1 mM EDTA and 1 mM PMSF, and once with 20 mM HEPES-NaOH buffer (pH 7.5) 
containing 1 mM PMSF as described previously (Long et al., 2010).  The membrane protein was 
then solubilized in 2 % (w/v) n-dodecyl-β-D-maltoside (DDM).  Insoluble material was removed 
by ultracentrifugation at 100,000 x g.  The extracted protein was purified with a Ni2+-affinity 
column.  The purified protein was dialyzed and concentrated to 20 mg/ml in a buffer containing 
20 mM Na-HEPES (pH 7.5) and 0.05% DDM.  The 6xHis tag at the N-terminus was then 
cleaved by adding 5 units of thrombin (GE Healthcare Bio-Sciences, Pittsburgh, PA) per mg of 
purified MtrF at room temperature for 20 h.  The protein was subsequently passed through a 
Ni2+-affinity column to remove the free 6xHis tag.  A final purification step was performed using 
a G200 size exclusion column loaded with buffer solution containing 20 mM Na-HEPES (pH 
7.5) and 0.05% DDM.  The purity of the MtrF protein (>95%) was judged using 10% SDS-
PAGE stained with Coomassie Brilliant Blue.  The purified protein was then concentrated to 20 
mg/ml in a buffer containing 20 mM Na-HEPES (pH 7.5) and 0.05% DDM. 
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Crystallization of MtrF 
Crystals of the MtrF transporter were obtained using sitting-drop vapor diffusion.  The 
MtrF crystals were grown at room temperature in 24-well plates with the following procedures.  
A 2 µL protein solution containing 20 mg/mL MtrF protein in 20 mM Na-HEPES (pH 7.5) and 
0.05% (w/v) DDM was mixed with a 2 µL of reservoir solution containing 30% PEG 400, 0.1 M 
sodium acetate (pH 5.0), 0.1 M magnesium acetate, 3% glycerol and 1% (w/v) Sucrose 
monododecanoate.  The resultant mixture was equilibrated against 500 µl of the reservoir 
solution.  Crystals of MtrF grew to a full size in the drops within a month.  Typically, the 
dimensions of the crystals were 0.2 mm x 0.2 mm x 0.2 mm.  Cryoprotection was achieved by 
raising the PEG 400 concentration to 32%. 
Crystals of the Ta6Br122+ cluster derivative were prepared by incubating the crystals of 
MtrF in solution containing 32% PEG 400, 0.1 M sodium acetate (pH 4.6), 0.05 M magnesium 
acetate, 5% glycerol, 1% (w/v) Sucrose monododecanoate, 0.05% (w/v) DDM and 0.5 mM 
Ta6Br12.2Br (Jena Bioscience GmbH, Jena, Germany) for 4 hours at 25oC. 
 
Data collection, structural determination and refinement  
All diffraction data were collected at 100 K at beamline 24ID-C located at the Advanced 
Photon Source, using an ADSC Quantum 315 CCD-based detector.  Diffraction data were 
processed using DENZO and scaled using SCALEPACK (Otwinowski and Minor, 1997).  
Crystals of MtrF belong to space group P61 (Table S1).  Based on the molecular weight of MtrF 
(56.3 kDa), two molecules per asymmetric unit with a solvent content of 71.9% were expected.  
The heavy-atom derivative (Ta6Br122+ cluster) (Jena Bioscience GmbH, Jena, Germany) was 
isomorphous with the native crystal (Table S1).  Four tantalum cluster sites were identified using 
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SHELXC and SHELXD (Schneider and Sheldrick, 2002) as implemented in the HKL2MAP 
package (Pape and Schneider, 2004).  Single isomorphous replacement with anomalous 
scattering (SIRAS) was employed to obtain experimental phases using the program MLPHARE 
(Otwinowski, 1991).  These heavy-atom sites were refined by MLPHARE (Otwinowski, 1991) 
as well.  The resulting phases were subjected to density modification and NCS averaging using 
the program RESOLVE (Terwilliger, 2001).  Density modified phases were good enough to 
allow us to visualize the secondary structural features of the molecule.  The resulting phases 
were of excellent quality and allowed for tracing of most of the molecule.  After tracing the 
initial model manually using the program Coot (Emsley and Cowtan, 2004), the model was 
refined against the native data at 3.95 Å-resolution using PHENIX (Adams et al., 2002), leaving 
5% of reflections in Free-R set.  Iterations of refinement using PHENIX (Adams et al., 2002) and 
CNS (Brünger et al., 1998) and model building in Coot (Emsley and Cowtan, 2004) lead to the 
structural model of the MtrF transporter (Table S1). 
 
Construction of the double knockout strain 
The double knockout E. coli strain BL21(DE3)∆abgT∆pabA was produced from the 
BL21(DE3) strain using an RED disruption system as described by Datsenko and Wanner 
(Datsenko and Wanner, 2000).  The ∆abgT::kan cassette, which was used to replace the 
chromosomal abgT gene, was produced by PCR, and then introduced into pKD46/BL21(DE3) 
by electroporation.  The knockout BL21(DE3)∆abgT::kan strain was selected on LB plate 
containing 30 µg/ml kanamycin, and verified by PCR.  The kanamycin resistant gene was then 
released to generate the BL21(DE3)∆abgT knockout strain.  The deletion of pabA from 
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BL21(DE3)∆abgT was done using similar procedures as described above to generate the final 
BL21(DE3)∆abgT∆pabA double knockout strain. 
 
Site-directed mutagenesis  
Site-directed point mutations on residues D193, S417, W420, P438, R446, D449, and 
P457, which are expected to be critical for the function of the MtrF efflux pump, were performed 
to generate the single point mutants D193A, S417A, W420A, P438A, R446A, D449A, and 
P457A.  The primers used for these mutations are listed in Table S2. All oligonucleotides were 
purchased from Integrated DNA Technologies, Inc. (Coralville, IA) in a salt-free grade. 
 
Accumulation assays of p-aminobenzoic acid 
In brief, E. coli BL21(DE3)∆abgT∆pabA carrying pET15bΩmtrF or pET15b were grown 
in LB broth with 100 µg/mL ampicillin at 37 oC.  When the OD600 nm reached 0.5, the culture was 
treated with 0.2 mM IPTG to induce mtrF expression, and cells were harvested within 2 h.  Cells 
were washed twice with buffer containing 50 mM potassium phosphate (pH 7.5), twice with 
buffer containing 100 mM Tris-HCl (pH 7.5), and then suspended in the same buffer to OD600 nm 
of 15.  [3H]-PABA (Moravek Biochemicals, Brea, CA) was then added to a final concentration 
of 0.3 µM.  Samples of 100 µl were taken at intervals, applied directly to prewetted glass-fiber 
filters, and washed twice with 5-ml aliquots of the same buffer; 0.5-µm glass-fiber filters (MFS, 
Dubbin, CA) were used with a filter apparatus.  Filters were then incubated for 30 min in 
scintillation fluid (ScintiVerse™ BD) and counted with a Packard Tri-Carb 1600TR liquid 
scintillation counter (Perkin Elmer, Waltham, MA). 
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For [3H]-PABA accumulations in cells expressing the MtrF mutants, the procedures for 
sample preparation were the same as above.  Cells were incubated with 0.3 µM [3H]-PABA for 
15 min, applied directly to prewetted glass-fiber filters, and washed immediately twice with 5-
mL aliquots of the same buffer.  Filters were then incubated for 30 min in scintillation fluid 
(ScintiVerse™ BD) and counted with a Packard Tri-Carb 1600TR liquid scintillation counter 
(Perkin Elmer, Waltham, MA).       
        
Assays of folic acid 
The concentration of folic acid in the double knockout BL21(DE3)∆abgT∆pabA strain 
transformed with pET15bΩmtrF or pET15b was measured using Lactobacillus casei based on 
the microbiological procedure of Wilson and Horne (1982).  The concentrations of folic acid in 
BL21(DE3)∆abgT∆pabA expressing the mutant transporters were measured using the same 
procedures. 
   
Drug susceptibility assays 
The susceptibilities to sulfamethazine and sulfanilamide of E. coli 
BL21(DE3)∆abgT∆pabA harboring pET15bΩmtrF expressing the wild-type or mutant 
transporters, or the pET15b empty vector were tested on agar plates.  Cells were grown in Luria 
Broth (LB) medium with 100 µg/mL ampicillin at 37 oC.  When the OD600 nm reached 0.5, the 
cultures were induced with 0.2 mM IPTG and harvested in two hours after induction.  The 
minimum growth inhibitory concentrations (MICs) to sulfamethazine and sulfanilamide of E. 
coli BL21(DE3)∆abgT∆pabA (incoculum, 500 cells/mL) harboring these vectors were then 
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determined using LB agar containing 50 µg/mL ampicillin, 0.1 mM IPTG and different 
concentrations of sulfamethazine and sulfanilamide, respectively. 
For the MIC studies with N. gonorrhoeae cells, we used strains FA140 and WV16 (as 
FA140 but mtrF::kan) described by Veal and Shafer (2003).  These strains were grown on GCB 
agar plates.  The susceptibilities to sulfanilamide were performed using the agar dilution assay 
described by Hagman et al. (1995).    
   
Accumulation assays of sulfamethazine 
The procedures for [3H]-sulfamethazine accumulation were the same as those for [3H]-
PABA accumulation.  Cells were incubated with 75 nM [3H]-sulfamethazine (Moravek 
Biochemicals, Brea, CA) for 15 min, applied directly to prewetted glass-fiber filters, and washed 
immediately twice with 5-ml aliquots of the same buffer.  Filters were then incubated for 30 min 
in scintillation fluid (ScintiVerse™ BD) and counted with a Packard Tri-Carb 1600TR liquid 
scintillation counter (Perkin Elmer, Waltham, MA).  For metal ion dependent experiments, cells 
were incubated with 75 nM [3H]-sulfamethazine in the presence of NaCl or KCl (5 or 100 mM) 
for 15 min, then applied directly to prewetted glass-fiber filters, and washed immediately twice 
with 5-ml aliquots of buffer containing 100 mM Tris-HCl (pH 7.5) and 5 or 100 mM salt (NaCl 
or KCl).    
 
Efflux assays of sulfamethazine 
E. coli BL21(DE3)∆abgT∆pabA carrying pET15bΩmtrF or pET15b were grown in LB 
broth with 100 µg/ml ampicillin at 37oC.  When the OD600 reached 0.5, the culture was induced 
with 0.2 mM IPTG, and cells were harvested within 2 h.  Cells were washed twice with buffer 
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containing 50 mM potassium phosphate (pH 7.5), twice with buffer containing 100 mM Tris-
HCl (pH 7.5), and then suspended in the same buffer to OD600 nm of 15.  CCCP was added to the 
cell suspension at a final concentration of 100 µM.  Cells were then incubated for 10 min, 
pelleted, washed twice and resuspended in the same buffer to OD600 nm of 10.  [3H]-
sulfamethazine was then added to a final concentration of 37 nM.  Cells were incubated for 15 
min, and a final concentration of 0.2% glucose was then added to the cell suspension.  When 
needed, a final concentration of 5 mM NaCl was also added at the same time.  At various time 
points, samples of 100 µl were applied directly to prewetted glass-fiber filters, and washed twice 
with 5-ml aliquots of buffer containing 100 mM Tris-HCl (pH 7.5).  Filters were then incubated 
for 30 min in scintillation fluid (ScintiVerse™ BD) and counted with a Packard Tri-Carb 
1600TR liquid scintillation counter (Perkin Elmer, Waltham, MA). 
 
Accession code 
Atomic coordinates and structure factors for the structure of MtrF have been deposited at 
the RCSB Protein Data Bank with an accession code 4R1I.  
 
Acknowledgements 
This work was supported by NIH Grants R37AI021150 (W.M.S.) and R01GM086431 
(E.W.Y.) and a VA Merit Award (W.M.S.) from the Medical Research Service of the 
Department of Veterans Affairs.  W.M.S. is the recipient of a Senior Research Career Scientist 
from the Medical Research Service of the Department of Veterans Affairs.  This work is based 
upon research conducted at the Northeastern Collaborative Access Team beamlines of the 
Advanced Photon Source, supported by an award GM103403 from the National Institutes of 
134 
 
 
General Medical Sciences. Use of the Advanced Photon Source is supported by the U.S. 
Department of Energy, Office of Basic Energy Sciences, under Contract No. DE-AC02-
06CH11357.   
 
References 
Adams, P.D., Grosse-Kunstleve, R.W., Hung, L.W., Ioerger, T.R., McCroy, A.J., Moriarty, N.W. 
et al. (2002). PHENIX: building new software for automated crystallographic structure 
determination. Acta Crystallogr. 58, 1948-1954. 
Brünger, A.T., Adams, P.D., Clore, G.M., DeLano, W.L., Gros, P., Grosse-Kunstleve, R.W., 
Jiang, J.S., Kuszewski, J., Nilges, M., Pannu, N.S., Read, R.J., Rice, L.M., Simonson, T., 
and Warren, G.L. (1998). Crystallography & NMR system: A new software suite for 
macromolecular structure determination. Acta Crystallogr. D54, 905-921. 
Bolla, J.R., Su, C.C., Do, S.V., Radhakrishnan, A., Kumar, N., Long, F., Chou, T.H., Delmar, 
J.A., Lei, H.T., Rajashankar, K.R., Shafer, W.M., and Yu, E.W. (2014). Crystal structure of 
the Neisseria gonorrhoeae MtrD inner membrane multidrug efflux pump. PLoS One 9, 
e97903. 
Carter, E.L., Jager, L., Gardner, L., Hall, C.C., Willis, S., and Green, J.M. (2007). Escherichia 
coli abg genes enable uptake and cleavage of the folate catabolite p-aminobenzoyl-
glutamate. J. Bacteriol. 189, 3329-3334. 
Datsenko, K.A., and Wanner, B.L. (2000). One-step inactivation of chromosomal genes in 
Escherichia coli K-12 using PCR products. Proc. Nat. Acad. Sci. 97, 6640-6645. 
Delahay, R.M., Robertson, B.D., Balthazar, J.T., and Ison, C.A. (1997). Involvement of the 
gonococcal MtrE protein in the resistance of Neisseria gonorrhoeae to toxic hydrophobic 
agents. Microbiology 143, 2127-2133. 
Emsley, P., and Cowtan, K. (2004). Coot: model-building tools for molecular graphics. Acta 
Crystallogr. D60, 2126. 
Folster, J.P., and Shafer, W.M. (2005). Regulation of mtrF expression in Neisseria gonorrhoeae 
and its role in high-level antimicrobial resistance. J. Bacteriol. 187, 3713-3720. 
Hagman, K.E., Pan, W., Spratt, B.G., Balthazar, J.T., Judd, R.C., and Shafer, W.M. (1995). 
Resistance of Neisseria gonorrhoeae to antimicrobial hydrophobic agents is modulated by 
the mtrRCDE efflux system. Microbiology 141, 611-622. 
135 
 
 
Hagman, K.E., and Shafer, W.M. (1995). Transcriptional control of the mtr efflux system of 
Neisseria gonorrhoeae. J. Bacteriol. 177, 4162-4165. 
Hagman, K.E., Lucas, C.E., Balthazar, J.T., Snyder, L.A., Nilles, M., Judd, R.C., and Shafer, 
W.M. (1997). The MtrD protein of Neisseria gonorrhoeae is a member of 
resistance/nodulation/division protein family constituting part of an efflux system. 
Microbiology 143, 2117-2125. 
Hussein, M.J., Green, J.M., and Nichols, B.P. (1998). Characterization of mutations that allow p-
aminobenozyl-glutamate utilization by Escherichia coli. J. Bacteriol. 180, 6260-6268. 
Janganan, T.K., Zhang, L., Bavro, V.N., Matak-Vinkovic, D., Barrera, N.P., Burton, M.F., Steel, 
P.G., Robinson, C.V., Borges-Walmsley, M.I., and Walmsley, A.R. (2011). Opening of the 
outer membrane protein channel in tripartite efflux pumps is induced by interaction with the 
membrane fusion partner. J. Biol. Chem. 286, 5484-5493. 
Janganan, T.K., Bavro, V.N., Zhang, L., Borges-Walmsley, M.I., and Walmsley, A.R. (2013). 
Tripartite efflux pumps: energy is required for dissociation, but not assembly or opening of 
the outer membrane channel of the pump. Mol. Microbiol. 88, 590-602. 
Kaplan, J. B., and Nichols, B. P. (1986). Nucleotide sequence of Escherichia coli pabA and its 
evolutionary relationship to trp(G)D.  J. Mol. Biol. 168, 451-468. 
Lee, E.H., and Shafer, W.M. (1999). The farAB-encoded efflux pump mediates resistance of 
gonococci to long-chained antibacterial fatty acids. Mol. Microbiol. 33, 7753-7758. 
Lei, H.T., Chou, T.H., Su, C.C., Bolla, J.R., Kumar, N., Radhakrishnan, A., Long, F., Delmar, 
J.A., Do, S.V., Rajashankar, K.R., Shafer, W.M., and Yu, E.W. (2014). Crystal structure of 
the open state of the Neisseria gonorrhoeae MtrE outer membrane channel. PLoS One 9, 
e97475.   
Long, F., Su, C.-C., Zimmermann, M.T., Boyken, S.E., Rajashankar, K.R., Jernigan, R.L., and 
Yu, E.W. (2010). Crystal structures of the CusA heavy-metal efflux pump suggest 
methionine-mediated metal transport mechanism. Nature 467, 484-488. 
Lucas, C.E., Hagman, K.E., Levin, J.C., Stein, D.C., and Shafer, W.M. (1995). Importance of 
lipooligosaccharide structure in determining gonococcal resistance to hydrophobic 
antimicrobial agents resulting from the mtr efflux system. Mol. Microbiol. 16, 1001-1009. 
Otwinowski, Z. (1991). ML-PHARE, CCP4 Proc. 80-88 (Daresbury Laboratory, Warrington, 
UK). 
Otwinowski, Z., and Minor, M. (1997). Processing of X-ray diffraction data collected in 
oscillation mode. Methods Enzymol. 276, 307-326. 
Pape, T., and Schneider, T.R. (2004). HKL2MAP: a graphical user interface for macromolecular 
phasing with SHELX programs. J. Appl. Crystallogr. 37, 843-844. 
136 
 
 
Prakash, S., Cooper, G., Singhi, S., and Saier, M.H. Jr. (2003). The ion transporter superfamily. 
Biochim. Biophys. Acta 1618, 79-92. 
Rouquette-Loughlin, C., Dunham, S.A., Kuhn, M., Balthazar, J.T., and Shafer, W.M. (2003). 
The NorM efflux pump of by Neisseria gonorrhoeae and Neisseria meningitidis recognizes 
antimicrobial cationic compounds. J. Bacteriol. 185, 1101-1106. 
Schneider, T.R., and Sheldrick, G.M. (2002). Substructure solution with SHELXD. Acta 
Crystallogr. D58, 1772–1779. 
Shafer, W.M., Qu, X.-D., Waring, A.J., and Lehrer, R.I. (1998). Modulation of Neisseria 
gonorrhoeae susceptibility to vertebrate antibacterial peptides due to a member of the 
resistance/nodulation/division efflux pump family. Proc. Natl. Acad. Sci. USA 95, 1829-
1833. 
Shafer, W.M., Veal, W.L., Lee, E.H., Zarentonelli, L., Balthazar, J.T., and Rouquette, C. (2001). 
Genetic organization and regulation of antimicrobial efflux systems possessed by Neisseria 
gonorrhoeae and Neisseria meningitidis. J. Mol. Microbiol. Biotechnol. 3, 219-225. 
Terwilliger, T. C. (2001). Maximum-likelihood density modification using pattern recognition of 
structural motifs. Acta Crystallogr. D57, 1755-1762. 
Tseng, T.T., Gratwick, K.S., Kollman, J., Park, D., Nies, D.H., Goffeau, A., and Saier, M.H. Jr. 
(1999). The RND permease superfamily: an ancient, ubiquitous and diverse family that 
includes human disease and development protein. J. Mol. Microbiol. Biotechnol. 1, 107-
125. 
Unemo, M., and Shafer, W.M. (2014).  Antimicrobial resistance in Neisseria gonorrhoeae in the 
21st Century: Past, Evolution, and Future. Clin. Microbiol. Rev. 27, 587-613.  
Veal, W.L., Nicholas, R.A., and Shafer, W.M. (2002). Overexpression of the MtrC-MtrD-MtrE 
efflux pump due to an mtrR mutation is required for chromosomally mediated penicillin 
resistance in Neisseria gonorrhoeae. J. Bacteriol. 184, 5619-24. 
Veal, W.L., and Shafer, W.M. (2003). Identification of a cell envelope protein (MtrF) involved 
in hydrophobic antimicrobial resistance in Neisseria gonorrhoeae. J. Antimicrob. 
Chemother. 51, 27-37. 
Warner, D.M., Shafer, W.M., and Jerse, A.E. (2008). Clinically relevant mutations that cause 
derepression of the Neisseria gonorrhoeae MtrC-MtrD-MtrE efflux pump system confer 
different levels of antimicrobial resistance and in vivo fitness. Mol. Microbiol. 70, 462-478. 
Wilson, S.D., and Horne, W.D. (1982). Use of glycerol-crypotected Lactobacillus casei for 
microbiological assay of folic acid. Clin. Chem. 28, 1198-1200. 
 
137 
 
 
 
Legends of figures 
α1#
2a#
2c#
HP1#
3b#
HP2#
8a#
8b#
9#
7c#
N#
C#
3a#
4# 5#
7b#
7a#
2b#
6#
1a#
1b#
(a)#
 
TM1a 
TM1b 
TM2a 
TM2b 
TM2C 
HP1a 
HP1b 
TM3a 
TM3b 
TM4 
α1 
TM5 
TM6 
TM7b 
TM7a 
TM7c 
HP2a HP2b 
TM8a 
TM8b 
TM9 
N 
C 
Inner 
Membrane 
Periplasm 
Cytoplasm 
(b)$
 
138 
 
 
Inner 
Membrane 
Periplasm 
Cytoplasm 
(c)$
 
(d)$
 
139 
 
 
Fig. 1.  Structure of the N. gonorrhoeae MtrF transporter.  (a) Transmembrane topology of N. 
gonorrhoeae MtrF.  The transporter contains nine transmembrane helices (TMs) and two 
hairpins (HPs).  (b) Ribbon diagram of a dimer of MtrF viewed in the membrane plane.  The 
right subunit of the dimer is colored using a rainbow gradient from the N-terminus (blue) to the 
C-terminus (red), whereas the left subunit is colored gray.  The MtrF dimer forms a bowl-shaped 
structure with a concave aqueous basin facing the intracellular solution.  (c) Surface 
representation of a cross section of the MtrF dimer sliced through the middle of the protein.  
Each protomer forms an internal cavity (red arrow), which is accessible to the cytoplasm.  (d) 
Bottom view of a surface representation of the MtrF dimer, indicating a solvent accessible cavity 
(red circle) from each protomer of the protein.  The two protomers are colored gray and yellow. 
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Fig. 2.  Outer and inner cores of MtrF. (a) The outer core of MtrF, comprising TMs 1, 2, 5, 6 and 
7 (colored slate), contributes to dimerization as well as formation of a frame-like structure 
housing the inner core of the protomer.  The inner core of MtrF is composed of TMs 3, 4, 8, 9 as 
well as HPs 1 and 2 (colored yellow).  (b) The inner core of MtrF forms a channel (colored 
purple) spanning approximately from the middle of the inner membrane up to the periplasmic 
space.  This channel was calculated using the program CAVER 
(http://loschmidt.chemi.muni.cz/caver).  The secondary structural elements of the MtrF protomer 
are in yellow.  Residues D193, S417, W420, P438, R446, D449, and P457 are in green sticks.        
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Fig. 3.  Accumulation of radioactive p-aminobenzoic acid.  (a) Time course of [3H]-PABA 
accumulation by E. coli BL21(DE3)∆abgT∆pabA double knockout cells transformed with 
pET15bΩmtrF or pET15b.  Cells expressing mtrF (red curve) show a significant decrease in 
[3H]-PABA accumulation when compared with cells carrying the empty vector (black curve).  
(b) Mutants of the MtrF transporter.  Cells possessing the mutant transporter D193A, W420A, 
P438A, D449A and P457A show a significant increase in the level of [3H]-PABA accumulations 
compared with cells expressing wild-type MtrF.  However, cells expressing S417A and R446A 
only show a modest change on the [3H]-PABA concentration when compared with cells carrying 
wild-type MtrF.  The data showed in (a) and (b) are the cumulative average of three successive 
recordings. 
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Fig. 4.  Intracellular folic acid concentration.  Folic acid concentration in E. coli 
BL21(DE3)∆abgT∆pabA double knockout cells expressing MtrF were markedly reduced in 
comparison with cells transformed with the empty vector.  When transformed with plasmid 
expressing the mutant transporter, D193A, S417A, W420A, P438A, D449A, and P457A, folic 
acid production was significantly increased in these cells.  However, the level of intracellular 
folic acid concentration in BL21(DE3)∆abgT∆pabA cells expressing R446A was nearly identical 
to that of the double knockout strain carrying wild-type MtrF.  Each bar represents the mean of 
three separate cultures. 
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Fig. 5.  Accumulation of radioactive sulfamethazine.  E. coli BL21(DE3)∆abgT∆pabA cells 
expressing MtrF show a significant decrease in [3H]-sulfamethazine accumulation when 
compared with cells carrying the empty vector.  When transformed with plasmids expressing the 
mutant transporters, D193A, S417A, W420A, P438A, R446A, D449A, and P457A, the levels of 
intracellular [3H]-sulfamethazine accumulation were much higher than that of cells expressing 
wild-type MtrF.  Each bar represents the mean of three different cultures. 
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Fig. 6.  Transport of sulfamethazine via MtrF.  (a) Accumulation of radioactive sulfamethazine 
in BL21(DE3)∆abgT∆pabA/pET15bΩmtrF cells with different sodium or potassium ion 
concentrations.  (b) Efflux of radioactive sulfamethazine in 
BL21(DE3)∆abgT∆pabA/pET15bΩmtrF cells in the absence and presence of sodium ions.  The 
presence of Na+ does not affect [3H]-sulfamethazine efflux in 
BL21(DE3)∆abgT∆pabA/pET15bΩmtrF cells (black, controlled cells transformed with empty 
vector; red, 0 mM NaCl; magenta, 5 mM NaCl).  The data showed in (a) and (b) are the 
cumulative average of three successive recordings. 
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NgMtrF       -------MSQTDARRSG--------------RFLRTVEWLGNMLPHPVTLFIIFIVLLLIASAVGAYFGLSVPDPRPVGAK---GRADDGL--IHVVSLLDADGLIKILTHTVKNFTGFA 94 
EcAbgT       -----MSMSSIPSSSQS-------------GKLYGWVERIGNKVPHPFLLFIYLIIVLMVTTAILSAFGVSAKNPTDG---------TP----VVVKNLLSVEGLHWFLPNVIKNFSGFA 89 
AbAbgT       -----------MTRTH---------------GWLARLEQLGNRLPHPTLLFVWFCLLLLPLTAVLGALDVTATHPLT-DET------------ITAHSLLDADGLRYLFTTLVGNFTGFA 81 
NmMtrF       -------MSQTDTQRDG--------------RFLRTVEWLGNMLPHPVTLFIIFIVLLLIASAVGAYFGLSVPDPRPVGAK---GRADDGL--IYIVSLLNADGFIKILTHTVKNFTGFA 94 
CcAbgT       MSDAAPPVSSPPPRQK---------------GLLGVVERLGNLLPEPVMIFVWLILGLMVLSAIGQALGWSASITYAGDEAPQFGELENGVLTYAASSLFSEANLARLFTEMPKTLTSFA 105 
SpAbgT       ------------------------------MRFLNIVERLGNLLPHPITLFALFCVAVILISGIAGYFELTVADPRPVGSH---GRSADGL--IHVVSLMNAEGLRMIVSNLVTNFTGFT 85 
PmMtrF       -------MTTTQQQKKGS-------------KFLHTVEWLGNMLPHPVTLFMIFIVLLLITSALGEYFGLAVADPRPEGVK---GRAADGM--IYVVSLLNAEGLSRILTNLVKNFTNFA 95 
VcAbgT       -------MTRREQMSSSASINQNAPKKPLITRFLDGVEYLGNLLPHPITLFAIFCVVLLVASGIAGYFELSVVDPRPEGAK---GRAADGM--IHVVSLLNADGLELIVTNLVKNFVGFA 108 
BhAbgT       -MKPAPHVELKPNQRG------------VFVRFLDIIEKYGNKLPDPIMLFVIMAVLILICSAIFSALGTSAVHPGTG---------EE----IEVVNLLNGEGFILILTELVNNFTSFP 94 
PdAbgT       ------------------------------MRALNVVERAGNKLPDPVTIFLLLCIIVVILSAVISNLGVEEIHPSTK---------EV----VKVVNLLEKEQIQSYLGSIVTNFQSFA 77 
SaAbgT       -------MTSKHQQKGS-----------IVNRFLNSVEKIGNKLPDPSVLFFLMCVGLAIMTWVISLFNVSVKHPGTH---------QT----IYIKNIISHDGFTMIMNDTIKNFSEFP 89 
TdAbgT       -------MDKKKNKEVS--------------GFLKGVERIGNKLPHPAMIFLILSIIVIIVSALAEAYGTPVTYFDAK--K---GKEVT----IGAVSLLNLDGLRYILNTATKNFTGFA 90 
CdAbgT       -----MSTTTPPHKTAP-------------SGFLGKIEQLGNRLPDPFWIFAFLAIIVAISSWIGSAIGMTAVNPQDG---------ST----VEVTNLLTKEGATKMVSEAVNNFVAFP 89 
                                                 :*  ** :*.*  :*  : : :   : :                                 .::        .     .:  *.  
 
 
 
 
 
NgMtrF       PLGTVLVSLLGVGIAEKSGLISALMRLLLTKSPRKLTTFMVVFTGILSNTASELGYVVLIPLSAVIFHSLGRHPLAGLAAAFAGVSGGYSANLFLGTIDPLLAGITQQAAQIIHPDYVVG 214 
EcAbgT       PLGAILALVLGAGLAERVGLLPALMVKMASHVNARYASYMVLFIAFFSHISSDAALVIMPPMGALIFLAVGRHPVAGLLAAIAGVGCGFTANLLIVTTDVLLSGISTEAAAAFNPQMHVS 209 
AbAbgT       PLGVVLVAMLGLGVAEQSGLLSVSLASLVRRSSGGALVFTVAFAGVLSSLTVDAGYVVLIPLAGLVFQLAGRPPIAGIATAFAAVSGGFSANLLVGPVDATLAGLSTEAAHIIDPDRTVA 201 
NmMtrF       PLGTVLVSLLGVGIAEKSGLISALMRLLLTKSPRKLTTFMVVFTGILSNTASELGYVVLIPLSAIIFHSLGRHPLAGLAAAFAGVSGGYSANLFLGTIDPLLAGITQQAAQIIHPDYVVG 214 
CcAbgT       PLGLVLVVILGAAVAERSGLFSALIRASLREAPKRILTPLVVIIGMVSHHASDAAYVVFIPLAGLLYAAVGRHPLAGIAAGFAAVSGGFAGNLTPGQFDVVLFGFTQEAARIIDPTWTMN 225 
SpAbgT       PLGTVLVALLGVGIAERSGLLSAAMRALVMGASKRLVTVTIVFAGIMSNTAAELGYVVLIPMAAMIFHSLGRHPLAGLAAAFAGVSGGYSANLLLGTVDPLLSGITEAAARMIDPDYSVG 205 
PmMtrF       PLGTVLVALLGVGIAEKAGLLSAVMRLLVTKSPRKLTTFTIVFAGILSNTASELGYVVLIPLAAIIFHSLGRHPLAGLAAAFAGVSGGYSANLLLGTIDPLLAGITQQAAQIIDPTYTVG 215 
VcAbgT       PLGTVLVAMLGVAIAEHSGLLSAAMRGLVMGASKRMVTFTVVFAGIISNTASELGYVVLIPLAAMLFHSLGRHPLAGLAAAFAGVSGGYSANLLIGTVDPLLSGITETAARMIDPTYSVG 228 
BhAbgT       PLGLVLVVMLGVGVAESTGLLSALMKTTILNAPRKLILPTIVLVAMLGNAAADAAMVVLPPIVAMIFIALGRHPLAGLAAAYASVAGGFSANLILSMLDPLVAGFTQTGAQMIDPDYVAN 214 
PdAbgT       PLGLVLVTMLGAGVAEKSGFMEVLMKKGISKVPQKLVTVAIVFAGMLSHTAADVGFIILPPLAALVFLGIGRHPLVGMFAAFAGVAGGFAANVMLSTTDVLLAGFTIPAAQMMDPSYQGN 197 
SaAbgT       ALGLVLAVMIGIGVAEKTGYFDKLMISVVNRAPRFLILPTIILIGILGSTAGDAATIILPPLAAMLFIKIGYHPIAGLTMAYASAVGGFAANIVVGMQDALVYSFTEPATRIVSDSIKTN 209 
TdAbgT       PLGTVLVAMLGVGVAEWTGLINTSLKKLLSGVHPRLLTVVVVFAGIMSNVASDAGYVVVIPLGAIVFANAGRHPMAGLAAAFAGVSGGFSANLMLGTIDPLLTGITVEALHNAGMDIAID 210 
CdAbgT       PLGVIITVMLGVSVAEHSGFISALVRAMVAKVGPKTLTYVVALAGVTGSIASDAVYVILISLGAMSFRALGRSPIVGAMVAFAASSAGFNASLILNITDVLLSGISTSAAQLVDPEYHVS 209 
             .** ::. ::* .:**  * :   :               : : .. .  : :   ::. .: .: :   *  *:.*   . *.   *: ..:     *  : .::  .             
 
 
 
 
 
NgMtrF       PEANWFFMAASTFVIALIGYFVTEKIVEPQLGPYQSDLSQEEKDIRHSNE------------------ITPLEYKGLIWAGVVFIALSALLAWSIV-----PADGILRHPET--GLVAGS 309 
EcAbgT       VIDNWYFMASSVVVLTIVGGLITDKIIEPRLGQWQG-----NSDEKLQT-------------------LTESQRFGLRIAGVVSLLFIAAIALMVI-----PQNGILRDPIN--HTVMPS 298 
AbAbgT       ATGNYWFIIASTFLVTGLVTLITRTLTEPRLAHANTVADASVDAPQIHS-------------------------RAMKWTGLT-LAILLAGLALLV----LPNDAPLR--HPDTGSVLGS 289 
NmMtrF       PEANWFFMVASTFVIALIGYFVTEKIVEPQLGPYQSDLSQEEKDIRHSNE------------------ITPLEYKGLIWAGVVFVALSALLAWSIV-----PADGILRHPET--GLVSGS 309 
CcAbgT       PLGNWWYILAIVVVFTPIAWFLTDKVVEPRLGPWGGQADDALKAELAKSA------------------VTADEKRGLKFAGLAALAIVALFAALSL----IPGFTPLID-ETKTGPAQLT 322 
SpAbgT       PEVNWYFMFVSTFVITFLGAFVTEKIVEPKLGKYQDGDADETVLQS-MES------------------VSAIEKRGLKWAGLSVLILAIMLALLVV-----PEGAPLRHPDT--GLVSGS 299 
PmMtrF       PEANWFFMAASTFVIAFIGYFITEKIVEPQLGPYNSHLSQEELDLQHSNE------------------VSPLERKGLRYAGLVFLILCALLAWTVV-----PENGILRDPKT--GLVTGS 310 
VcAbgT       PEVNWYFMAASTFVIAILGAFVTEKIVEPKLGKYDVSEASDDLSQDKMGS------------------LTALEKKALAYAGLAVVVVSALLAWTIV-----PADGVLRGED---GLVSGS 322 
BhAbgT       PAMNYYFLVASCLVLVPVAVWVTTKIVEPRLGTYTG-----EVEEITG--------------------VTKEEKKGLRWAGISVVILAVVFLFLTV-----PEQALLRDPETGS--LTVS 302 
PdAbgT       PAMNLYFAFISAIVLTFAGAFVTEKFIAPRFTKYNDS----TNDKDIQE-------------------LSELENKGIKYALLSLLVVVVVIVALCI-----GDNAFMKDPETGSILSSNA 289 
SaAbgT       VAMNWYFIAASVVVLLPTILLVTTKLIIPRLGKYDDSLMHDDHEETSSH-------------------ITDKEAHALKWANISFIVTIILLIITAI-----PEHSFLRNAKTGSL-LDDA 304 
TdAbgT       PTCNWFFMIVSTFILTVVGTFVTEKIVEKNLGTYNGSYKPDNMPIS------------------------DVENKGLKLAGISVLIMAVILIIGLFGLPKLPGLAVLREIDPKTGESSIS 306 
CdAbgT       TLANYFFVVASFLVLALIITAVTELFVKNRARQLVDHDHIDHSELSFRDDDHPDLGAKTDEELAEEIALHSGEIRALTIAGVAFIGMLAVYFALLF----VPASPFYSE-ES----AMSS 320 
                * ::     .:.      :*  .   .                                             .:  : :  :          .                       :  
 
 
 
 
 
NgMtrF       PFLKS-IVVFIFLLFALPGIVYGRITRSLRGEREVVNAMAESMSTLGLYLVIIFFAAQFVAFFNWTNIGQYIAVKGAVFLKEVGLAGSVLFIGFILICAFINLMIGSASAQWAVTAPIFV 428 
EcAbgT       PFIKG-IVPLIILFFFVVSLAYGIATRTIRRQADLPHLMIEPMKEMAGFIVMVFPLAQFVAMFNWSNMGKFIAVGLTDILESSGLSGIPAFVGLALLSSFLCMFIASGSAIWSILAPIFV 417 
AbAbgT       PFIHG-LVVIVALIAGICGAVYGRVSGQFRNSGAVITAMEVTMASMAGYLVLMFFAAQFVAWFNYSQLGLLLAVKGAAWLGALTVPKVVLLLLFVVLTALINLMIGSASAKWSILAPVFI 408 
NmMtrF       PFLKS-IVVFIFLLFALPGIVYGRVTRSLRGEQEVVNAMAESMSTLGLYLVIIFFAAQFVAFFNWTNIGQYIAVKGATFLKEVGLGGSVLFIGFILICAFINLMIGSASAQWAVTAPIFV 428 
CcAbgT       PFYGA-LIAGFMMLFLAGGVAYGVGVGTVKTEGDVVNMMADGVRSVAPYIVFAFFAAHFVAMFNWSRLGPIAAIHGAETLKAMNLPAPLLLVSVLGFSSVLDLFIGSASAKWSALAPVVV 441 
SpAbgT       PFLKG-IVAFIFICFAIPGFVYGKVVGSINNDRDVINAMSHSMSTMGLYIVLVFFAAQFVAFFNWSNLGAVLAVLGADALQSIGLTGPILFLFFIMLCGFINLMLGSASAQWAITAPIFV 418 
PmMtrF       PFLKS-IVAFIFILFAIPGTVYGIVTKSIRSEKDVVNAMAEAMSTLGLYLVIIFFASQFVAFFNWTNIGQYIAVKGANFLNEVGLHGGILFMGFILICAFINLMIGSASAQWAVTAPIFV 429 
VcAbgT       PFLKS-IVAFIFIFFAIPGYVYGRVVGTMKTDRDVINAMAKSMSSMGMYIVLVFFAAQFVAFFSWTKFGQVLAVLGADFLKDIGLTGPMLFFAFILMCGYINLMIGSASAQWAVTAPIFV 441 
BhAbgT       PFMTG-IVPIMMVFFLVPALVYGFVAKVFTSSKDVADHLAKSMSNMGTYIVIAFVAAQMIAFFNWSQLGPIVAIKGANFLQTIGFTGLPLLLGFIVIAALINLMVASASAKWAILAPVFV 421 
PdAbgT       PLMKG-IVPIITIIFLTPGLVYGKVSKKIKSDKDLVSMMGSSMSDMGGYIVLAFIASQFINLFNLSNLGTILSITGAKLLAESGIPSYGLIIGFILLSGFINLFVGSASAKWAILAPIFV 408 
SaAbgT       PLING-VGLIILVVFLVPGLVYGILSKEIKNTKDLGKMFGDAVGSMGTFIVIVFFAAQLLAYLKWSNLGIIAAVKGAKLLEHQ--NGIVLILGIIVLSAMVNMLIGSASAKWGILGPIFV 421 
TdAbgT       NFMHGGLLPVILLLFLIPGLIYGKKTGKINSSHDLVKGMSQAMSSMGGYLVLSFFAAQFVNYFGKTNLGTIISVNGANFLKSIGFTGLPLIISFVIISAFLNLFMGSASAKWAIMAPIFV 426 
CdAbgT       PLVKA-VTVPISLMFLGLGVVYGITIKSITSLGDIPAFMAKGLTTLIPMVVLFFMVAQFLAWFQWSNLGIWTAIKGAELLQRWDLPVYVLFAAVVLAVALLNLTITSGSAQWALMAPVIV 439 
              :  . :   . :     .  **     .     :   :   :  :   :*: *  ::::  :  :.:*   ::  :  *          :  .    . : : : *.** *.  .*:.:  
 
 
 
 
 
NgMtrF       PMLMLAGYAPEVIQAAYRIGDSVTNIITPMMSYFGLIMATVMKYKKDAGVGTLISMMLPYSAFFLIAWIALFCIWVFVLGLPVGPGAPTLYPAP----- 522 
EcAbgT       PMFMLLGFHPAFAQILFRIADSSVLPLAPVSPFVPLFLGFLQRYKPDAKLGTYYSLVLPYPLIFLVVWLLMLLAW-YLVGLPIGPGIYPRLS------- 508 
AbAbgT       PMLMLLGISPEASQAAYRVGDSSTNIITPLMPYFVLVLGFARRYQPETGIGTLIALMLPYSLTLLLGWSVLLGVW-IGFGWPLGP-------------- 492 
NmMtrF       PMLMLAGYAPEVIQAAYRIGDSVTNIITPMMSYFGLIMATVIKYKKDAGVGTLISMMLPYSAFFLIAWIALFCIWVFVLGLPVGPGAPTFYPAP----- 522 
CcAbgT       PMFMLLGISPEMTTAAYRMGDSFTNLMTPLMSYFPLVLAMTRRWDPSMGVGSLLALMLPYALAFMVAGVAMTLAW-VAFDWPLGPAAQVHYTPPGGLLK 539 
SpAbgT       PMLMLVGYAPETIQAAYRIGDSVTNLVTPMMSYFGLILAVACRYQKNLGIGTLIATMLPYTLVFFVGWTAFFFLWVFGFGLPVGPGAATYYTP------ 511 
PmMtrF       PMLMLTGYSPEIIQAAYRIGDSVTNIITPMMSYFGLIMATVLKYKKDAGVGTLVSMMLPYSVAFLVAWSAMFFIWVFVLGLPVGPNSPMFYPAQ----- 523 
VcAbgT       PMLMLVGYAPEVIQAAYRIGDSVTNIITPMMSYFGLILAVATRYMKNLGIGTLIATMLPYSVVFMVGWSLLFYVWVFVLGLPVGPGAATYYTP------ 534 
BhAbgT       PMFMLLEYSPAFTQAAYRVGDSITNPITPMLPYFAIALTFAKKYDPKIGIGTFMSSLLPYSIAFAVIWIILFTVW-YLLGLPLGPGEYIHLHT------ 513 
PdAbgT       PMFMLLDFNPALTQIAYRIGDASTNPISPLFPYFPVILAFARRYDKDIGIGTVISNMIPYSVVFTLIEIIILLLF-MGIGIPLGPGGGISYVL------ 500 
SaAbgT       PMLILIGFHPAFTQVIYRVGDSITNPITPMMPYLPLLLTYAQKYDKRMKLGALLSSLMPYSIALSIVWTVFVIIW-FLLGIPVGPGGPIFVK------- 512 
TdAbgT       PMMVNLGLSPALTQVAYRIGDSSTNLITPLMSYFAMIVVFMKKYDEDSGLGTLISTMLPYSIAFLLSWIGLMIIW-YIFGLPLGPGAFIHI-------- 516 
CdAbgT       PMMMYVGISPEVTQMLFRIGDSPTNIITPMSPYFALALTFLQRYYKPAGVGTLVSLALPYSIAMLVGWFVFFIVW-YALGVPLGPGTPMHFQQG----- 532 
             **::     *      :*:.*: .  ::*: .:. : :    ::     :*:  :  :**.  : :    :   :   .. *:**                                     
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Fig. S1. Sequence and topology of N.gonorrhoeae MtrF.  Alignment of the amino acid 
sequences of the AbgT family of transporters was done using CLUSTAL W.  *, identical 
residues; :, >60% homologous residues.  Secondary structural elements are indicated: TM, 
transmembrane helix; α, helix.  The sequence and topology of N. gonorrhoeae MtrF are shown 
at the top.  Conserved residues involved in lining the channel of the inner core of the protein are 
highlight with green bars. 
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Fig. S2. Stereo view of the electron density maps of MtrF at a resolution of 3.95 Å.  (a) The 
electron density maps are contoured at 1.2 σ.  The Cα traces of the MtrF dimer in the 
asymmetric unit are included.  Anomalous signals of the four Ta6Br122+ cluster sites (contoured 
at 4 σ) found in the asymmetric unit are colored red.  (b) Representative section of the electron 
density at the interface of TM1 and TM7 of MtrF.  The electron density (colored slate) is 
contoured at the 1.2 σ level and superimposed with the final refined model (green, carbon; red, 
oxygen; blue, nitrogen).  
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Fig. S3.  Expression level of the MtrF pumps.  An immunoblot against MtrF of crude extracts 
from 50 µg dry cells of strain BL21(DE3)∆abgT∆pabA expressing the MtrF wild-type and 
mutant (D193A, S417A, W420A, P438A, R446A, D449A, and P457A) pumps are shown.   
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Table S1. Data collection, phasing and structural refinement statistics of MtrF. 
 
Data set MtrF 
 
Ta6Br122+ 
derivative 
 Data Collection   
   Wavelength (Å) 0.98 
 
1.25 
 Space group P65 
 
P65 
 Resolution (Å) 50 – 3.95 
 
50 – 6.53 
 
 
(4.11 – 3.95) 
 
(6.74 – 6.53) 
 Cell constants (Å) 
         a 120.77 
 
120.57 
      b 120.77 
 
120.57 
      c 233.90 
 
231.33 
      α, β, γ (°) 90, 90,120 
 
90,90,120 
 Molecules in ASU 2 
 
2 
 Redundancy 4.7 (4.0) 
 
5.7 (5.8) 
 Total reflections 868,348 
 
28,1275 
 Unique reflections 16,832 
 
3814 
 Completeness (%) 98.2 (92.8) 
 
99.9 (99.9) 
 Rmerge (%) 5.8 (46.8) 
 
5.3 (49.5) 
 I / σ 29.65 (0.88) 
 
45.42 (2.6) 
 Phasing   
Number of sites  
  
4 
 Phasing power (acentric/centric) 
 
1.31/0.67 
 Figure of merit 
 
0.52 (0.40) 
 Refinement MtrF       
Resolution (Å) 50 – 3.95 
   Rwork (%)  29.9 
   Rfree (%) 33.5 
   RMSD bond lengths (Å) 0.009 
   RMSD bond angles (°) 1.52 
   Ramachandran plot         
most favoured (%) 88.2 
   additional allowed (%) 10.8 
   generously allowed (%) 1.0 
   disallowed (%) 0.0 
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Table S2. Primers for site-directed mutagenesis. 
 
       Primer Sequence 
D193A-forward 5ʹ′-CTGTTCCTGGGCACCATTGCTCCGCTGCTGGCCGGTATC-3ʹ′ 
D193A-reverse 5ʹ′-GATACCGGCCAGCAGCGGAGCAATGGTGCCCAGGAACAG-3ʹ′ 
S417A-forward 5ʹ′-GGTAGTGCTGCCGCACAATGGGCAGTGACCGCACCGATCT-3ʹ′ 
S417A-reverse 5ʹ′-CCATTGTGCGGCAGCACTACCGATCATCAGGTTAATAAA-3ʹ′ 
W420A-forward 5ʹ′-CGCACAAGCGGCAGTGACCGCACCGATCTTCGTTCCG-3ʹ′ 
W420A-reverse 5ʹ′-GGTCACTGCCGCTTGTGCGGAAGCACTACCGATCATCAG-3ʹ′ 
P438A-forward 5ʹ′-GGCTATGCTGCGGAAGTCATTCAGGCCGCATACCGC-3ʹ′ 
P438A-reverse 5ʹ′-GACTTCCGCAGCATAGCCTGCCAGCATCAGCATCGG-3ʹ′ 
R446A-forward 5ʹ′-GTCATTCAGGCCGCATACGCCATCGGTGATTCAGTTACC-3ʹ′ 
R446A-reverse 5ʹ′-GGTAACTGAATCACCGATGGCGTATGCGGCCTGAATGAC-3ʹ′ 
D449A-forward 5ʹ′-GCCGCATACCGCATCGGTGCTTCAGTTACCAATATTATC-3ʹ′ 
D449A-reverse 5ʹ′-GATAATATTGGTAACTGAAGCACCGATGCGGTATGCGGC-3ʹ′ 
P457A-forward 5ʹ′-ATCACGGCGATGATGTCGTATTTTGGTCTGATTATG-3ʹ′ 
P457A-reverse 5ʹ′-CGACATCATCGCCGTGATAATATTGGTAACTGAATC-3ʹ′ 
 
 
 
Table S3.  MICs of sulfamethazine and sulfanilamide for different MtrF variants expressed in E. 
coli BL21(DE3)∆abgT∆pabA. 
                                                                                                
Gene in BL21(DE3)∆abgT∆pabA Sulfamethazine (µg/mL) Sulfanilamide (µg/mL) 
Empty vector 62.5 500 
mtrF (wild-type) 2000 4000 
mtrF (D193A) 1000 2000 
mtrF (S417A) 125 2000 
mtrF (W420A) 125 2000 
mtrF (P438A) 62.5 1000 
mtrF (R446A) 1000 2000 
mtrF (D449A) 62.5 1000 
mtrF (P457A) 62.5 1000 
   
 
 
 
 
 
154 
 
 
CHAPTER 6 
YDAH IS AN EFFLUX PUMP THAT MEDIATES RESISTANCE TO SULFONAMIDE 
ANTIMETABOLITES  
Manuscript submitted to the journal Nature Communications 
 
Jani Reddy Bolla1,ψ, Chih-Chia Su2,ψ, Jared A. Delmar2, Abhijith Radhakrishnan1, Nitin 
Kumar1, Tsung-Han Chou2, Kanagalaghatta R. Rajashankar3, and Edward W. Yu1,2* 
 
1Department of Chemistry, Iowa State University, Ames, IA 50011. 
2Department of Physics and Astronomy, Iowa State University, Ames, IA 50011. 
3NE-CAT and Department of Chemistry and Chemical Biology, Cornell University, Bldg. 436E, 
Argonne National Laboratory, 9700 S. Cass Avenue, Argonne. IL 60439. 
 
ψJ.R.B. and C.S. contributed equally to this work.  
 
* To whom correspondence should be addressed. E-mail: ewyu@iastate.edu  
155 
 
 
 
The potential of the folic acid biosynthesis pathway as a target for the development of 
antibiotics has been corroborated by the clinical use of several drugs.  However, many pathogens 
have developed resistance to these antibiotics, prompting a reevaluation of potential drug targets 
in the pathway.  The gene ydaH of Alcanivorax borkumensis encodes an integral membrane 
protein of the AbgT family of transporters.  Approximately 13,000 putative transporters of the 
family have been identified.  However, no structural information has been made available and 
even functional data are fairly minimal for this family of membrane proteins.  Here, we report 
the crystal structure of A. borkumensis YdaH at a resolution of 2.96 Å, revealing a dimeric 
molecule with architecture distinct from all other families of transporters.  YdaH is a bowl-
shaped dimer with a solvent-filled basin extending from the cytoplasm to halfway across the 
membrane bilayer.  Each subunit of the transporter contains nine transmembrane helices and two 
hairpins.  The structure directly suggests a plausible pathway for substrate transport.  A 
combination of the crystal structure, genetic analysis and substrate accumulation assay indicates 
that YdaH is an exporter, capable of removing the folate metabolite p-aminobenzoic acid from 
bacterial cells.  Further experimental data based on drug susceptibility and radioactive transport 
assay suggest that YdaH is an antibiotic efflux pump, which mediates bacterial resistance to 
sulfonamide antimetabolite drugs. The AbgT-family transporters may be important targets for 
the rational design of novel antibiotics to combat bacterial infections. 
 
 
All cells, both prokaryotic and eukaryotic, require folic acid for the biosynthesis of a 
diverse range of cellular components.  Folic acid is of particular importance in aiding cell growth 
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and division.  While the cellular requirement for folates is universal, methods to acquire them 
vary between prokaryotes and eukaryotes.  For example, mammals cannot make folates 
themselves.  Instead, they rely on active transport systems, utilizing membrane-associated folate 
transport proteins to import this essential vitamin1.  In plants and most microorganisms, folates 
must be synthesized de novo through the folate biosynthetic pathway2.  Because of the presence 
of this pathway in pathogenic bacteria and, most importantly, its absence in mammals, the folate 
biosynthetic pathway has been an attractive target for the design of novel antimicrobial drugs. 
The process of de novo synthesis of folates in bacteria can be simply interpreted as 
chemically linking pterin, p-aminobenzoic acid (PABA) and glutamic acid together.  In 
Escherichia coli, mutations or deletions of enzymes in the folate pathway are known to generate 
non-viable phenotypes3.  The possibility of targeting the folate biosynthesis system for 
antimicrobial therapeutics was proposed several decades ago based on the observation that 
sulfonamides prevented bacteria from using the metabolite PABA for folate biosynthesis4.  
Indeed, as early as the 1930s, sulfonamides were widely used as synthetic antibiotics to treat 
infections caused by a variety of pathogenic bacteria, including Neisseria meningitidis and 
Pneumococcal pneumonia5,6. 
Because of the rapid adaption of bacterial pathogens to antimicrobials, drug resistance to 
currently administered antibiotics is a serious problem that is rising at an alarming rate.  For 
instance, it only took two years for N. meningitidis to develop resistant strains following the 
introduction of sulfonamides7.  The problem is of particular severity in treating the parasitic 
malaria disease.  A strong correlation has been found between mutations in Plasmodum 
falciparum and resistance to sulfonamides8-10. 
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The initial identification of enzymes involved in folate biosynthesis was largely carried 
out in the 1960-70s, leading to the detailed description of this enzymatic pathway11-16.  However, 
recent work demonstrated that E. coli AbgT17,18 is capable of catalyzing the uptake of the 
catabolite p-aminobenzoyl-glutamate for de novo folic acid synthesis18.  Because of this finding, 
it is hypothesized that AbgT-family transporters19 contribute to the bacterial folate synthesis 
pathway by importing p-aminobenzoyl-glutamate for producing this essential vitamin.  On the 
other hand, it has been observed that N. gonorrhoeae MtrF20,21, also belonging to the AbgT 
family, functions as an antimicrobial resistant protein.  It is needed for the high-level resistance 
of gonococci to hydrophobic antimicrobials20,21.  To date, approximately 13,000 putative 
transporters of the AbgT family have been identified.  However, among proteins in this diverse 
family, only E. coli AbgT17,18 and N. gonorrhoeae MtrF20,21 have been partially characterized.  
Thus far, there is no structural information available for this family of membrane proteins. 
In A. borkumensis, the gene ydaH22 encodes a membrane protein YdaH of previously 
unknown structure and function.  Alignment of protein sequences suggests that this protein 
belongs to the AbgT family of transporters19.  To understand how members of the AbgT family 
work, we here present the crystal structure of YdaH, revealing a novel topology distinct from 
other families of transporters.   
In this paper, we also show that YdaH is capable of exporting the folate metabolite 
PABA from the bacterial cell.  A combination of the three-dimensional structure and genetic 
analysis allows us to identify important residues for the function of this membrane protein.  Our 
data demonstrate that A. borkumensis YdaH is an antibiotic efflux pump, which is able to remove 
sulfonamides from the cell and mediate bacterial resistance to this class of antimetabolites. 
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A. borkumensis YdaH consists of 492 amino acids, sharing 34% sequence identity with E. 
coli AbgT (Fig. S1).  The crystal structure of YdaH was determined to a resolution of 2.96 Å 
(Fig. 1 and Table S1).  Four molecules of YdaH were found in the asymmetric unit, forming two 
independent assembled dimers (Fig. S2).  Superimposition of these two dimers gives an RMSD 
of 0.8 Å (942 Cα atoms), suggesting that their conformations are nearly identical to each other.  
The topology of YdaH is unique among all known transporters (Fig. 1a).  The YdaH dimer is 
bowl-shaped with a concave aqueous basin facing the intracellular solution.  Viewed in parallel 
to the membrane, the dimer is about 60 Å tall, 80 Å wide and 60 Å thick, with the 
transmembrane portion of the transporter lying approximately in the middle (Fig. 1b).  Thus, the 
transporter protrudes about 10 Å from each side of the membrane.  The rim of the basin is as 
large as 50 Å.  The bowl-shaped structure is 20 Å in depth and deeply penetrates into the inner 
leaflet of the cytoplasmic membrane.  This basin probably allows aqueous solution to reach the 
midpoint of the membrane bilayer.   
Each protomer of YdaH in the dimer contains nine transmembrane helices (TMs 1-9 and 
TMs 1ʹ′-9ʹ′, respectively) and two helical hairpins (HPs 1-2 and HPs 1ʹ′-2ʹ′, respectively)  (Figs. 1a 
and S1).  The TMs and HPs are designated numerically from the N- to C-termini: TM1 (21-42), 
TM2 (a (63-79), b (83-99) and c (101-112)), HP1 (a (115-131) and b (135-151)), TM3 (a (155-
168) and b (178-194)), TM4 (204-228), TM5 (250-272), TM6 (290-314), TM7 (a (320-334), b 
(336-354) and c (356-371)), HP2 (a (375-392) and b (396-414)), TM8 (a (418-432) and b (441-
452)) and TM9 (458-486).  Of the nine TMs, four (TM2, TM3, TM7 and TM8) are broken into 
segments within the membrane.  In addition, the helices making up HPs 1 and 2 are relatively 
short and can only span a portion of the inner membrane.  Interestingly, the intramembrane loops 
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of several of these TMs and HPs are right next to one another, allowing the protein to form an 
internal cavity within the membrane (Fig. 1c and d).  
The YdaH protomer also possesses a relatively small periplasmic domain formed by two 
loops, between TM1 and TM2 and between TM5 and TM6, respectively.  The loop between 
TM1 and TM2 is found to form two β-strands (S1 and S2), which appears to run anti-parallel 
against one another.  In the cytoplasmic region, there is a relatively long loop of 22 residues.  
This loop connects TM4 and TM5, forming a small cytoplasmic domain of the protomer. 
The structure of the YdaH protomer can be roughly divided into two cores (Fig. 2a).  The 
outer core contains TMs 1, 2, 5, 6 and 7, whereas the inner core comprises TMs 3, 4, 8, 9 as well 
as HPs 1 and 2.  Viewed along the membrane normal, TMs 2a, 2b, 7a and 7b as well as the N-
terminal ends of TMs 1 and 6 form a distinct dimerization domain of the transporter.  In 
particular, TM2a (as well as TM2aʹ′) crosses over to the next subunit, securing the formation of 
this dimer.  Each YdaH protomer shares a substantial intersubunit interface, with a volume of 
~10,000 Å3 per protomer.  The residues lining the dimerization motif are predominantly 
hydrophobic in nature. 
While the outer core of YdaH creates a frame-like architecture, the inner core of each 
protomer forms a cylindrical structure (Fig. 2a).  It is most likely that this inner core cylinder 
forms a substrate-binding site and transport pathway.  Interestingly, we found that the inner core 
cylinder indeed forms a channel spanning approximately from the middle of the inner membrane 
up to the periplasmic space (Fig. 2b).  The entrance of this channel is formed by the internal 
cavity located at the basin of the bowl-shaped structure (Fig. 1c and d).  This cavity constitutes 
the loop regions of HP1, HP2, TM3 and TM8 and is accessible to the cytoplasm.  Based on its 
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location, this internal cavity may form a substrate-binding site of YdaH.  Several conserved 
residues, including D180, W400, P418 and R426, line the wall of the channel (Fig. 2b).  These 
residues are expected to play an important role in the function of this transporter. 
In each protomer of YdaH, a strong spherical electron density sits in the flexible loops 
between HP2 and TM8.  Because Na+ ions were used at all stages of purification and 
crystallization, it is possible that the extra electron density originates from a Na+ ion.  We then 
used valence calculations23 to predict if this location can form a metal ion-binding site.  The 
results indicated that this site is most likely Na+-specific.  Coordinating with this bound Na+ ion 
are the side chains of N390, D429, N433 and the backbone carbonyl oxygens of G394 and D429 
(Fig. 2c).  A water molecule also participates in the interaction, forming another coordinate bond 
with the Na+ ion. 
As E. coli AbgT has been shown to enable uptake of the folate catabolite p-
aminobenzoyl-glutamate, we investigated if cells expressing YdaH are able to grow on p-
aminobenzoyl-glutamate.  We made an E. coli knockout strain BL21(DE3)∆abgT∆pabA that 
lacked both the E. coli abgT17,18 and pabA24 genes.  We then expressed the YdaH transporter in 
this double knockout strain using the plasmid pET15bΩydaH.  Surprisingly, the double knockout 
BL21(DE3)∆abgT∆pabA cells, either transformed with pET15bΩydaH or the empty vector 
pET15b, could not grow in liquid minimal medium (containing 90.4 mM Na2HPO4, 22.0 mM 
KH2PO4, 8.5 mM NaCl, 0.1 mM CaCl2, 1.0 mM MgSO4, 20.0 mM NH4Cl, and 22.2 glucose) 
supplemented with p-aminobenzoyl-glutamate up to 1 µM.  Instead, these cells were able to 
grow in liquid minimal medium when supplemented with 30 nM of the folate metabolite PABA.  
It should be noted that PABA is capable of diffusing into bacterial cells and participating as an 
intermediate in the synthesis of the essential folic acid. 
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We thought that YdaH probably could not import p-aminobenzoyl-glutamate as a nutrient 
for growth.  However, this membrane protein may facilitate the transport of PABA across the 
membrane.  Thus, we directly measured the accumulation of PABA in BL21(DE3)∆abgT∆pabA 
expressing YdaH.  We compared the radioactive PABA content over time in cells transformed 
with either pET15bΩydaH, encoding A. borkumensis ydaH, or the empty vector pET15b.  
Surprisingly, cells expressing YdaH show a significant decrease in the level of [3H]-PABA when 
compared with cells transformed with the empty pET15b vector (Fig. 3a) suggesting that YdaH 
may act as an efflux pump to export PABA from the cell. 
To determine whether the conserved YdaH residues D180, W400, P418 and R426 (lining 
the inner wall of the tunnel formed by each protomer) are important for the function of the 
transporter, we mutated these residues into alanines, individually (Table S2).  Based on the 
crystal structure, we found that residues N390, D429, N433 are involved in coordinating the 
bound Na+ ion.  Therefore, these three residues were also replaced by alanines, respectively 
(Table S2).  We then expressed these mutant transporters in BL21(DE3)∆abgT∆pabA.  Western 
analysis indicated that the expression levels of these mutant transporters were comparable with 
that of wild-type YdaH (Fig. S3).  We then measured the accumulation of [3H]-PABA in cells 
expressing these mutant transporters.  The results showed a significant increase in the levels of 
[3H]-PABA accumulation in cells possessing the mutant transporter D180A, N390A, W400A, 
P418A, D429A or N433A, when compared with cells expressing wild-type YdaH (Fig. 3b).  
However, cells expressing R426A indicated a significant decrease in the [3H]-PABA 
concentration when compared with cells carrying wild-type YdaH (Fig. 3b).  The data strongly 
suggest that YdaH is an efflux pump and these amino acids are important for the function of the 
pump. 
162 
 
 
We hypothesized that YdaH is capable of catalyzing the efflux of PABA and related 
compounds.  If this is the case, then cells expressing YdaH may contain a lower level of folic 
acid content.  Therefore, we decided to measure the intracellular folic acid concentration 
microbiologically using Lactobacillus casei25.  Cells transformed with pET15bΩydaH or 
pET15b were grown in liquid minimal medium supplemented with 30 nM PABA and harvested 
when the optical density (OD600 nm) reached 0.5.  Cells were then assayed to obtain their folic 
acid concentrations.  Consistent with the results from PABA accumulation, the folic acid 
concentration in cells expressing YdaH was markedly reduced in comparison with cells 
transformed with the empty vector (Fig. 4).  The data strongly support the idea that YdaH acts as 
an efflux pump and participates in exporting PABA from the cell.   
When transformed with plasmids expressing the mutant transporters D180A, N390A, 
W400A, P418A, D429A and N433A, folic acid production was significantly increased in these 
cells.  However, the level of intracellular folic acid concentration in cells expressing R426A was 
nearly identical to that of the double knockout strain carrying wild-type YdaH (Fig. 4).  
As PABA is an important precursor for producing essential folic acid in bacteria, we did 
not understand why the function of YdaH appeared to lower the intracellular PABA 
concentration.  Clearly, there was a significant reduction in PABA content, which led to the 
decrease in intracellular folic acid concentration in cells expressing the YdaH transporter.  We 
hypothesized that this efflux pump may protect bacterial cells by extruding antimetabolites, such 
as sulfonamides.  Sulfonamides are antimicrobial agents, antimetabolites or growth factor 
analogs, which specifically inhibit the essential folic acid metabolic pathway in bacterial 
pathogens.  At the chemical level, sulfonamides are structurally similar to PABA, making them 
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ideal competitive inhibitors.  Therefore, A. borkumensis YdaH may act as a drug efflux pump, 
capable of extruding sulfonamide antimetabolites. 
To determine if A. borkumensis YdaH behaves as a sulfonamide efflux pump, we 
transformed BL21(DE3)∆abgT∆pabA with pET15bΩydaH or pET15b and tested the 
susceptibility of these transformants to two different sulfonamide drugs (Table S3).  Specifically, 
sulfamethazine was chosen because of the availability of its radioactive analog.  We found that 
the BL21(DE3)∆abgT∆pabA cells expressing A. borkumensis YdaH were 32-fold less sensitive 
to sulfamethazine when compared with BL21(DE3)∆abgT∆pabA cells containing the empty 
pET15b vector.  In addition, these BL21(DE3)∆abgT∆pabA/pET15bΩydaH cells were eight 
times more resistant to sulfanilamide when compared with the double knockout cells transformed 
with the empty pET15b vector.  These data indeed show that YdaH functions as a drug efflux 
pump, which confers resistance to sulfonamides. 
Mutant transporters D180A, N390, W400A, P418A, R426A, D429A and N433A 
expressed in BL21(DE3)∆abgT∆pabA were then tested for their ability to confer sulfamethazine 
and sulfanilamide resistance.  We found that strain BL21(DE3)∆abgT∆pabA carrying these 
YdaH mutants were more sensitive to sulfamethazine and sulfanilamide in comparison with cells 
expressing wild-type YdaH (Table S3), thus agreeing well with the idea that these residues are 
essential for the function of A. borkumensis YdaH. 
To support the drug susceptibility testing results, we measured the accumulation of 
radioactive sulfamethazine in BL21(DE3)∆abgT∆pabA cells that carried pET15bΩydaH or 
pET15b.  For these experiments, we compared the accumulation of sulfamethazine over time in 
these cells.  As shown in Fig. 5, the results indicated a lower level of [3H]-sulfamethazine 
accumulation in BL21(DE3)∆abgT∆pabA cells producing A. borkumensis YdaH compared to 
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controlled cells harboring the empty pET15b vector, suggesting that A. borkumensis YdaH is 
capable of exporting sulfamethazine from the cell.  
When transformed with plasmids expressing the mutant transporters D180A, N390A, 
W400A, P418A, R426A, D429A and N433A, the levels of intracellular sulfamethazine 
accumulation were much higher than that of cells expressing wild-type YdaH (Fig. 5).  Again, 
these data indicate that residues D180, N390, W400, P418, R426, D429 and N433 are critical for 
the function of the A. borkumensis YdaH efflux pump.  
It has been suggested that members of the AbgT family use the proton-motive-force 
(PMF) to transport substrates across the membrane19.  To determine which source of energy A. 
borkumensis YdaH utilizes to export substrates, we measured the level of intracellular 
sulfamethazine accumulation in the presence of carbonyl cyanide m-chlorophenylhydrazone 
(CCCP), an uncoupler of the membrane proton gradient.  After the addition of CCCP into the 
assay solution, the accumulation of [3H]-sulfamethazine increased drastically in the YdaH-
expressing cells (Fig. 6a), suggesting that the uncoupler CCCP was able to inhibit the function of 
this pump.  As the crystal structure suggests that a Na+ ion is bound within each subunit of the 
YdaH transporter, we then investigated the accumulation level of radioactive sulfamethazine in 
strain BL21(DE3)∆abgT∆pabA/pET15bΩydaH in the presence of 5 or 100 mM NaCl.  In both 
cases, the levels of accumulation of [3H]-sulfamethazine were significantly lower compared with 
that in the YdaH-producing strain without the addition of Na+ ions (Fig. 6a).  The results strongly 
indicate that the function of A. borkumensis YdaH is Na+-ion dependent. 
To confirm that YdaH is a Na+-ion dependent efflux pump, we next measured the efflux 
of radioactive sulfamethazine that had accumulated in strain 
BL21(DE3)∆abgT∆pabA/pET15bΩydaH, both in the absence and prc esence of Na+ or K+.  
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Cells were first loaded with [3H]-sulfamethazine and CCCP was added to inhibit the pump.  
Thereafter, CCCP was removed and glucose was added to re-energize these cells.  Cellular [3H]-
sulfamethazine levels were measured over time both in the absence and presence of 5 mM NaCl 
or KCl.  As shown in Fig. 6b, the addition of Na+, but not K+, has a strong effect on 
sulfamethazine efflux in BL21(DE3)∆abgT∆pabA/pET15bΩydaH, confirming that A. 
borkumensis YdaH is a Na+-dependent efflux pump. 
In this paper, we reported the crystal structure of the A. borkumensis YdaH transporter, 
which reveals a dimeric molecule with a fold very distinct from other families of transporters.  
Based on our experimental data, we propose that YdaH is a drug efflux pump, capable of 
removing sulfonamide antimetabolites and mediating resistance to this class of drugs in bacterial 
cells.  It is likely that many members of the AbgT family of transporters may serve as 
antimetabolite efflux pumps to protect cells against these noxious agents.  Our data also suggest 
a novel mechanism for sulfonamide antimetabolite resistance in bacteria.  
 
Accession code 
Atomic coordinates and structure factors for the structure of YdaH have been deposited at 
the RCSB Protein Data Bank with an accession code 4R0C.  
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Fig. 1.  Structure of the A. borkumensis YdaH transporter.  (a) Transmembrane topology of A. 
borkumensis YdaH.  The transporter contains nine transmembrane helices (TMs) and two 
hairpins (HPs).  (b) Ribbon diagram of a dimer of YdaH viewed in the membrane plane.  The 
right subunit of the dimer is colored using a rainbow gradient from the N-terminus (blue) to the 
C-terminus (red), whereas the left subunit is colored gray.  The YdaH dimer forms a bowl-
shaped structure with a concave aqueous basin facing the intracellular solution.  (c) Surface 
representation of the YdaH dimer sliced through the middle of the protein.  Each protomer forms 
an internal cavity (red arrow), which is accessible to the cytoplasm.  (d) Bottom view of a 
surface representation of the YdaH dimer, indicating a solvent accessible cavity (red circle) from 
each protomer of the protein.  The two protomers are colored gray and blue. 
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Fig. 2.  Outer and inner cores of YdaH. (a) The outer core of YdaH, comprising TMs 1, 2, 5, 6 
and 7 (colored slate), contributes to dimerization as well as formation of a frame-like structure 
housing the inner core of the protomer.  The inner core of YdaH is composed of TMs 3, 4, 8, 9 as 
well as HPs 1 and 2 (colored yellow).  (b) The inner core of YdaH forms a channel (colored 
purple) spanning approximately from the middle of the inner membrane up to the periplasmic 
space.  This channel was calculated using the program CAVER 
(http://loschmidt.chemi.muni.cz/caver).  The secondary structural elements of the YdaH 
protomer are in yellow.  Residues D180, N390, W400, P418, R426, D429 and N433 are in green 
sticks.  The bound sodium ion is shown as an orange sphere.  (c) The bound Na+ (orange sphere) 
is found to coordinate with N390, G394, D429, N433 and a water molecule (red sphere).  The 
Fo-Fc map, showing the bound Na+ and H2O, is contoured at 3.0 σ (blue mesh).        
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Fig. 3.  Accumulation of radioactive p-aminobenzoic acid.  (a) Time course of [3H]-PABA 
accumulation by E. coli BL21(DE3)∆abgT∆pabA double knockout cells transformed with 
pET15bΩydaH or pET15b.  Cells expressing ydaH (blue curve) show a significant decrease in 
[3H]-PABA accumulation when compared with cells carrying the empty vector (black curve).  
(b) Mutants of the YdaH transporter.  Cells possessing the mutant transporter D180A, N390, 
W400A, P418A, D429A and N433A show a significant increase in the level of [3H]-PABA 
accumulations compared with cells expressing wild-type YdaH.  However, cells expressing 
R426A are able to decrease the [3H]-PABA concentration when compared with cells carrying 
wild-type YdaH.  The data showed in (a) and (b) are the cumulative average of three successive 
recordings. 
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Fig. 4.  Intracellular folic acid concentration.  Folic acid concentration in E. coli 
BL21(DE3)∆abgT∆pabA double knockout cells expressing YdaH were markedly reduced in 
comparison with cells transformed with the empty vector.  When transformed with plasmid 
expressing the mutant transporter, D180A, N390, W400A, P418A, D429A and N433A, folic 
acid production was significantly increased in these cells.  However, the level of intracellular 
folic acid concentration in BL21(DE3)∆abgT∆pabA cells expressing R426A was nearly identical 
to that of the double knockout strain carrying wild-type YdaH.  Each bar represents the mean of 
three separate cultures. 
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Fig. 5.  Accumulation of radioactive sulfamethazine.  E. coli BL21(DE3)∆abgT∆pabA cells 
expressing YdaH show a significant decrease in [3H]-sulfamethazine accumulation when 
compared with cells carrying the empty vector.  When transformed with plasmids expressing the 
mutant transporters, D180A, N390, W400A, P418A, R426A, D429A and N433A, the levels of 
intracellular [3H]-sulfamethazine accumulation were much higher than that of cells expressing 
wild-type YdaH.  Each bar represents the mean of three different cultures. 
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Fig. 6.  Sodium ion enhances sulfamethazine efflux via YdaH.  (a) Accumulation of radioactive 
sulfamethazine in BL21(DE3)∆abgT∆pabA/pET15bΩydaH cells with difference sodium ion 
concentrations.  Cells showed a significant decrease in [3H]-sulfamethazine accumulation in the 
presence of Na+.  (b) Efflux of radioactive sulfamethazine in 
BL21(DE3)∆abgT∆pabA/pET15bΩydaH cells in the presence of sodium or potassium ions.  The 
presence of Na+ significantly enhances [3H]-sulfamethazine efflux in 
BL21(DE3)∆abgT∆pabA/pET15bΩydaH cells (red, 0 mM NaCl; magenta, 5 mM KCl; blue, 5 
mM NaCl).  The data showed in (a) and (b) are the cumulative average of three successive 
recordings. 
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Methods 
Cloning, expression and purification of A. borkumensis YdaH 
Briefly, the full-length YdaH membrane protein containing a 6xHis tag at the N-terminus 
was overproduced in E. coli BL21(DE3)ΔacrB cells, which harbors a deletion in the 
chromosomal acrB gene,  possessing pET15bΩydaH.  Cells were grown in 12 L of LB medium 
with 100 µg/ml ampicillin at 25oC.  When the OD600 reached 0.5, the culture was treated with 0.2 
mM isopropyl-β-D-thiogalactopyranoside (IPTG) to induce ydaH expression, and cells were 
harvested within 15 h.  The collected bacteria were resuspended in low salt buffer containing 100 
mM sodium phosphate (pH 7.2), 10 % glycerol, 1 mM ethylenediaminetetraacetic acid (EDTA) 
and 1 mM phenylmethanesulfonyl fluoride (PMSF), and then disrupted with a French pressure 
cell.  The membrane fraction was collected and washed twice with high salt buffer containing 20 
mM sodium phosphate (pH 7.2), 2 M KCl, 10 % glycerol, 1 mM EDTA and 1 mM PMSF, and 
once with 20 mM HEPES-NaOH buffer (pH 7.5) containing 1 mM PMSF as described 
previously26.  The membrane protein was then solubilized in 2% (w/v) n-dodecyl-β-D-maltoside 
(DDM).  Insoluble material was removed by ultracentrifugation at 100,000 x g.  The extracted 
protein was purified with a Ni2+-affinity column.  The purified protein was dialyzed and 
concentrated to 20 mg/ml in a buffer containing 20 mM Na-HEPES (pH 7.5) and 0.05% DDM.  
The 6xHis tag at the N-terminus was then cleaved by adding 5 units of thrombin (GE Healthcare 
Bio-Sciences, Pittsburgh, PA) per mg of purified YdaH at room temperature for 20 h.  The 
protein was subsequently passed through a Ni2+-affinity column to remove the free 6xHis tag.  A 
final purification step was performed using a G200 size exclusion column loaded with buffer 
solution containing 20 mM Na-HEPES (pH 7.5) and 0.05% DDM.  The purity of the YdaH 
protein (>95%) was judged using 10% SDS-PAGE stained with Coomassie Brilliant Blue.  The 
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purified protein was then concentrated to 20 mg/ml in a buffer containing 20 mM Na-HEPES 
(pH 7.5) and 0.05% DDM. 
For 6xHis selenomethionyl-substituted (SeMet)-YdaH protein expression, a 10 ml LB 
broth overnight culture containing E. coli BL21(DE3)ΔacrB/pET15bΩydaH cells was 
transferred into 120 ml of LB broth containing 100 µg/ml ampicillin and grown at 37oC.  When 
the OD600 value reached 1.2, cells were harvested by centrifugation at 6000 rev/min for 10 min, 
and then washed two times with 20 ml of M9 minimal salts solution.  The cells were re-
suspended in 120 ml of M9 media and then transferred into a 12 L pre-warmed M9 solution 
containing 100 µg/ml ampicillin.  The cell culture was incubated at 25oC with shaking. When the 
OD600 reached 0.4, 100 mg/l of lysine, phenylalanine and threonine, 50 mg/l isoleucine, leucine 
and valine, and 60 mg/l of L-selenomethionine were added.  The culture was induced with 0.2 
mM IPTG after 15 min.  Cells were then harvested within 15 h after induction.  The procedures 
for purifying SeMet-YdaH were identical to those of the native protein. 
 
Crystallization of YdaH 
Crystals of the YdaH protein were obtained using sitting-drop vapor diffusion.  The 
YdaH crystals were grown at room temperature in 24-well plates with the following procedures.  
A 2 µl protein solution containing 20 mg/ml YdaH in 20 mM Na-HEPES (pH 7.5) and 0.05% 
(w/v) DDM was mixed with a 2 µl of reservoir solution containing 28% PEG 400, 0.1 M sodium 
acetate (pH 5.0), 0.05 M magnesium acetate, 3% glycerol and 2% (w/v) n-octyl-β-D-glucoside 
(OG).  The resultant mixture was equilibrated against 500 µl of the reservoir solution at 25oC.  
The crystallization conditions for SeMet-YdaH were the same as those for the native YdaH 
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protein.  Crystals of both YdaH and SeMet-YdaH grew to a full size in the drops within a month.  
Typically, the dimensions of the crystals were 0.2 mm x 0.2 mm x 0.2 mm.  Cryoprotection was 
achieved by raising the PEG 400 concentration to 32% in a single step.  Crystals of the tungsten 
cluster derivative were prepared by incubating the crystals of YdaH in solution containing 32% 
PEG 400, 0.1 M sodium acetate (pH 5.0), 0.05 M magnesium acetate, 3% glycerol and 2% (w/v) 
OG, 0.05% (w/v) DDM and 0.5 mM Na9[β-SiW9O34H]•23H2O for 4 hours at 25oC. 
 
Data collection, structural determination and refinement  
All diffraction data were collected at 100K at beamline 24ID-C located at the Advanced 
Photon Source, using a Platus 6M detector.  Diffraction data were processed using DENZO and 
scaled using SCALEPACK27.  Crystals of YdaH belonged to space group P21 (Table S1).  Based 
on the molecular weight of YdaH (51.6 kDa), four molecules per asymmetric unit with a solvent 
content of 73.4% were expected.  The heavy-atom derivative ([β-SiW9O34H]9- cluster)28 was 
isomorphous with the native crystal (Table S1).  Six heavy-atom sites for the tungsten derivative 
were identified using SHELXC and SHELXD29 as implemented in the HKL2MAP package30.  
These heavy-atom sites were refined using the program MLPHARE31,32.  The resulting phases 
were subjected to density modification and fourfold NCS averaging by RESOLVE33 using the 
native structure factor amplitudes.  Density modified phases allowed us to visualize the helical 
structural features of the molecule.  The initial model was built manually using Coot34.  The 
SeMet data was then used to help determine the 4.10 Å-resolution structure of YdaH by 
molecular replacement with single-wavelength anomalous diffraction using the program 
Phaser35.  The manually built model was used as initial search model.  The full-length YdaH 
protein consists of 11 methionine residues and all of these 11 selenium sites were identified in 
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each protomer of the protein (44 total selenium sites in the asymmetric unit).  These phases were 
then improved by NCS averaging with density modification using the program RESOLVE33.  
The resulting phases were of excellent quality, which enabled us to trace of most of the 
molecule.  After tracing the initial model manually using the program Coot34, the model was 
refined using PHENIX36 leaving 5% of reflections in Free-R set.  Iterations of refinement using 
PHENIX36 and CNS37 and model building in Coot34 lead to the 4.10 Å-resolution structural 
model of the YdaH transporter.  This structure was then used to refine against the 2.96 Å-
resolution data using PHENIX36 as described above.  Iterations of refinement using PHENIX36 
and CNS37 and model building in Coot34 lead to the current 2.96 Å-resolution model with 
excellent geometrical characteristics (Table S1). 
 
Construction of the double knockout strain 
The double knockout E. coli strain BL21(DE3)∆abgT∆pabA was produced from the 
BL21(DE3) strain using an RED disruption system as described by Datsenko and Wanner38.  The 
∆abgT::kan cassette, which was used to replace the chromosomal abgT gene, was produced by 
PCR, and then introduced into pKD46/BL21(DE3) by electroporation.  The knockout 
BL21(DE3)∆abgT::kan strain was selected on LB plate containing 30 µg/ml kanamycin, and 
verified by PCR.  The kanamycin resistant gene was then released to generate the 
BL21(DE3)∆abgT knockout strain.  The deletion of pabA from BL21(DE3)∆abgT was done 
using similar procedures as described above to generate the final BL21(DE3)∆abgT∆pabA 
double knockout strain. 
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Site-directed mutagenesis  
Site-directed point mutations on residues D180, N390, W400, P418, R426, D429 and 
N433, which are expected to be critical for the function of the YdaH efflux pump, were 
performed to generate the single point mutants D180A, N390A, W400A, P418A, R426A, 
D429A and N433A.  The primers used for these mutations are listed in Table S2. All 
oligonucleotides were purchased from (Integrated DNA Technologies, Inc., Coralville, IA) in a 
salt-free grade. 
 
Accumulation assays of p-aminobenzoic acid 
In brief, E. coli BL21(DE3)∆abgT∆pabA carrying pET15bΩydaH or pET15b were 
grown in LB broth with 100 µg/ml ampicillin at 37oC.  When the OD600 reached 0.5, the culture 
was treated with 0.2 mM IPTG to induce ydaH expression, and cells were harvested within 2 h.  
Cells were washed twice with buffer containing 50 mM potassium phosphate (pH 7.5), twice 
with buffer containing 100 mM Tris-HCl (pH 7.5) and 5 mM NaCl, and then suspended in the 
same buffer to OD600 of 15.  [3H]-PABA (Moravek Biochemicals, Brea, CA) was then added to a 
final concentration of 0.3 µM.  Samples of 100 µl were taken at intervals, applied directly to 
prewetted glass-fiber filters, and washed twice with 5-ml aliquots of the same buffer; 0.5-µm 
glass-fiber filters (MFS, Dubbin, CA) were used with a filter apparatus.  Filters were then 
incubated for 30 min in scintillation fluid (ScintiVerse™ BD) and counted with a Packard Tri-
Carb 1600TR liquid scintillation counter (Perkin Elmer, Waltham, MA). 
For [3H]-PABA accumulations in cells expressing the YdaH mutants, the procedures for 
sample preparation were the same as above.  Cells were incubated with 0.3 µM [3H]-PABA for 
15 min, applied directly to prewetted glass-fiber filters, and washed immediately twice with 5-ml 
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aliquots of the same buffer.  Filters were then incubated for 30 min in scintillation fluid 
(ScintiVerse™ BD) and counted with a Packard Tri-Carb 1600TR liquid scintillation counter 
(Perkin Elmer, Waltham, MA).       
        
Assays of folic acid 
The concentration of folic acid in the double knockout BL21(DE3)∆abgT∆pabA strain 
transformed with pET15bΩydaH or pET15b was measured using Lactobacillus casei based on 
the microbiological procedure of Wilson and Horne25.  The concentrations of folic acid in 
BL21(DE3)∆abgT∆pabA expressing the mutant transporters were measured using the same 
procedures. 
   
Drug susceptibility assays 
The susceptibilities to sulfamethazine and sulfanilamide of E. coli 
BL21(DE3)∆abgT∆pabA harboring pET15bΩydaH expressing the wild-type or mutant 
transporters, or the pET15b empty vector were tested on agar plates.  Cells were grown in Luria 
Broth (LB) medium with 100 µg/ml ampicillin at 37 oC.  When the OD600 reached 0.5, the 
cultures were induced with 0.2 mM IPTG and harvested in two hours after induction.  The 
minimum growth inhibitory concentrations (MICs) of sulfamethazine and sulfanilamide for E. 
coli BL21(DE3)∆abgT∆pabA (incoculum, 500 cells/ml) harboring these vectors were then 
determined using LB agar containing 50 µg/ml ampicillin, 0.1 mM IPTG and different 
concentrations of sulfamethazine and sulfanilamide, respectively.   
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Accumulation assays of sulfamethazine 
The procedures for [3H]-sulfamethazine accumulation were the same as those for [3H]-
PABA accumulation.  Cells were incubated with 75 nM [3H]-sulfamethazine (Moravek 
Biochemicals, Brea, CA) for 15 min, applied directly to prewetted glass-fiber filters, and washed 
immediately twice with 5-ml aliquots of the same buffer.  Filters were then incubated for 30 min 
in scintillation fluid (ScintiVerse™ BD) and counted with a Packard Tri-Carb 1600TR liquid 
scintillation counter (Perkin Elmer, Waltham, MA).  For the Na+-dependent experiments, cells 
were incubated with 75 nM [3H]-sulfamethazine in the presence of NaCl (0, 5 or 100 mM) for 15 
min, then applied directly to prewetted glass-fiber filters, and washed immediately twice with 5-
ml aliquots of buffer containing 100 mM Tris-HCl (pH 7.5) and 0, 5 or 100 mM NaCl.    
 
Efflux assays of sulfamethazine 
E. coli BL21(DE3)∆abgT∆pabA carrying pET15bΩydaH or pET15b were grown in LB 
broth with 100 µg/ml ampicillin at 37oC.  When the OD600 reached 0.5, the culture was induced 
with 0.2 mM IPTG, and cells were harvested within 2 h.  Cells were washed twice with buffer 
containing 50 mM potassium phosphate (pH 7.5), twice with buffer containing 100 mM Tris-
HCl (pH 7.5), and then suspended in the same buffer to OD600 of 15.  CCCP was added to the 
cell suspension at a final concentration of 100 µM.  Cells were then incubated for 10 min, 
pelleted, washed twice and resuspended in the same buffer to OD600 of 10.  [3H]-sulfamethazine 
was then added to a final concentration of 37 nM.  Cells were incubated for 15 min, and a final 
concentration of 0.2% glucose was then added to the cell suspension.  When needed, a final 
concentration of 5 mM NaCl or KCl was also added at the same time.  At various time points, 
samples of 100 µl were applied directly to prewetted glass-fiber filters, and washed twice with 5-
186 
 
 
ml aliquots of buffer containing 100 mM Tris-HCl (pH 7.5).  Filters were then incubated for 30 
min in scintillation fluid (ScintiVerse™ BD) and counted with a Packard Tri-Carb 1600TR 
liquid scintillation counter (Perkin Elmer, Waltham, MA). 
 
References 
26. Long, F., Su, C.-C., Zimmermann, M.T., Boyken, S.E., Rajashankar, K.R., Jernigan, R.L. & 
Yu, E.W. Crystal structures of the CusA heavy-metal efflux pump suggest methionine-
mediated metal transport mechanism. Nature 467, 484-488 (2010). 
27. Otwinowski, Z. & Minor, M. Processing of X-ray diffraction data collected in oscillation 
mode. Methods Enzymol. 276, 307-326 (1997).  
28. Tézé, A. & Hervé, G. α-, β-, and γ-dodecatungstosilicic acids: isomers and related lacunary 
compounds.  Inorganic Synthesis 27, 85-96 (1990).  
29. Schneider, T.R. & Sheldrick, G.M. Substructure solution with SHELXD. Acta Cryst. D58, 
1772–1779 (2002). 
30. Pape, T. & Schneider, T.R. HKL2MAP: a graphical user interface for macromolecular 
phasing with SHELX programs. J. Appl. Cryst. 37, 843–844 (2004). 
31. Otwinowski, Z. MLPHARE, CCP4 Proc. 80 (Daresbury Laboratory, Warrington, UK, 
1991). 
32. Collaborative Computational Project No. 4. The CCP4 suite: programs for protein 
crystallography. Acta Cryst. D50, 760-763 (1994). 
33. Terwilliger, T.C. Maximum-likelihood density modification using pattern recognition of 
structural motifs. Acta Cryst. D57, 1755-1762 (2001). 
34. Emsley, P. & Cowtan, K. Coot: model-building tools for molecular graphics. Acta Cryst. 
D60, 2126 (2004). 
35. McCoy, A.J., Grosse-Kunstleve, R.W., Adams, P.D., Winn, M.D., Storoni, L.C. & Read, 
R.J. Phaser crystallographic software. J. Appl. Cryst. 40, 658-674. 
36. Adams, P.D., Grosse-Kunstleve, R.W., Hung, L.W., Ioerger, T.R., McCroy, A.J., Moriarty, 
N.W. et al. PHENIX: building new software for automated crystallographic structure 
determination. Acta Cryst. 58, 1948-1954 (2002). 
37.  Brünger, A.T., Adams, P.D., Clore, G.M., DeLano, W.L., Gros, P., Grosse-Kunstleve, R.W, 
Jiang, J.S., Kuszewski, J., Nilges, M., Pannu, N.S., Read, R.J., Rice, L.M., Simonson, T. & 
187 
 
 
Warren, G.L. Crystallography & NMR system: A new software suite for macromolecular 
structure determination. Acta Cryst. D54, 905-921 (1998). 
38. Datsenko, K.A. & Wanner, B.L. One-step inactivation of chromosomal genes in Escherichia 
coli K-12 using PCR products. Proc. Nat. Acad. Sci. USA 97, 6640-6645 (2000). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
188 
 
 
Supplemental figures 
 
 
     
AbYdaH       -----------MTRTH---------------GWLARLEQLGNRLPHPTLLFVWFCLLLLPLTAVLGALDVTATHPLT-DET------------ITAHSLLDADGLRYLFTTLVGNFTGFA 81 
EcAbgT       -----MSMSSIPSSSQS-------------GKLYGWVERIGNKVPHPFLLFIYLIIVLMVTTAILSAFGVSAKNPTDG---------TP----VVVKNLLSVEGLHWFLPNVIKNFSGFA 89 
NgMtrF       -------MSQTDARRSG--------------RFLRTVEWLGNMLPHPVTLFIIFIVLLLIASAVGAYFGLSVPDPRPVGAK---GRADDGL--IHVVSLLDADGLIKILTHTVKNFTGFA 94 
NmMtrF       -------MSQTDTQRDG--------------RFLRTVEWLGNMLPHPVTLFIIFIVLLLIASAVGAYFGLSVPDPRPVGAK---GRADDGL--IYIVSLLNADGFIKILTHTVKNFTGFA 94 
CcAbgT       MSDAAPPVSSPPPRQK---------------GLLGVVERLGNLLPEPVMIFVWLILGLMVLSAIGQALGWSASITYAGDEAPQFGELENGVLTYAASSLFSEANLARLFTEMPKTLTSFA 105 
SpAbgT       ------------------------------MRFLNIVERLGNLLPHPITLFALFCVAVILISGIAGYFELTVADPRPVGSH---GRSADGL--IHVVSLMNAEGLRMIVSNLVTNFTGFT 85 
PmMtrF       -------MTTTQQQKKGS-------------KFLHTVEWLGNMLPHPVTLFMIFIVLLLITSALGEYFGLAVADPRPEGVK---GRAADGM--IYVVSLLNAEGLSRILTNLVKNFTNFA 95 
VcAbgT       -------MTRREQMSSSASINQNAPKKPLITRFLDGVEYLGNLLPHPITLFAIFCVVLLVASGIAGYFELSVVDPRPEGAK---GRAADGM--IHVVSLLNADGLELIVTNLVKNFVGFA 108 
BhAbgT       -MKPAPHVELKPNQRG------------VFVRFLDIIEKYGNKLPDPIMLFVIMAVLILICSAIFSALGTSAVHPGTG---------EE----IEVVNLLNGEGFILILTELVNNFTSFP 94 
PdAbgT       ------------------------------MRALNVVERAGNKLPDPVTIFLLLCIIVVILSAVISNLGVEEIHPSTK---------EV----VKVVNLLEKEQIQSYLGSIVTNFQSFA 77 
SaAbgT       -------MTSKHQQKGS-----------IVNRFLNSVEKIGNKLPDPSVLFFLMCVGLAIMTWVISLFNVSVKHPGTH---------QT----IYIKNIISHDGFTMIMNDTIKNFSEFP 89 
TdAbgT       -------MDKKKNKEVS--------------GFLKGVERIGNKLPHPAMIFLILSIIVIIVSALAEAYGTPVTYFDAK--K---GKEVT----IGAVSLLNLDGLRYILNTATKNFTGFA 90 
CdAbgT       -----MSTTTPPHKTAP-------------SGFLGKIEQLGNRLPDPFWIFAFLAIIVAISSWIGSAIGMTAVNPQDG---------ST----VEVTNLLTKEGATKMVSEAVNNFVAFP 89 
                                                 :*  ** :*.*  :*  : : :   : :                                 .::        .     .:  *.  
 
 
 
 
 
AbYdaH       PLGVVLVAMLGLGVAEQSGLLSVSLASLVRRSSGGALVFTVAFAGVLSSLTVDAGYVVLIPLAGLVFQLAGRPPIAGIATAFAAVSGGFSANLLVGPVDATLAGLSTEAAHIIDPDRTVA 201 
EcAbgT       PLGAILALVLGAGLAERVGLLPALMVKMASHVNARYASYMVLFIAFFSHISSDAALVIMPPMGALIFLAVGRHPVAGLLAAIAGVGCGFTANLLIVTTDVLLSGISTEAAAAFNPQMHVS 209 
NgMtrF       PLGTVLVSLLGVGIAEKSGLISALMRLLLTKSPRKLTTFMVVFTGILSNTASELGYVVLIPLSAVIFHSLGRHPLAGLAAAFAGVSGGYSANLFLGTIDPLLAGITQQAAQIIHPDYVVG 214 
NmMtrF       PLGTVLVSLLGVGIAEKSGLISALMRLLLTKSPRKLTTFMVVFTGILSNTASELGYVVLIPLSAIIFHSLGRHPLAGLAAAFAGVSGGYSANLFLGTIDPLLAGITQQAAQIIHPDYVVG 214 
CcAbgT       PLGLVLVVILGAAVAERSGLFSALIRASLREAPKRILTPLVVIIGMVSHHASDAAYVVFIPLAGLLYAAVGRHPLAGIAAGFAAVSGGFAGNLTPGQFDVVLFGFTQEAARIIDPTWTMN 225 
SpAbgT       PLGTVLVALLGVGIAERSGLLSAAMRALVMGASKRLVTVTIVFAGIMSNTAAELGYVVLIPMAAMIFHSLGRHPLAGLAAAFAGVSGGYSANLLLGTVDPLLSGITEAAARMIDPDYSVG 205 
PmMtrF       PLGTVLVALLGVGIAEKAGLLSAVMRLLVTKSPRKLTTFTIVFAGILSNTASELGYVVLIPLAAIIFHSLGRHPLAGLAAAFAGVSGGYSANLLLGTIDPLLAGITQQAAQIIDPTYTVG 215 
VcAbgT       PLGTVLVAMLGVAIAEHSGLLSAAMRGLVMGASKRMVTFTVVFAGIISNTASELGYVVLIPLAAMLFHSLGRHPLAGLAAAFAGVSGGYSANLLIGTVDPLLSGITETAARMIDPTYSVG 228 
BhAbgT       PLGLVLVVMLGVGVAESTGLLSALMKTTILNAPRKLILPTIVLVAMLGNAAADAAMVVLPPIVAMIFIALGRHPLAGLAAAYASVAGGFSANLILSMLDPLVAGFTQTGAQMIDPDYVAN 214 
PdAbgT       PLGLVLVTMLGAGVAEKSGFMEVLMKKGISKVPQKLVTVAIVFAGMLSHTAADVGFIILPPLAALVFLGIGRHPLVGMFAAFAGVAGGFAANVMLSTTDVLLAGFTIPAAQMMDPSYQGN 197 
SaAbgT       ALGLVLAVMIGIGVAEKTGYFDKLMISVVNRAPRFLILPTIILIGILGSTAGDAATIILPPLAAMLFIKIGYHPIAGLTMAYASAVGGFAANIVVGMQDALVYSFTEPATRIVSDSIKTN 209 
TdAbgT       PLGTVLVAMLGVGVAEWTGLINTSLKKLLSGVHPRLLTVVVVFAGIMSNVASDAGYVVVIPLGAIVFANAGRHPMAGLAAAFAGVSGGFSANLMLGTIDPLLTGITVEALHNAGMDIAID 210 
CdAbgT       PLGVIITVMLGVSVAEHSGFISALVRAMVAKVGPKTLTYVVALAGVTGSIASDAVYVILISLGAMSFRALGRSPIVGAMVAFAASSAGFNASLILNITDVLLSGISTSAAQLVDPEYHVS 209 
             .** ::. ::* .:**  * :   :               : : .. .  : :   ::. .: .: :   *  *:.*   . *.   *: ..:     *  : .::  .             
 
 
 
 
 
AbYdaH       ATGNYWFIIASTFLVTGLVTLITRTLTEPRLAHANTVADASVDAPQIHS-------------------------RAMKWTGLT-LAILLAGLALLV----LPNDAPLR--HPDTGSVLGS 289 
EcAbgT       VIDNWYFMASSVVVLTIVGGLITDKIIEPRLGQWQG-----NSDEKLQT-------------------LTESQRFGLRIAGVVSLLFIAAIALMVI-----PQNGILRDPIN--HTVMPS 298 
NgMtrF       PEANWFFMAASTFVIALIGYFVTEKIVEPQLGPYQSDLSQEEKDIRHSNE------------------ITPLEYKGLIWAGVVFIALSALLAWSIV-----PADGILRHPET--GLVAGS 309 
NmMtrF       PEANWFFMVASTFVIALIGYFVTEKIVEPQLGPYQSDLSQEEKDIRHSNE------------------ITPLEYKGLIWAGVVFVALSALLAWSIV-----PADGILRHPET--GLVSGS 309 
CcAbgT       PLGNWWYILAIVVVFTPIAWFLTDKVVEPRLGPWGGQADDALKAELAKSA------------------VTADEKRGLKFAGLAALAIVALFAALSL----IPGFTPLID-ETKTGPAQLT 322 
SpAbgT       PEVNWYFMFVSTFVITFLGAFVTEKIVEPKLGKYQDGDADETVLQS-MES------------------VSAIEKRGLKWAGLSVLILAIMLALLVV-----PEGAPLRHPDT--GLVSGS 299 
PmMtrF       PEANWFFMAASTFVIAFIGYFITEKIVEPQLGPYNSHLSQEELDLQHSNE------------------VSPLERKGLRYAGLVFLILCALLAWTVV-----PENGILRDPKT--GLVTGS 310 
VcAbgT       PEVNWYFMAASTFVIAILGAFVTEKIVEPKLGKYDVSEASDDLSQDKMGS------------------LTALEKKALAYAGLAVVVVSALLAWTIV-----PADGVLRGED---GLVSGS 322 
BhAbgT       PAMNYYFLVASCLVLVPVAVWVTTKIVEPRLGTYTG-----EVEEITG--------------------VTKEEKKGLRWAGISVVILAVVFLFLTV-----PEQALLRDPETGS--LTVS 302 
PdAbgT       PAMNLYFAFISAIVLTFAGAFVTEKFIAPRFTKYNDS----TNDKDIQE-------------------LSELENKGIKYALLSLLVVVVVIVALCI-----GDNAFMKDPETGSILSSNA 289 
SaAbgT       VAMNWYFIAASVVVLLPTILLVTTKLIIPRLGKYDDSLMHDDHEETSSH-------------------ITDKEAHALKWANISFIVTIILLIITAI-----PEHSFLRNAKTGSL-LDDA 304 
TdAbgT       PTCNWFFMIVSTFILTVVGTFVTEKIVEKNLGTYNGSYKPDNMPIS------------------------DVENKGLKLAGISVLIMAVILIIGLFGLPKLPGLAVLREIDPKTGESSIS 306 
CdAbgT       TLANYFFVVASFLVLALIITAVTELFVKNRARQLVDHDHIDHSELSFRDDDHPDLGAKTDEELAEEIALHSGEIRALTIAGVAFIGMLAVYFALLF----VPASPFYSE-ES----AMSS 320 
                * ::     .:.      :*  .   .                                             .:  : :  :          .                       :  
 
 
 
 
 
AbYdaH       PFIHG-LVVIVALIAGICGAVYGRVSGQFRNSGAVITAMEVTMASMAGYLVLMFFAAQFVAWFNYSQLGLLLAVKGAAWLGALTVPKVVLLLLFVVLTALINLMIGSASAKWSILAPVFI 408 
EcAbgT       PFIKG-IVPLIILFFFVVSLAYGIATRTIRRQADLPHLMIEPMKEMAGFIVMVFPLAQFVAMFNWSNMGKFIAVGLTDILESSGLSGIPAFVGLALLSSFLCMFIASGSAIWSILAPIFV 417 
NgMtrF       PFLKS-IVVFIFLLFALPGIVYGRITRSLRGEREVVNAMAESMSTLGLYLVIIFFAAQFVAFFNWTNIGQYIAVKGAVFLKEVGLAGSVLFIGFILICAFINLMIGSASAQWAVTAPIFV 428 
NmMtrF       PFLKS-IVVFIFLLFALPGIVYGRVTRSLRGEQEVVNAMAESMSTLGLYLVIIFFAAQFVAFFNWTNIGQYIAVKGATFLKEVGLGGSVLFIGFILICAFINLMIGSASAQWAVTAPIFV 428 
CcAbgT       PFYGA-LIAGFMMLFLAGGVAYGVGVGTVKTEGDVVNMMADGVRSVAPYIVFAFFAAHFVAMFNWSRLGPIAAIHGAETLKAMNLPAPLLLVSVLGFSSVLDLFIGSASAKWSALAPVVV 441 
SpAbgT       PFLKG-IVAFIFICFAIPGFVYGKVVGSINNDRDVINAMSHSMSTMGLYIVLVFFAAQFVAFFNWSNLGAVLAVLGADALQSIGLTGPILFLFFIMLCGFINLMLGSASAQWAITAPIFV 418 
PmMtrF       PFLKS-IVAFIFILFAIPGTVYGIVTKSIRSEKDVVNAMAEAMSTLGLYLVIIFFASQFVAFFNWTNIGQYIAVKGANFLNEVGLHGGILFMGFILICAFINLMIGSASAQWAVTAPIFV 429 
VcAbgT       PFLKS-IVAFIFIFFAIPGYVYGRVVGTMKTDRDVINAMAKSMSSMGMYIVLVFFAAQFVAFFSWTKFGQVLAVLGADFLKDIGLTGPMLFFAFILMCGYINLMIGSASAQWAVTAPIFV 441 
BhAbgT       PFMTG-IVPIMMVFFLVPALVYGFVAKVFTSSKDVADHLAKSMSNMGTYIVIAFVAAQMIAFFNWSQLGPIVAIKGANFLQTIGFTGLPLLLGFIVIAALINLMVASASAKWAILAPVFV 421 
PdAbgT       PLMKG-IVPIITIIFLTPGLVYGKVSKKIKSDKDLVSMMGSSMSDMGGYIVLAFIASQFINLFNLSNLGTILSITGAKLLAESGIPSYGLIIGFILLSGFINLFVGSASAKWAILAPIFV 408 
SaAbgT       PLING-VGLIILVVFLVPGLVYGILSKEIKNTKDLGKMFGDAVGSMGTFIVIVFFAAQLLAYLKWSNLGIIAAVKGAKLLEHQ--NGIVLILGIIVLSAMVNMLIGSASAKWGILGPIFV 421 
TdAbgT       NFMHGGLLPVILLLFLIPGLIYGKKTGKINSSHDLVKGMSQAMSSMGGYLVLSFFAAQFVNYFGKTNLGTIISVNGANFLKSIGFTGLPLIISFVIISAFLNLFMGSASAKWAIMAPIFV 426 
CdAbgT       PLVKA-VTVPISLMFLGLGVVYGITIKSITSLGDIPAFMAKGLTTLIPMVVLFFMVAQFLAWFQWSNLGIWTAIKGAELLQRWDLPVYVLFAAVVLAVALLNLTITSGSAQWALMAPVIV 439 
              :  . :   . :     .  **     .     :   :   :  :   :*: *  ::::  :  :.:*   ::  :  *          :  .    . : : : *.** *.  .*:.:  
 
 
 
 
 
AbYdaH       PMLMLLGISPEASQAAYRVGDSSTNIITPLMPYFVLVLGFARRYQPETGIGTLIALMLPYSLTLLLGWSVLLGVW-IGFGWPLGP-------------- 492 
EcAbgT       PMFMLLGFHPAFAQILFRIADSSVLPLAPVSPFVPLFLGFLQRYKPDAKLGTYYSLVLPYPLIFLVVWLLMLLAW-YLVGLPIGPGIYPRLS------- 508 
NgMtrF       PMLMLAGYAPEVIQAAYRIGDSVTNIITPMMSYFGLIMATVMKYKKDAGVGTLISMMLPYSAFFLIAWIALFCIWVFVLGLPVGPGAPTLYPAP----- 522 
NmMtrF       PMLMLAGYAPEVIQAAYRIGDSVTNIITPMMSYFGLIMATVIKYKKDAGVGTLISMMLPYSAFFLIAWIALFCIWVFVLGLPVGPGAPTFYPAP----- 522 
CcAbgT       PMFMLLGISPEMTTAAYRMGDSFTNLMTPLMSYFPLVLAMTRRWDPSMGVGSLLALMLPYALAFMVAGVAMTLAW-VAFDWPLGPAAQVHYTPPGGLLK 539 
SpAbgT       PMLMLVGYAPETIQAAYRIGDSVTNLVTPMMSYFGLILAVACRYQKNLGIGTLIATMLPYTLVFFVGWTAFFFLWVFGFGLPVGPGAATYYTP------ 511 
PmMtrF       PMLMLTGYSPEIIQAAYRIGDSVTNIITPMMSYFGLIMATVLKYKKDAGVGTLVSMMLPYSVAFLVAWSAMFFIWVFVLGLPVGPNSPMFYPAQ----- 523 
VcAbgT       PMLMLVGYAPEVIQAAYRIGDSVTNIITPMMSYFGLILAVATRYMKNLGIGTLIATMLPYSVVFMVGWSLLFYVWVFVLGLPVGPGAATYYTP------ 534 
BhAbgT       PMFMLLEYSPAFTQAAYRVGDSITNPITPMLPYFAIALTFAKKYDPKIGIGTFMSSLLPYSIAFAVIWIILFTVW-YLLGLPLGPGEYIHLHT------ 513 
PdAbgT       PMFMLLDFNPALTQIAYRIGDASTNPISPLFPYFPVILAFARRYDKDIGIGTVISNMIPYSVVFTLIEIIILLLF-MGIGIPLGPGGGISYVL------ 500 
SaAbgT       PMLILIGFHPAFTQVIYRVGDSITNPITPMMPYLPLLLTYAQKYDKRMKLGALLSSLMPYSIALSIVWTVFVIIW-FLLGIPVGPGGPIFVK------- 512 
TdAbgT       PMMVNLGLSPALTQVAYRIGDSSTNLITPLMSYFAMIVVFMKKYDEDSGLGTLISTMLPYSIAFLLSWIGLMIIW-YIFGLPLGPGAFIHI-------- 516 
CdAbgT       PMMMYVGISPEVTQMLFRIGDSPTNIITPMSPYFALALTFLQRYYKPAGVGTLVSLALPYSIAMLVGWFVFFIVW-YALGVPLGPGTPMHFQQG----- 532 
             **::     *      :*:.*: .  ::*: .:. : :    ::     :*:  :  :**.  : :    :   :   .. *:**                                     
!
TM1 β1 β2 TM2a 
TM2b TM2c HP1a HP1b TM3a TM3b 
TM4 TM5 
TM6 TM7a TM7b TM7c HP2a HP2b 
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Fig. S1. Sequence and topology of A. borkumensis YdaH.  Alignment of the amino acid 
sequences of the AbgT family of transporters were done using CLUSTAL W.  *, identical 
residues; :, >60% homologous residues.  Secondary structural elements are indicated: TM, 
transmembrane helix; β, strand.  The sequence and topology of A. borkumensis YdaH are shown 
at the top.  Conserved residues involved in lining the channel of the inner core of the protein are 
highlight with green bars.  Residues coordinating with the bound Na+ are indicated with red 
arrows.   
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Fig. S2. Stereo view of the electron density maps of YdaH at a resolution of 2.96 Å.  (a) The 
electron density maps are contoured at 1.2 σ.  The Cα traces of the two YdaH dimers in the 
asymmetric unit are included.  (b) Anomalous maps of the 44 selenium sites (contoured at 4 σ).  
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Four protomers forming two dimers of YdaH are found in the asymmetric unit.  Each protomer 
contributes 11 selenium sites corresponding to the 11 methionines (magenta).  The Cα traces of 
the four YdaH monomers are colored green, orange, cyan and yellow.  (c) Representative section 
of the electron density within HP2 of YdaH.  The electron density (colored white) is contoured at 
the 1.2 σ level and superimposed with the final refined model (yellow, carbon; red, oxygen; blue, 
nitrogen).  
M
ar
ke
r 
Yd
aH
 
D1
80
A 
N3
90
A 
P4
18
A 
R4
26
A 
D4
29
A 
N4
33
A 
W
40
0A
 
 
192 
 
 
Fig. S3.  Expression level of the YdaH pumps.  An immunoblot against YdaH of crude extracts 
from 50 µg dry cells of strain BL21(DE3)∆abgT∆pabA expressing the YdaH wild-type and 
mutant (D180A, N390, W400A, P418A, R426A, D429A and N433A) pumps are shown.   
 
Table S1.  Data collection, phasing and structural refinement statistics.  
 
 
Native YdaH [β-SiW9O34H]9-  Se (peak)  
Data Collection        
Wavelength (Å) 0.98 1.02 0.98   
Space group P21 P21 P21   
Resolution (Å) 50 – 2.96       50 – 7.70 50 – 4.10   
 
(3.09 – 2.96)    (7.98 – 7.70) (4.25 – 4.10)   
Cell constants (Å) 
   
  
     a 94.15 94.31 98.26,   
     b 200.98 199.33 193.57,   
     c 101.49 102.95 102.83   
     α, β, γ (°) 90, 92.82, 90 90, 93.46, 90 90, 94.72, 90   
Molecules in ASU 4 4 4   
Redundancy 3.7 (3.5) 1.9 (1.9) 1.8 (1.7)   
Total reflections 2813,494 243,367 509,675   
Unique reflections 83,133 12,402 19,264   
Completeness (%) 99.3 (97.4) 96.2 (97.9) 97.1 (94.9)   
Rsym (%) 5.4 (46.5) 4.4 (39.4) 6.1 (46.2)   
I / σ 19.9 (2.2) 24.6 (2.0) 12.5 (1.5)   
Phasing   
Number of sites  
 
6 44  
Phasing power (acentric/centric) 1.45 / 0.94 1.34/0.96  
Rcullis (acentric/centric) 
 
0.80/0.90 0.87/0.87  
Figure of merit  0.285  0.486  
Refinement YdaH       
Resolution (Å) 50 – 2.96 
   Rwork (%)  20.05 
   Rfree (%)  24.37 
   Average B-factor (Å2) 74.70 
   
193 
 
 
RMSD bond lengths (Å) 0.009 
   RMSD bond angles (°) 1.392 
   Ramachandran plot         
most favoured (%) 94.2 
   additional allowed (%) 5.6 
   generously allowed (%) 0.2 
   disallowed (%) 0 
    
 
 
Table S2. Primers for site-directed mutagenesis. 
 
       Primer Sequence 
D180A-forward 5ʹ′-CCCGGTGGCTGCAACCCTGGCTGGTCTGTCAACGGA-3ʹ′ 
D180A-reverse 5ʹ′-CAGGGTTGCAGCCACCGGGCCGACCAGCAGATTCGCC-3ʹ′ 
N390A-forward 5ʹ′-GTGCTGACGGCCCTGATTGCCCTGATGATCGGTAGTGCG-3ʹ′ 
N390A-reverse 5ʹ′-CGCACTACCGATCATCAGGGCAATCAGGGCCGTCAGCAC-3ʹ′ 
W400A-forward 5ʹ′-CGCCAAGGCGAGTATTCTGGCCCCGGTGTTCATCCCG-3ʹ′ 
W400A-reverse 5ʹ′-CAGAATACTCGCCTTGGCGGACGCACTACCGATCATCAG-3ʹ′ 
P418A-forward 5ʹ′-CATCAGTGCGGAAGCATCCCAGGCAGCTTATCGCGT-3ʹ′ 
P418A-reverse 5ʹ′-GATGCTTCCGCACTGATGCCCAGCAGCATCAGCATC-3ʹ′ 
R426A-forward 5ʹ′-GCATCCCAGGCAGCTTATGCCGTTGGTGATTCATCGACC-3ʹ′ 
R426A-reverse 5ʹ′-GGTCGATGAATCACCAACGGCATAAGCTGCCTGGGATGC-3ʹ′ 
D429A-forward 5ʹ′-GCAGCTTATCGCGTTGGTGCTTCATCGACCAATATTATC-3ʹ′ 
D429A-reverse 5ʹ′-GATAATATTGGTCGATGAAGCACCAACGCGATAAGCTGC-3ʹ′ 
N433A-forward 5ʹ′-GTTGGTGATTCATCGACCGCTATTATCACGCCGCTGATG-3ʹ′ 
N433A-reverse 5ʹ′-CATCAGCGGCGTGATAATAGCGGTCGATGAATCACCAAC-3ʹ′ 
 
 
Table S3.  MICs of sulfamethazine and sulfanilamide for different YdaH variants expressed in E. 
coli BL21(DE3)∆abgT∆pabA. 
                                                                                                
Gene in BL21(DE3)∆abgT∆pabA Sulfamethazine (µg/mL) Sulfanilamide (µg/mL) 
Empty vector 62.5 500 
ydaH (wild-type) 2000 4000 
ydaH (D180A) 1000 2000 
ydaH (N390A) 62.5 2000 
ydaH (W400A) 62.5 2000 
ydaH (P418A) 250 2000 
ydaH (R426A) 125 2000 
ydaH (D429A) 62.5 2000 
ydaH (N433A) 62.5 2000 
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CHAPTER 7 
GENERAL CONCLUSIONS AND FUTURE DIRECTIONS 
 
The continual emergence of multidrug resistance among pathogenic bacteria has kept up 
a great demand for developing or designing more new effective antibiotics and smarter treatment 
strategies. Bacterial multidrug efflux pumps constitute a major mechanism for conferring 
multidrug resistance and thus provide attractive therapeutic targets [1]. Understanding the action 
mechanisms of these efflux pumps and their transcriptional regulators is essential for the 
development of efflux pump inhibitors. This dissertation is focused on the study of bacterial 
multidrug efflux transporters, MtrD and MtrF of N. gonorrhoeae and YdaH of A. borkumensis 
and a transcriptional regulator, Rv3066 of M. tuberculosis.  
The Mmr multidrug efflux pump (belongs to the SMR family) of M. tuberculosis, has 
been shown to mediate resistance to several toxic compounds, including acriflavine, ethidium 
bromide, erythromycin, pyronin Y, safranin O, tetraphenyl phosphonium and thioridazine [2-4]. 
Although, homolog structures of this family of proteins are available, knowledge of their gene 
regulation is fairly minimal.  
In Chapter 2, we proposed that the expression of Mmr efflux pump is controlled by the 
transcriptional regulator Rv3066, whose open reading frame is located downstream of the mmr 
operon. To understand the structural basis of Rv3066 regulation, we have determined the crystal 
structures of Rv3066, both in the absence and presence of bound ethidium. Comparison of the 
apo-Rv3066 and Rv3066-ethidium crystal structures suggests that the conformational changes 
leading to drug-mediated derepression is primarily due to a rigid body rotational motion within 
the dimer interface of the regulator. The Rv3066 regulator creates a multidrug-binding pocket; 
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important residues for drug binding were identified using mutagenesis and fluorescence 
polarization. In vitro studies reveal that the dimeric Rv3066 regulator binds to a 14-bp 
palindromic inverted repeat sequence in the nanomolar range. Together with the experimental 
data from electrophoretic mobility shift, footprinting analysis, qRT–PCR, mutagenesis, gel 
filtration and fluorescence polarization, the crystal structures support the role of Rv3066 in 
regulating the expression level of the multidrug efflux pump Mmr in M. tuberculosis. 
In Chapter 3, we outlined different methods for use in the crystallization of membrane 
proteins. All the known multidrug efflux transporters and targets of more than 50% of currently 
administrative pharmaceutical agents are integral membrane proteins. Unfortunately, the 
understanding of the structure and function of these membrane proteins hampered by difficulties 
associated with obtaining crystals that diffract to high resolution. This brief summary will 
provide a useful guide for researchers working in the field of membrane proteins.    
In Chapter 4, the wild-type N. gonorrhoeae MtrD of MtrCDE tripartite complex has been 
cloned, expressed and crystallized. The findings reveal a novel structural feature that is not found 
in other known members of RND efflux pumps. MtrD contains an extended region that protrudes 
into the periplasm and contributes part of the periplasmic domain. Protein sequence alignment 
suggests that this region is only found in MtrD and not other homologous RND proteins. The 
spatial arrangement between the extra elongated helix and loop (upper portion of TM9) and the 
periplasmic cleft formed between PC1 and PC2 suggests that these extra structural features may 
help the pump to transport its substrates more effectively from the outer leaflet of the inner 
membrane to the multidrug binding site at the periplasmic domain. Protein sequence alignment 
reveals that many of the amino acids forming the large periplasmic binding site of AcrB are 
conserved between MexB and MtrD, indicating that these three multidrug efflux pumps may 
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have a similar substrate binding profile for drug recognition. The MtrD multidrug efflux pump 
should operate through an alternating-access mechanism, similar to the AcrB transporter. Thus, 
the pump has to go through the transport cycle, which should involve different transient 
conformations, including the ‘‘access’’, ‘‘binding’’ and ‘‘extrusion’’ states of this protein. In 
comparison with the structures of AcrB; the conformation of MtrD is closer to that of the 
‘‘access’’ protomer of AcrB [5].  
In Chapter 5, the wild-type N. gonorrhoeae MtrF, which belongs to the AbgT family of 
transporters, has been cloned, expressed, crystallized.  The findings from the structure of MtrF 
highlight a unique fold of dimeric molecule distinct from all other families of transporters. MtrF 
is a bowl shaped dimer with a solvent-filled basin extending from the cytoplasm to halfway 
across the membrane bilayer. The structure directly suggests a plausible pathway for substrate 
transport. A combination of the crystal structure, genetic analysis and substrate accumulation 
assay indicate that MtrF is an exporter, capable of removing the metabolite p-aminobenzoic acid 
from bacterial cells. Further experimental data based on drug susceptibility and radioactive 
transport assay suggest that N. gonorrhoeae is an antibiotic efflux pump, which mediates 
bacterial resistance to sulfonamide antimetabolite drugs. Our data also suggest that MtrF is 
proton motive force dependent efflux pump and important residues for the function of this 
protein were identified. Our data strongly agrees with the previous observation that MtrF is 
needed for high-level resistance of gonococci to hydrophobic agents.  
In Chapter 6, the crystal structure of A. borkumensis YdaH, which is a distinct member of 
the AbgT family, has been determined to a resolution of 2.96 Å. The dimeric architecture of 
YdaH is distinct from all other transporters, but is similar to that of MtrF. The residues lining 
along the wall of the predicted channel for substrate pathway are well conserved between YdaH 
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and MtrF. Different from MtrF, we observed a bound Na+ ion in each protomer of YdaH. Our 
initial attempts to see whether YdaH function to catalyze the uptake of p-aminobenzoyl-
glutamate for de novo folic acid synthesis (similar to E. coli AbgT) or function as an 
antimicrobial resistant protein (similar to N. gonorrhoeae), reveal that YdaH behaves similar to 
MtrF. From our accumulation assays, drug susceptibility assays and radioactive transport assay, 
we demonstrated that A. borkumensis YdaH is an antibiotic efflux pump, which is able to remove 
sulfonamides from the cell and mediate resistance to this class of antimetabolites. In addition, we 
identified important residues for the function of this protein and our results strongly suggest that 
function of YdaH is Na+ -ion dependent. It is likely that many members of the AbgT family 
transporters may serve as antimetabolite efflux pumps to protect cells against these noxious 
agents. 
Towards understanding the molecular mechanism used by the MtrCDE efflux pump of N. 
gonorrhoeae to expel various classes of antibiotics, we have determined the crystal structure of 
the MtrD and the accessory protein MtrF. Much more structural and biochemical information 
will be necessary for a detailed understanding of how these two membrane proteins work 
together and transport mechanism of these multidrug efflux pumps. Such understanding may 
prompt the use of new approaches to manipulate the function of these proteins, thereby inhibiting 
their efflux activity. Approaches to prevent the overexpression of Mmr efflux pump by targeting 
the Rv3066 regulator provide an alternative strategy to combat drug resistant M. tuberculosis 
pathogenic bacteria. The inhibition of AbgT family proteins would aid in restoring the 
effectiveness of sulfonamide drugs. The use of small molecule efflux system blockers will be an 
expanding research discipline in the treatment of infectious diseases [6-8].  
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